Stress and anxiety management pdf

Deborah C. Escalante

  1. Kessler RC, Angermeyer M, Anthony JC, R DG, Demyttenaere K, Gasquet I, G DG, Gluzman S, Gureje O, Haro JM, et al: Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization’s World Mental Health Survey Initiative. World Psychiatry. 2007, 6: 168-176.

  2. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE: Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005, 62: 593-602.

  3. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005, 62: 617-627.

  4. Somers JM, Goldner EM, Waraich P, Hsu L: Prevalence and incidence studies of anxiety disorders: a systematic review of the literature. Can J Psychiatry. 2006, 51: 100-113.

  5. Martin-Merino E, Ruigomez A, Wallander MA, Johansson S, Garcia-Rodriguez LA: Prevalence, incidence, morbidity and treatment patterns in a cohort of patients diagnosed with anxiety in UK primary care. Fam Pract. 2010, 27: 9-16.

  6. Vermani M, Marcus M, Katzman MA: Rates of detection of mood and anxiety disorders in primary care: a descriptive, cross-sectional study. Prim Care Companion CNS Disord. 2011, 13: doi 10.4088/PCC.4010m01013

  7. Kroenke K, Spitzer RL, Williams JB, Monahan PO, Lowe B: Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007, 146: 317-325.

  8. Weisberg RB, Dyck I, Culpepper L, Keller MB: Psychiatric treatment in primary care patients with anxiety disorders: a comparison of care received from primary care providers and psychiatrists. Am J Psychiatry. 2007, 164: 276-282.

  9. McLean CP, Asnaani A, Litz BT, Hofmann SG: Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illness. J Psychiatr Res. 2011, 45: 1027-1035.

  10. Stein M, Fuetsch M, Muller N, Hofler M, Lieb R, Wittchen H: Social anxiety disorder and the risk of depression: a prospective community study of adolescents and young adults. Arch Gen Psychiatry. 2001, 58: 251-256.

  11. Pine DS, Cohen P, Gurley D, Brook J, Ma Y: The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders. Arch Gen Psychiatry. 1998, 55: 56-64.

  12. Wittchen HU, Kessler RC, Pfister H, Lieb M: Why do people with anxiety disorders become depressed? A prospective-longitudinal community study. Acta Psychiatr Scand Suppl. 2000, 14-23.

  13. Senaratne R, Van Ameringen M, Mancini C, Patterson B: The burden of anxiety disorders on the family. J Nerv Ment Dis. 2010, 198: 876-880.

  14. Erickson SR, Guthrie S, Vanetten-Lee M, Himle J, Hoffman J, Santos SF, Janeck AS, Zivin K, Abelson JL: Severity of anxiety and work-related outcomes of patients with anxiety disorders. Depress Anxiety. 2009, 26: 1165-1171.

  15. Sherbourne CD, Sullivan G, Craske MG, Roy-Byrne P, Golinelli D, Rose RD, Chavira DA, Bystritsky A, Stein MB: Functioning and disability levels in primary care out-patients with one or more anxiety disorders. Psychol Med. 2010, 40: 2059-2068.

  16. Comer JS, Blanco C, Hasin DS, Liu SM, Grant BF, Turner JB, Olfson M: Health-related quality of life across the anxiety disorders: results from the national epidemiologic survey on alcohol and related conditions (NESARC). J Clin Psychiatry. 2011, 72: 43-50.

  17. Barrera TL, Norton PJ: Quality of life impairment in generalized anxiety disorder, social phobia, and panic disorder. J Anxiety Disord. 2009, 23: 1086-1090.

  18. Wittchen HU: Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety. 2002, 16: 162-171.

  19. Waghorn G, Chant D, White P, Whiteford H: Disability, employment and work performance among people with ICD-10 anxiety disorders. Aust N Z J Psychiatry. 2005, 39: 55-66.

  20. Nepon J, Belik SL, Bolton J, Sareen J: The relationship between anxiety disorders and suicide attempts: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Depress Anxiety. 2010, 27: 791-798.

  21. Bolton JM, Cox BJ, Afifi TO, Enns MW, Bienvenu OJ, Sareen J: Anxiety disorders and risk for suicide attempts: findings from the Baltimore Epidemiologic Catchment area follow-up study. Depress Anxiety. 2008, 25: 477-481.

  22. Sareen J, Cox BJ, Afifi TO, de Graaf R, Asmundson GJ, ten Have M, Stein MB: Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Arch Gen Psychiatry. 2005, 62: 1249-1257.

  23. Cougle JR, Keough ME, Riccardi CJ, Sachs-Ericsson N: Anxiety disorders and suicidality in the National Comorbidity Survey-Replication. J Psychiatr Res. 2009, 43: 825-829.

  24. Pfeiffer PN, Ganoczy D, Ilgen M, Zivin K, Valenstein M: Comorbid anxiety as a suicide risk factor among depressed veterans. Depress Anxiety. 2009, 26: 752-757.

  25. Schaffer A, Levitt A, Bagby R, Kennedy S, Levitan R, Joffe R: Suicidal ideation in major depression: sex differences and impact of comorbid anxiety. Can J Psychiatry. 2000, 45: 822-826.

  26. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 2013, Washington, DC: American Psychiatric Association, Fifth

  27. Van Ameringen M, Pollack M: Generalized Anxiety Disorder (Oxford Psychiatry Library). 2010, New York, NY: Oxford University Press

  28. Connor K, Kobak K, Churchill L, Katzelnick D, Davidson J: Mini-SPIN: A brief screening assessment for generalized social anxiety disorder. Depress Anxiety. 2001, 14: 137-140.

  29. Mancini C, Van Ameringen M, Pipe B, Oakman J: Development and validation of self-report psychiatric screening tool: MACSCREEN [poster]. Anxiety Disorders Association of America 23rd Annual Conference; March 27-30; Toronto, Canada. 2003

  30. Van Ameringen M, Mancini C, Simpson W, Patterson B: Potential use of Internet-based screening for anxiety disorders: a pilot study. Depress Anxiety. 2010, 27: 1006-1010.

  31. Ballenger J, Davidson J, Lecrubier Y, Nutt D, Borkovec T, Rickels K, Stein D, Wittchen H: Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 2001, 62 (Suppl 11): 53-58.

  32. Swinson R, Antony M, Bleau P, Chokka P, Craven M, Fallu A, Kjernisted K, Lanius R, Manassis K, McIntosh D, et al: Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry. 2006, 51: 9S-91S.

  33. Milne BJ, Caspi A, Harrington H, Poulton R, Rutter M, Moffitt TE: Predictive value of family history on severity of illness: the case for depression, anxiety, alcohol dependence, and drug dependence. Arch Gen Psychiatry. 2009, 66: 738-747.

  34. Batelaan NM, Smit F, de Graaf R, van Balkom AJ, Vollebergh WA, Beekman AT: Identifying target groups for the prevention of anxiety disorders in the general population. Acta Psychiatr Scand. 2010, 122: 56-65.

  35. Karsten J, Hartman CA, Smit JH, Zitman FG, Beekman AT, Cuijpers P, van der Does AJ, Ormel J, Nolen WA, Penninx BW: Psychiatric history and subthreshold symptoms as predictors of the occurrence of depressive or anxiety disorder within 2 years. Br J Psychiatry. 2011, 198: 206-212.

  36. McLaughlin KA, Hatzenbuehler ML: Stressful life events, anxiety sensitivity, and internalizing symptoms in adolescents. J Abnorm Psychol. 2009, 118: 659-669.

  37. Chu DA, Williams LM, Harris AW, Bryant RA, Gatt JM: Early life trauma predicts self-reported levels of depressive and anxiety symptoms in nonclinical community adults: Relative contributions of early life stressor types and adult trauma exposure. J Psychiatr Res. 2013, 47: 23-32.

  38. Flensborg-Madsen T, Tolstrup J, Sorensen HJ, Mortensen EL: Social and psychological predictors of onset of anxiety disorders: results from a large prospective cohort study. Soc Psychiatry Psychiatr Epidemiol. 2012, 47: 711-721.

  39. Heider D, Matschinger H, Bernert S, Alonso J, Brugha TS, Bruffaerts R, de Girolamo G, Dietrich S, Angermeyer MC: Adverse parenting as a risk factor in the occurrence of anxiety disorders : a study in six European countries. Soc Psychiatry Psychiatr Epidemiol. 2008, 43: 266-272.

  40. Strine TW, Mokdad AH, Balluz LS, Gonzalez O, Crider R, Berry JT, Kroenke K: Depression and anxiety in the United States: findings from the 2006 Behavioral Risk Factor Surveillance System. Psychiatr Serv. 2008, 59: 1383-1390.

  41. Kagan J, Snidman N: Early childhood predictors of adult anxiety disorders. Biol Psychiatry. 1999, 46: 1536-1541.

  42. Muris P, van Brakel AM, Arntz A, Schouten E: Behavioral inhibition as a risk factor for the development of childhood anxiety disorders: A longitudinal study. J Child Fam Stud. 2011, 20: 157-170.

  43. Schaffer A, Cairney J, Cheung A, Veldhuizen S, Levitt A: Community survey of bipolar disorder in Canada: lifetime prevalence and illness characteristics. Can J Psychiatry. 2006, 51: 9-16.

  44. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS: The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003, 289: 3095-3105.

  45. Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, Faraone SV, Greenhill LL, Howes MJ, Secnik K, et al: The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006, 163: 716-723.

  46. Klein Hofmeijer-Sevink M, Batelaan NM, van Megen HJ, Penninx BW, Cath DC, van den Hout MA, van Balkom AJ: Clinical relevance of comorbidity in anxiety disorders: a report from the Netherlands Study of Depression and Anxiety (NESDA). J Affect Disord. 2012, 137: 106-112.

  47. Bruce S, Machan J, Dyck I, Keller M: Infrequency of “pure” GAD: impact of psychiatric comorbidity on clinical course. Depress Anxiety. 2001, 14: 219-225.

  48. Shankman S, Klein D: The impact of comorbid anxiety disorders on the course of dysthymic disorder: a 5-year prospective longitudinal study. J Affect Disord. 2002, 70: 211-217.

  49. Boylan K, Bieling P, Marriott M, Begin H, Young L, MacQueen G: Impact of comorbid anxiety disorders on outcome in a cohort of patients with bipolar disorder. J Clin Psychiatry. 2004, 65: 1106-1113.

  50. Mackenzie CS, Reynolds K, Cairney J, Streiner DL, Sareen J: Disorder-specific mental health service use for mood and anxiety disorders: associations with age, sex, and psychiatric comorbidity. Depress Anxiety. 2012, 29: 234-242.

  51. McLaughlin T, Geissler E, Wan G: Comorbidities and associated treatment charges in patients with anxiety disorders. Pharmacotherapy. 2003, 23: 1251-1256.

  52. Sareen J, Jacobi F, Cox BJ, Belik SL, Clara I, Stein MB: Disability and poor quality of life associated with comorbid anxiety disorders and physical conditions. Arch Intern Med. 2006, 166: 2109-2116.

  53. Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O’Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, et al: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009, 11: 225-255.

  54. van Balkom AJ, Bakker A, Spinhoven P, Blaauw BM, Smeenk S, Ruesink B: A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments. J Nerv Ment Dis. 1997, 185: 510-516.

  55. Siev J, Chambless DL: Specificity of treatment effects: cognitive therapy and relaxation for generalized anxiety and panic disorders. J Consult Clin Psychol. 2007, 75: 513-522.

  56. Sanchez-Meca J, Rosa-Alcazar AI, Marin-Martinez F, Gomez-Conesa A: Psychological treatment of panic disorder with or without agoraphobia: a meta-analysis. Clin Psychol Rev. 2010, 30: 37-50.

  57. Wolitzky-Taylor KB, Horowitz JD, Powers MB, Telch MJ: Psychological approaches in the treatment of specific phobias: a meta-analysis. Clin Psychol Rev. 2008, 28: 1021-1037.

  58. Fedoroff I, Taylor S: Psychological and pharmacological treatments of social phobia: a meta-analysis. J Clin Psychopharmacol. 2001, 21: 311-324.

  59. Acarturk C, Cuijpers P, van Straten A, de Graaf R: Psychological treatment of social anxiety disorder: a meta-analysis. Psychol Med. 2009, 39: 241-254.

  60. Rosa-Alcazar AI, Sanchez-Meca J, Gomez-Conesa A, Marin-Martinez F: Psychological treatment of obsessive-compulsive disorder: a meta-analysis. Clin Psychol Rev. 2008, 28: 1310-1325.

  61. Jonsson H, Hougaard E: Group cognitive behavioural therapy for obsessive-compulsive disorder: a systematic review and meta-analysis. Acta Psychiatr Scand. 2009, 119: 98-106.

  62. Gava I, Barbui C, Aguglia E, Carlino D, Churchill R, De Vanna M, McGuire HF: Psychological treatments versus treatment as usual for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev. 2007, CD005333-

  63. Ougrin D: Efficacy of exposure versus cognitive therapy in anxiety disorders: systematic review and meta-analysis. BMC Psychiatry. 2011, 11: 200-

  64. Borkovec T, Ruscio A: Psychotherapy for generalized anxiety disorder. J Clin Psychiatry. 2001, 62 (Suppl 11): 37-42. discussion 43-35

  65. Hunot V, Churchill R, Silva de Lima M, Teixeira V: Psychological therapies for generalised anxiety disorder. Cochrane Database Syst Rev. 2007, CD001848-

  66. Bisson J, Andrew M: Psychological treatment of post-traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2007, CD003388-

  67. Bisson JI, Ehlers A, Matthews R, Pilling S, Richards D, Turner S: Psychological treatments for chronic post-traumatic stress disorder. Systematic review and meta-analysis. Br J Psychiatry. 2007, 190: 97-104.

  68. Seidler GH, Wagner FE: Comparing the efficacy of EMDR and trauma-focused cognitive-behavioral therapy in the treatment of PTSD: a meta-analytic study. Psychol Med. 2006, 36: 1515-1522.

  69. Powers MB, Halpern JM, Ferenschak MP, Gillihan SJ, Foa EB: A meta-analytic review of prolonged exposure for posttraumatic stress disorder. Clin Psychol Rev. 2010, 30: 635-641.

  70. Hofmann SG, Smits JA: Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry. 2008, 69: 621-632.

  71. Roshanaei-Moghaddam B, Pauly MC, Atkins DC, Baldwin SA, Stein MB, Roy-Byrne P: Relative effects of CBT and pharmacotherapy in depression versus anxiety: is medication somewhat better for depression, and CBT somewhat better for anxiety?. Depress Anxiety. 2011, 28: 560-567.

  72. Hofmann SG, Sawyer AT, Witt AA, Oh D: The effect of mindfulness-based therapy on anxiety and depression: A meta-analytic review. J Consult Clin Psychol. 2010, 78: 169-183.

  73. Boschen MJ, Oei TP: A cognitive behavioral case formulation framework for treatment planning in anxiety disorders. Depress Anxiety. 2008, 25: 811-823.

  74. Coull G, Morris PG: The clinical effectiveness of CBT-based guided self-help interventions for anxiety and depressive disorders: a systematic review. Psychol Med. 2011, 41: 2239-2252.

  75. Lewis C, Pearce J, Bisson JI: Efficacy, cost-effectiveness and acceptability of self-help interventions for anxiety disorders: systematic review. Br J Psychiatry. 2012, 200: 15-21.

  76. Lucock M, Padgett K, Noble R, Westley A, Atha C, Horsefield C, Leach C: Controlled clinical trial of a self-help for anxiety intervention for patients waiting for psychological therapy. Behav Cog Psychother. 2008, 36: 541-551.

  77. Craske MG, Rose RD, Lang A, Welch SS, Campbell-Sills L, Sullivan G, Sherbourne C, Bystritsky A, Stein MB, Roy-Byrne PP: Computer-assisted delivery of cognitive behavioral therapy for anxiety disorders in primary-care settings. Depress Anxiety. 2009, 26: 235-242.

  78. Cavanagh K, Seccombe N, Lidbetter N: The implementation of computerized cognitive behavioural therapies in a service user-led, third sector self help clinic. Behav Cogn Psychother. 2011, 39: 427-442.

  79. Titov N, Andrews G, Johnston L, Robinson E, Spence J: Transdiagnostic Internet treatment for anxiety disorders: a randomized controlled trial. Behav Res Ther. 2010, 48: 890-899.

  80. Opris D, Pintea S, Garcia-Palacios A, Botella C, Szamoskozi S, David D: Virtual reality exposure therapy in anxiety disorders: a quantitative meta-analysis. Depress Anxiety. 2012, 29: 85-93.

  81. Powers MB, Emmelkamp PM: Virtual reality exposure therapy for anxiety disorders: a meta-analysis. J Anxiety Disord. 2008, 22: 561-569.

  82. Bandelow B, Seidler-Brandler U, Becker A, Wedekind D, Ruther E: Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatry. 2007, 8: 175-187.

  83. Hofmann SG, Sawyer AT, Korte KJ, Smits JA: Is it beneficial to add pharmacotherapy to cognitive-behavioral therapy when treating anxiety disorders? a meta-analytic review. Int J Cogn Ther. 2009, 2: 160-175.

  84. Drug product database. [http://webprod5.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp]

  85. Practice guideline for the treatment of patients with panic disorder. [http://psychiatryonline.org/content.aspx?bookid=28&sectionid=1680635]

  86. Brambilla P, Cipriani A, Hotopf M, Barbui C: Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data. Pharmacopsychiatry. 2005, 38: 69-77.

  87. Hu X, Bull S, Hunkeler E, Ming E, Lee J, Fireman B, Markson L: Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry. 2004, 65: 959-965.

  88. Cascade E, Kalali AH, Kennedy SH: Real-world data on SSRI antidepressant side effects. Psychiatry (Edgmont). 2009, 6: 16-18.

  89. Hirschfeld R: Long-term side effects of SSRIs: sexual dysfunction and weight gain. J Clin Psychiatry. 2003, 64 (Suppl 18): 20-24.

  90. Dall M, Schaffalitzky de Muckadell OB, Lassen AT, Hansen JM, Hallas J: An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. Clin Gastroenterol Hepatol. 2009, 7: 1314-1321.

  91. de Abajo FJ, Garcia-Rodriguez LA: Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry. 2008, 65: 795-803.

  92. Haney EM, Chan BK, Diem SJ, Ensrud KE, Cauley JA, Barrett-Connor E, Orwoll E, Bliziotes MM: Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med. 2007, 167: 1246-1251.

  93. Williams LJ, Henry MJ, Berk M, Dodd S, Jacka FN, Kotowicz MA, Nicholson GC, Pasco JA: Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. Int Clin Psychopharmacol. 2008, 23: 84-87.

  94. Eom CS, Lee HK, Ye S, Park SM, Cho KH: Use of selective serotonin reuptake inhibitors and risk of fracture: a systematic review and meta-analysis. J Bone Miner Res. 2012, 27: 1186-1195.

  95. Smith JM: Clinical implications of treating depressed older adults with SSRIs: possible risk of hyponatremia. J Gerontol Nurs. 2010, 36: 22-27. quiz 28-29

  96. Shelton RC: The nature of the discontinuation syndrome associated with antidepressant drugs. J Clin Psychiatry. 2006, 67 (Suppl 4): 3-7.

  97. Kondro W: UK bans, Health Canada warns about antidepressants. CMAJ. 2004, 171: 23-

  98. Labeling change request letter for antidepressant medications. [http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm096352.htm]

  99. Barbui C, Esposito E, Cipriani A: Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. CMAJ. 2009, 180: 291-297.

  100. Olmer A, Iancu I, Strous RD: Exposure to antidepressant medications and suicide attempts in adult depressed inpatients. J Nerv Ment Dis. 2012, 200: 531-534.

  101. Degner D, Grohmann R, Bleich S, Ruther E: New antidepressant drugs. What side effects and interactions are to be expected?. MMW Fortschr Med. 2000, 142: 35-38. 40

  102. Chouinard G: Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry. 2004, 65 (Suppl 5): 7-12.

  103. Ciraulo DA, Nace EP: Benzodiazepine treatment of anxiety or insomnia in substance abuse patients. Am J Addict. 2000, 9: 276-279. discussion 280-274

  104. Petrovic M, Mariman A, Warie H, Afschrift M, Pevernagie D: Is there a rationale for prescription of benzodiazepines in the elderly? Review of the literature. Acta Clin Belg. 2003, 58: 27-36.

  105. Allain H, Bentue-Ferrer D, Polard E, Akwa Y, Patat A: Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review. Drugs Aging. 2005, 22: 749-765.

  106. Barker MJ, Greenwood KM, Jackson M, Crowe SF: Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs. 2004, 18: 37-48.

  107. Barker MJ, Greenwood KM, Jackson M, Crowe SF: An evaluation of persisting cognitive effects after withdrawal from long-term benzodiazepine use. J Int Neuropsychol Soc. 2005, 11: 281-289.

  108. Chessick CA, Allen MH, Thase M, Batista Miralha da Cunha AB, Kapczinski FF, de Lima MS, dos Santos Souza JJ: Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev. 2006, 3: CD006115-

  109. Baker RA, Pikalov A, Tran QV, Kremenets T, Arani RB, Doraiswamy PM: Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis. Psychopharmacol Bull. 2009, 42: 11-31.

  110. Yatham LN, Kennedy SH, O’Donovan C, Parikh SV, MacQueen G, McIntyre RS, Sharma V, Beaulieu S: Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord. 2006, 8: 721-739.

  111. Yatham LN, Kennedy SH, O’Donovan C, Parikh S, MacQueen G, McIntyre R, Sharma V, Silverstone P, Alda M, Baruch P, et al: Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 2005, 7 (Suppl 3): 5-69.

  112. Sumiyoshi T, Roy A, Anil AE, Jayathilake K, Ertugrul A, Meltzer HY: A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs: a survey for clozapine, risperidone, olanzapine, and quetiapine. J Clin Psychopharmacol. 2004, 24: 345-348.

  113. Citrome LL, Holt RI, Zachry WM, Clewell JD, Orth PA, Karagianis JL, Hoffmann VP: Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics. Ann Pharmacother. 2007, 41: 1593-1603.

  114. Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L’Italien GJ: Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry. 2006, 163: 1821-1825.

  115. Depping AM, Komossa K, Kissling W, Leucht S: Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev. 2010, CD008120-

  116. LaLonde CD, Van Lieshout RJ: Treating generalized anxiety disorder with second generation antipsychotics: a systematic review and meta-analysis. J Clin Psychopharmacol. 2011, 31: 326-333.

  117. Torrent C, Martinez-Aran A, Daban C, Amann B, Balanza-Martinez V, Del Mar Bonnin C, Cruz N, Franco C, Tabares-Seisdedos R, Vieta E: Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients. Compr Psychiatry. 2011, 52: 613-622.

  118. Correll CU, Sheridan EM, DelBello MP: Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord. 2010, 12: 116-141.

  119. Doyle A, Pollack M: Establishment of remission criteria for anxiety disorders. J Clin Psychiatry. 2003, 64 (Suppl 15): 40-45.

  120. Kjernisted KD, Bleau P: Long-term goals in the management of acute and chronic anxiety disorders. Can J Psychiatry. 2004, 49: 51S-63S.

  121. Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE: The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2006, 63: 415-424.

  122. Grant BF, Hasin DS, Stinson FS, Dawson DA, Goldstein RB, Smith S, Huang B, Saha TD: The epidemiology of DSM-IV panic disorder and agoraphobia in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2006, 67: 363-374.

  123. Kinley DJ, Cox BJ, Clara I, Goodwin RD, Sareen J: Panic attacks and their relation to psychological and physical functioning in Canadians: results from a nationally representative sample. Can J Psychiatry. 2009, 54: 113-122.

  124. Goodwin RD, Lieb R, Hoefler M, Pfister H, Bittner A, Beesdo K, Wittchen HU: Panic attack as a risk factor for severe psychopathology. Am J Psychiatry. 2004, 161: 2207-2214.

  125. Kjernisted K, McIntosh D: Venlafaxine extended release (XR) in the treatment of panic disorder. Ther Clin Risk Manag. 2007, 3: 59-69.

  126. Culpepper L: Identifying and treating panic disorder in primary care. J Clin Psychiatry. 2004, 65 (Suppl 5): 19-23.

  127. Craske MG, Tsao JC: Assessment and treatment of nocturnal panic attacks. Sleep Med Rev. 2005, 9: 173-184.

  128. Romans S, Cohen M, Forte T: Rates of depression and anxiety in urban and rural Canada. Soc Psychiatry Psychiatr Epidemiol. 2011, 46: 567-575.

  129. Galderisi S, Mancuso F, Mucci A, Garramone S, Zamboli R, Maj M: Alexithymia and cognitive dysfunctions in patients with panic disorder. Psychother Psychosom. 2008, 77: 182-188.

  130. Deckersbach T, Moshier SJ, Tuschen-Caffier B, Otto MW: Memory dysfunction in panic disorder: an investigation of the role of chronic benzodiazepine use. Depress Anxiety. 2011, 28: 999-1007.

  131. Pastucha P, Prasko J, Grambal A, Latalova K, Sigmundova Z, Sykorova T, Tichackova A: Panic disorder and dissociation – comparison with healthy controls. Neuro Endocrinol Lett. 2009, 30: 774-778.

  132. Kessler H, Roth J, von Wietersheim J, Deighton RM, Traue HC: Emotion recognition patterns in patients with panic disorder. Depress Anxiety. 2007, 24: 223-226.

  133. Tull MT, Roemer L: Emotion regulation difficulties associated with the experience of uncued panic attacks: evidence of experiential avoidance, emotional nonacceptance, and decreased emotional clarity. Behav Ther. 2007, 38: 378-391.

  134. Batelaan N, Smit F, de Graaf R, van Balkom A, Vollebergh W, Beekman A: Economic costs of full-blown and subthreshold panic disorder. J Affect Disord. 2007, 104: 127-136.

  135. Gros DF, Frueh BC, Magruder KM: Prevalence and features of panic disorder and comparison to posttraumatic stress disorder in VA primary care. Gen Hosp Psychiatry. 2011, 33: 482-488.

  136. de Graaf R, Tuithof M, van Dorsselaer S, Ten Have M: Comparing the effects on work performance of mental and physical disorders. Soc Psychiatry Psychiatr Epidemiol. 2012, 47: 1873-1883.

  137. Mathew AR, Norton PJ, Zvolensky MJ, Buckner JD, Smits JA: Smoking behavior and alcohol consumption in individuals with panic attacks. J Cogn Psychother. 2011, 25: 61-70.

  138. Bienvenu OJ, Onyike CU, Stein MB, Chen LS, Samuels J, Nestadt G, Eaton WW: Agoraphobia in adults: incidence and longitudinal relationship with panic. Br J Psychiatry. 2006, 188: 432-438.

  139. Korczak DJ, Goldstein BI, Levitt AJ: Panic disorder, cardiac diagnosis and emergency department utilization in an epidemiologic community sample. Gen Hosp Psychiatry. 2007, 29: 335-339.

  140. Senaratne R, Van Ameringen M, Mancini C, Patterson B, Bennett M: The prevalence of migraine headaches in an anxiety disorders clinic sample. CNS Neurosci Ther. 2010, 16: 76-82.

  141. Yamada K, Moriwaki K, Oiso H, Ishigooka J: High prevalence of comorbidity of migraine in outpatients with panic disorder and effectiveness of psychopharmacotherapy for both disorders: a retrospective open label study. Psychiatry Res. 2011, 185: 145-148.

  142. Marshall EC, Zvolensky MJ, Sachs-Ericsson N, Schmidt NB, Bernstein A: Panic attacks and physical health problems in a representative sample: singular and interactive associations with psychological problems, and interpersonal and physical disability. J Anxiety Disord. 2008, 22: 78-87.

  143. Craske MG, Kircanski K, Epstein A, Wittchen HU, Pine DS, Lewis-Fernandez R, Hinton D: Panic disorder: a review of DSM-IV panic disorder and proposals for DSM-V. Depress Anxiety. 2010, 27: 93-112.

  144. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, text revision (DSM-IV-TR). 2000, Washington, DC: American Psychiatric Association, Fourth

  145. Wittchen HU, Gloster AT, Beesdo-Baum K, Fava GA, Craske MG: Agoraphobia: a review of the diagnostic classificatory position and criteria. Depress Anxiety. 2010, 27: 113-133.

  146. Clum GA, Surls R: A meta-analysis of treatments for panic disorder. J Consult Clin Psychol. 1993, 61: 317-326.

  147. Gould R, Otto M, Pollack M: A meta-analysis of treatment outcome for panic disorder. Clin Psychol Psychother. 1995, 15: 819-844.

  148. Marchand A, Roberge P, Primiano S, Germain V: A randomized, controlled clinical trial of standard, group and brief cognitive-behavioral therapy for panic disorder with agoraphobia: a two-year follow-up. J Anxiety Disord. 2009, 23: 1139-1147.

  149. Roberge P, Marchand A, Reinharz D, Savard P: Cognitive-behavioral treatment for panic disorder with agoraphobia: a randomized, controlled trial and cost-effectiveness analysis. Behav Modif. 2008, 32: 333-351.

  150. Meyerbroker K, Emmelkamp PM: Virtual reality exposure therapy in anxiety disorders: a systematic review of process-and-outcome studies. Depress Anxiety. 2010, 27: 933-944.

  151. Botella C, García-Palacios A, Villa H, Baños RM, Quero S, Alcañiz M, Riva G: Virtual reality exposure in the treatment of panic disorder and agoraphobia: A controlled study. Clin Psychol Psychother. 2007, 14: 164-175.

  152. Malbos E, Rapee RM, Kavakli M: Isolating the effect of virtual reality based exposure therapy for agoraphobia: a comparative trial. Stud Health Technol Inform. 2011, 167: 45-50.

  153. Perez-Ara MA, Quero S, Botella C, Banos R, Andreu-Mateu S, Garcia-Palacios A, Breton-Lopez J: Virtual reality interoceptive exposure for the treatment of panic disorder and agoraphobia. Stud Health Technol Inform. 2010, 154: 77-81.

  154. Vincelli F, Anolli L, Bouchard S, Wiederhold BK, Zurloni V, Riva G: Experiential cognitive therapy in the treatment of panic disorders with agoraphobia: a controlled study. Cyberpsychol Behav. 2003, 6: 321-328.

  155. Hecker J, Losee M, Fritzler B, Fink C: Self-directed versus therapist-directed cognitive behavioural treatment for panic disorder. J Anxiety Disord. 1996, 10: 253-265.

  156. Lidren DM, Watkins PL, Gould RA, Clum GA, Asterino M, Tulloch HL: A comparison of bibliotherapy and group therapy in the treatment of panic disorder. J Consult Clin Psychol. 1994, 62: 865-869.

  157. Carlbring P, Maurin T, Sjomark J, Maurin L, Westling BE, Ekselius L, Cuijpers P, Andersson G: All at once or one at a time? A randomized controlled trial comparing two ways to deliver bibliotherapy for panic disorder. Cogn Behav Ther. 2011, 40: 228-235.

  158. Nordin S, Carlbring P, Cuijpers P, Andersson G: Expanding the limits of bibliotherapy for panic disorder: randomized trial of self-help without support but with a clear deadline. Behav Ther. 2010, 41: 267-276.

  159. McNamee G, O’Sullivan G, Lelliott P, Marks I: Telephone-guided treatment for housebound agoraphobics with panic disorder: exposure versus relaxation. Behav Ther. 1989, 20: 491-497.

  160. Swinson RP, Fergus KD, Cox BJ, Wickwire K: Efficacy of telephone-administered behavioral therapy for panic disorder with agoraphobia. Behav Res Ther. 1995, 33: 465-469.

  161. Bouchard S, Paquin B, Payeur R, Allard M, Rivard V, Fournier T, Renaud P, Lapierre J: Delivering cognitive-behavior therapy for panic disorder with agoraphobia in videoconference. Telemed J E Health. 2004, 10: 13-25.

  162. Carlbring P, Ekselius L, Andersson G: Treatment of panic disorder via the Internet: a randomized trial of CBT vs. applied relaxation. J Behav Ther Exp Psychiatry. 2003, 34: 129-140.

  163. Newman MG, Kenardy J, Herman S, Taylor CB: Comparison of palmtop-computer-assisted brief cognitive-behavioral treatment to cognitive-behavioral treatment for panic disorder. J Consult Clin Psychol. 1997, 65: 178-183.

  164. Bergstrom J, Andersson G, Ljotsson B, Ruck C, Andreewitch S, Karlsson A, Carlbring P, Andersson E, Lindefors N: Internet-versus group-administered cognitive behaviour therapy for panic disorder in a psychiatric setting: a randomised trial. BMC Psychiatry. 2010, 10: 54-

  165. Carlbring P, Bohman S, Brunt S, Buhrman M, Westling BE, Ekselius L, Andersson G: Remote treatment of panic disorder: a randomized trial of internet-based cognitive behavior therapy supplemented with telephone calls. Am J Psychiatry. 2006, 163: 2119-2125.

  166. Kiropoulos LA, Klein B, Austin DW, Gilson K, Pier C, Mitchell J, Ciechomski L: Is internet-based CBT for panic disorder and agoraphobia as effective as face-to-face CBT?. J Anxiety Disord. 2008, 22: 1273-1284.

  167. Wims E, Titov N, Andrews G, Choi I: Clinician-assisted Internet-based treatment is effective for panic: a randomized controlled trial. Aust N Z J Psychiatry. 2010, 44: 599-607.

  168. Klein B, Austin D, Pier C, Kiropoulos L, Shandley K, Mitchell J, Gilson K, Ciechomski L: Internet-based treatment for panic disorder: does frequency of therapist contact make a difference?. Cogn Behav Ther. 2009, 38: 100-113.

  169. Ruwaard J, Broeksteeg J, Schrieken B, Emmelkamp P, Lange A: Web-based therapist-assisted cognitive behavioral treatment of panic symptoms: a randomized controlled trial with a three-year follow-up. J Anxiety Disord. 2010, 24: 387-396.

  170. Clark DM, Salkovskis PM, Hackmann A, Wells A, Ludgate J, Gelder M: Brief cognitive therapy for panic disorder: a randomized controlled trial. J Consult Clin Psychol. 1999, 67: 583-589.

  171. Bohni MK, Spindler H, Arendt M, Hougaard E, Rosenberg NK: A randomized study of massed three-week cognitive behavioural therapy schedule for panic disorder. Acta Psychiatr Scand. 2009, 120: 187-195.

  172. Dow MG, Kenardy JA, Johnston DW, Newman MG, Taylor CB, Thomson A: Prognostic indices with brief and standard CBT for panic disorder: II. Moderators of outcome. Psychol Med. 2007, 37: 1503-1509.

  173. Craske MG, Roy-Byrne P, Stein MB, Sullivan G, Hazlett-Stevens H, Bystritsky A, Sherbourne C: CBT intensity and outcome for panic disorder in a primary care setting. Behav Ther. 2006, 37: 112-119.

  174. Haby MM, Donnelly M, Corry J, Vos T: Cognitive behavioural therapy for depression, panic disorder and generalized anxiety disorder: a meta-regression of factors that may predict outcome. Aust N Z J Psychiatry. 2006, 40: 9-19.

  175. Dow MG, Kenardy JA, Johnston DW, Newman MG, Taylor CB, Thomson A: Prognostic indices with brief and standard CBT for panic disorder: I. Predictors of outcome. Psychol Med. 2007, 37: 1493-1502.

  176. Bouchard S, Gauthier J, Nouwen A, Ivers H, Vallieres A, Simard S, Fournier T: Temporal relationship between dysfunctional beliefs, self-efficacy and panic apprehension in the treatment of panic disorder with agoraphobia. J Behav Ther Exp Psychiatry. 2007, 38: 275-292.

  177. Feske U, Goldstein AJ: Eye movement desensitization and reprocessing treatment for panic disorder: a controlled outcome and partial dismantling study. J Consult Clin Psychol. 1997, 65: 1026-1035.

  178. Goldstein AJ, de Beurs E, Chambless DL, Wilson KA: EMDR for panic disorder with agoraphobia: comparison with waiting list and credible attention-placebo control conditions. J Consult Clin Psychol. 2000, 68: 947-956.

  179. Furukawa TA, Watanabe N, Churchill R: Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: systematic review. Br J Psychiatry. 2006, 188: 305-312.

  180. Furukawa TA, Watanabe N, Churchill R: Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. Cochrane Database Syst Rev. 2007, CD004364-

  181. Mitte K: A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. J Affect Disord. 2005, 88: 27-45.

  182. Watanabe N, Churchill R, Furukawa TA: Combined psychotherapy plus benzodiazepines for panic disorder. Cochrane Database Syst Rev. 2009, CD005335-

  183. Koszycki D, Taljaard M, Segal Z, Bradwejn J: A randomized trial of sertraline, self-administered cognitive behavior therapy, and their combination for panic disorder. Psychol Med. 2011, 41: 373-383.

  184. Kim YW, Lee SH, Choi TK, Suh SY, Kim B, Kim CM, Cho SJ, Kim MJ, Yook K, Ryu M, et al: Effectiveness of mindfulness-based cognitive therapy as an adjuvant to pharmacotherapy in patients with panic disorder or generalized anxiety disorder. Depress Anxiety. 2009, 26: 601-606.

  185. Kim B, Lee SH, Kim YW, Choi TK, Yook K, Suh SY, Cho SJ, Yook KH: Effectiveness of a mindfulness-based cognitive therapy program as an adjunct to pharmacotherapy in patients with panic disorder. J Anxiety Disord. 2010, 24: 590-595.

  186. Schmidt NB, Wollaway-Bickel K, Trakowski JH, Santiago HT, Vasey M: Antidepressant discontinuation in the context of cognitive behavioral treatment for panic disorder. Behav Res Ther. 2002, 40: 67-73.

  187. Otto MW, McHugh RK, Simon NM, Farach FJ, Worthington JJ, Pollack MH: Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: further evaluation. Behav Res Ther. 2010, 48: 720-727.

  188. Bruce T, Spiegel D, Hegel M: Cognitive-behavioral therapy helps prevent relapse and recurrence of panic disorder following alprazolam discontinuation: a long-term follow-up of the Peoria and Dartmouth studies. J Consult Clin Psychol. 1999, 67: 151-156.

  189. Katon W, Russo J, Sherbourne C, Stein MB, Craske M, Fan MY, Roy-Byrne P: Incremental cost-effectiveness of a collaborative care intervention for panic disorder. Psychol Med. 2006, 36: 353-363.

  190. Cottraux J, Note ID, Cungi C, Legeron P, Heim F, Chneiweiss L, Bernard G, Bouvard M: A controlled study of cognitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia. Br J Psychiatry. 1995, 167: 635-641.

  191. Otto MW, Tolin DF, Simon NM, Pearlson GD, Basden S, Meunier SA, Hofmann SG, Eisenmenger K, Krystal JH, Pollack MH: Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry. 2010, 67: 365-370.

  192. Siegmund A, Golfels F, Finck C, Halisch A, Rath D, Plag J, Strohle A: D-cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. J Psychiatr Res. 2011, 45: 1042-1047.

  193. Nations KR, Smits JA, Tolin DF, Rothbaum BO, Hofmann SG, Tart CD, Lee A, Schipper J, Sjogren M, Xue D, et al: Evaluation of the glycine transporter inhibitor Org 25935 as augmentation to cognitive-behavioral therapy for panic disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2012, 73: 647-653.

  194. Fava GA, Rafanelli C, Grandi S, Conti S, Ruini C, Mangelli L, Belluardo P: Long-term outcome of panic disorder with agoraphobia treated by exposure. Psychol Med. 2001, 31: 891-898.

  195. Bakker A, van Balkom A, Spinhoven P: SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand. 2002, 106: 163-167.

  196. Otto MW, Tuby KS, Gould RA, McLean RY, Pollack MH: An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry. 2001, 158: 1989-1992.

  197. Andrisano C, Chiesa A, Serretti A: Newer antidepressants and panic disorder: a meta-analysis. Int Clin Psychopharmacol. 2013, 28: 33-45.

  198. Stahl SM, Gergel I, Li D: Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2003, 64: 1322-1327.

  199. Wade AG, Lepola U, Koponen HJ, Pedersen V, Pedersen T: The effect of citalopram in panic disorder. Br J Psychiatry. 1997, 170: 549-553.

  200. Seedat S, van Rheede van Oudtshoorn E, Muller JE, Mohr N, Stein DJ: Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study. Int Clin Psychopharmacol. 2003, 18: 279-284.

  201. Michelson D, Lydiard RB, Pollack MH, Tamura RN, Hoog SL, Tepner R, Demitrack MA, Tollefson GD: Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry. 1998, 155: 1570-1577.

  202. Michelson D, Allgulander C, Dantendorfer K, Knezevic A, Maierhofer D, Micev V, Paunovic V, Timotijevic I, Sarkar N, Skoglund L, Pemberton S: Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial. Br J Psychiatry. 2001, 179: 514-518.

  203. Ribeiro L, Busnello J, Kauer-Sant’Anna M, Madruga M, Quevedo J, Busnello E, Kapczinski F: Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res. 2001, 34: 1303-1307.

  204. Tiller JW, Bouwer C, Behnke K: Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. Eur Arch Psychiatry Clin Neurosci. 1999, 249 (Suppl 1): S7-10.

  205. Black DW, Wesner R, Bowers W, Gabel J: A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry. 1993, 50: 44-50.

  206. Asnis G, Hameedi F, Goddard A, Potkin S, Black D, Jameel M, Desagani K, Woods S: Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Res. 2001, 103: 1-14.

  207. Bakish D, Hooper CL, Filteau MJ, Charbonneau Y, Fraser G, West DL, Thibaudeau C, Raine D: A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacol Bull. 1996, 32: 135-141.

  208. Den Boer JA, Westenberg HG: Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology (Berl). 1990, 102: 85-94.

  209. Hoehn-Saric R, McLeod DR, Hipsley PA: Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol. 1993, 13: 321-326.

  210. Sharp DM, Power KG, Simpson RJ, Swanson V, Anstee JA: Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care. Br J Gen Pract. 1997, 47: 150-155.

  211. Bakker A, van Dyck R, Spinhoven P, van Balkom AJ: Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. J Clin Psychiatry. 1999, 60: 831-838.

  212. Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP: Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry. 1998, 155: 36-42.

  213. Lecrubier Y, Bakker A, Dunbar G, Judge R: A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand. 1997, 95: 145-152.

  214. Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, Calberg H, Judge R, Ohrstrom JK, Manniche PM: Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry. 1995, 167: 374-379.

  215. Pollack M, Mangano R, Entsuah R, Tzanis E, Simon NM, Zhang Y: A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berl). 2007, 194: 233-242.

  216. Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G, Tzanis E, Salinas E, Whitaker T, Gao B: A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety. 2007, 24: 1-14.

  217. Prosser JM, Yard S, Steele A, Cohen LJ, Galynker II: A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study. BMC Psychiatry. 2009, 9: 25-

  218. Nardi AE, Valenca AM, Freire RC, Mochcovitch MD, Amrein R, Sardinha A, Levitan MN, Nascimento I, de-Melo-Neto VL, King AL, et al: Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine. Braz J Med Biol Res. 2011, 44: 366-373.

  219. Bertani A, Perna G, Migliarese G, Di Pasquale D, Cucchi M, Caldirola D, Bellodi L: Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study. Pharmacopsychiatry. 2004, 37: 206-210.

  220. Londborg PD, Wolkow R, Smith WT, DuBoff E, England D, Ferguson J, Rosenthal M, Weise C: Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry. 1998, 173: 54-60.

  221. Pohl RB, Wolkow RM, Clary CM: Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry. 1998, 155: 1189-1195.

  222. Pollack MH, Otto MW, Worthington JJ, Manfro GG, Wolkow R: Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry. 1998, 55: 1010-1016.

  223. Pollack M, Rapaport M, Clary C, Mardekian J, Wolkow R: Sertraline treatment of panic disorder: response in patients at risk for poor outcome. J Clin Psychiatry. 2000, 61: 922-927.

  224. Lepola U, Arato M, Zhu Y, Austin C: Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. J Clin Psychiatry. 2003, 64: 654-662.

  225. Sheehan DV, Burnham DB, Iyengar MK, Perera P: Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. J Clin Psychiatry. 2005, 66: 34-40.

  226. Perna G, Dacco S, Menotti R, Caldirola D: Antianxiety medications for the treatment of complex agoraphobia: pharmacological interventions for a behavioral condition. Neuropsychiatr Dis Treat. 2011, 7: 621-637.

  227. Pollack MH, Worthington JJ, Otto MW, Maki KM, Smoller JW, Manfro GG, Rudolph R, Rosenbaum JF: Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull. 1996, 32: 667-670.

  228. Bradwejn J, Ahokas A, Stein DJ, Salinas E, Emilien G, Whitaker T: Venlafaxine extended-release capsules in panic disorder: Flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry. 2005, 187: 352-359.

  229. Liebowitz MR, Asnis G, Mangano R, Tzanis E: A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder. J Clin Psychiatry. 2009, 70: 550-561.

  230. Simon NM, Kaufman RE, Hoge EA, Worthington JJ, Herlands NN, Owens ME, Pollack MH: Open-label support for duloxetine for the treatment of panic disorder. CNS Neurosci Ther. 2009, 15: 19-23.

  231. Blaya C, Seganfredo AC, Dornelles M, Torres M, Paludo A, Heldt E, Manfro GG: The efficacy of milnacipran in panic disorder: an open trial. Int Clin Psychopharmacol. 2007, 22: 153-158.

  232. Kruger MB, Dahl AA: The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder. Eur Arch Psychiatry Clin Neurosci. 1999, 249 (Suppl 1): S19-24.

  233. Modigh K, Westberg P, Eriksson E: Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol. 1992, 12: 251-261.

  234. Cox BJ, Endler NS, Lee PS, Swinson RP: A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposure. J Behav Ther Exp Psychiatry. 1992, 23: 175-182.

  235. Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Cross-National Collaborative Panic Study, Second Phase Investigators. Br J Psychiatry. 1992, 160: 191-202. discussion 202-195

  236. Andersch S, Rosenberg NK, Kullingsjo H, Ottosson JO, Bech P, Bruun-Hansen J, Hanson L, Lorentzen K, Mellergard M, Rasmussen S, et al: Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta Psychiatr Scand Suppl. 1991, 365: 18-27.

  237. Taylor CB, Hayward C, King R, Ehlers A, Margraf J, Maddock R, Clark D, Roth WT, Agras WS: Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 1990, 10: 112-118.

  238. Barlow D, Gorman J, Shear M, Woods S: Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA. 2000, 283: 2529-2536.

  239. Marchand A, Coutu MF, Dupuis G, Fleet R, Borgeat F, Todorov C, Mainguy N: Treatment of panic disorder with agoraphobia: randomized placebo-controlled trial of four psychosocial treatments combined with imipramine or placebo. Cogn Behav Ther. 2008, 37: 146-159.

  240. Sheehan DV, Ballenger J, Jacobsen G: Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry. 1980, 37: 51-59.

  241. Uhlenhuth EH, Warner TD, Matuzas W: Interactive model of therapeutic response in panic disorder: moclobemide, a case in point. J Clin Psychopharmacol. 2002, 22: 275-284.

  242. Loerch B, Graf-Morgenstern M, Hautzinger M, Schlegel S, Hain C, Sandmann J, Benkert O: Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia. Br J Psychiatry. 1999, 174: 205-212.

  243. Nardi AE, Lopes FL, Valenca AM, Freire RC, Nascimento I, Veras AB, Mezzasalma MA, de-Melo-Neto VL, Soares-Filho GL, King AL, et al: Double-blind comparison of 30 and 60 mg tranylcypromine daily in patients with panic disorder comorbid with social anxiety disorder. Psychiatry Res. 2010, 175: 260-265.

  244. Versiani M, Cassano G, Perugi G, Benedetti A, Mastalli L, Nardi A, Savino M: Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry. 2002, 63: 31-37.

  245. Boshuisen M, Slaap B, Vester-Blokland E, den Boer J: The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period. Int Clin Psychopharmacol. 2001, 16: 363-368.

  246. Sarchiapone M, Amore M, De Risio S, Carli V, Faia V, Poterzio F, Balista C, Camardese G, Ferrari G: Mirtazapine in the treatment of panic disorder: an open-label trial. Int Clin Psychopharmacol. 2003, 18: 35-38.

  247. Sheehan DV, Davidson J, Manschreck T, Van Wyck Fleet J: Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. J Clin Psychopharmacol. 1983, 3: 28-31.

  248. Simon NM, Emmanuel N, Ballenger J, Worthington JJ, Kinrys G, Korbly NB, Farach FJ, Pollack MH: Bupropion sustained release for panic disorder. Psychopharmacol Bull. 2003, 37: 66-72.

  249. Boyer W: Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol. 1995, 10: 45-49.

  250. Tesar GE, Rosenbaum JF, Pollack MH, Otto MW, Sachs GS, Herman JB, Cohen LS, Spier SA: Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry. 1991, 52: 69-76.

  251. Schweizer E, Pohl R, Balon R, Fox I, Rickels K, Yeragani VK: Lorazepam vs. alprazolam in the treatment of panic disorder. Pharmacopsychiatry. 1990, 23: 90-93.

  252. Moylan S, Staples J, Ward SA, Rogerson J, Stein DJ, Berk M: The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder. J Clin Psychopharmacol. 2011, 31: 647-652.

  253. Marquez M, Arenoso H, Caruso N: Efficacy of alprazolam sublingual tablets in the treatment of the acute phase of panic disorders. Actas Esp Psiquiatr. 2011, 39: 88-94.

  254. Sheehan D, Raj A, Harnett-Sheehan K, Soto S, Knapp E: The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr Scand. 1993, 88: 1-11.

  255. Beauclair L, Fontaine R, Annable L, Holobow N, Chouinard G: Clonazepam in the treatment of panic disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. J Clin Psychopharmacol. 1994, 14: 111-118.

  256. Moroz G, Rosenbaum JF: Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages. J Clin Psychiatry. 1999, 60: 604-612.

  257. Rosenbaum JF, Moroz G, Bowden CL: Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. Clonazepam Panic Disorder Dose-Response Study Group. J Clin Psychopharmacol. 1997, 17: 390-400.

  258. Valenca A, Nardi A, Nascimento I, Mezzasalma M, Lopes F, Zin W: Double-blind clonazepam vs placebo in panic disorder treatment. Arq Neuropsiquiatr. 2000, 58: 1025-1029.

  259. Charney DS, Woods SW: Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam. J Clin Psychiatry. 1989, 50: 418-423.

  260. de Jonghe F, Swinkels J, Tuynman-Qua H, Jonkers F: A comparative study of suriclone, lorazepam and placebo in anxiety disorder. Pharmacopsychiatry. 1989, 22: 266-271.

  261. Dunner DL, Ishiki D, Avery DH, Wilson LG, Hyde TS: Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study. J Clin Psychiatry. 1986, 47: 458-460.

  262. Noyes R, Anderson DJ, Clancy J, Crowe RR, Slymen DJ, Ghoneim MM, Hinrichs JV: Diazepam and propranolol in panic disorder and agoraphobia. Arch Gen Psychiatry. 1984, 41: 287-292.

  263. Noyes R, Burrows GD, Reich JH, Judd FK, Garvey MJ, Norman TR, Cook BL, Marriott P: Diazepam versus alprazolam for the treatment of panic disorder. J Clin Psychiatry. 1996, 57: 349-355.

  264. Pollack MH, Simon NM, Worthington JJ, Doyle AL, Peters P, Toshkov F, Otto MW: Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol. 2003, 17: 276-282.

  265. Goddard AW, Brouette T, Almai A, Jetty P, Woods SW, Charney D: Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry. 2001, 58: 681-686.

  266. Katzelnick DJ, Saidi J, Vanelli MR, Jefferson JW, Harper JM, McCrary KE: Time to response in panic disorder in a naturalistic setting: combination therapy with alprazolam orally disintegrating tablets and serotonin reuptake inhibitors compared to serotonin reuptake inhibitors alone. Psychiatry (Edgmont). 2006, 3: 39-49.

  267. Galynker I, Khan A, Grebchenko Y, Ten A, Malaya L, Yanowitch P, Cohen LJ: Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression [Letter]. J Clin Psychiatry. 2005, 66: 544-

  268. Hollifield M, Thompson PM, Ruiz JE, Uhlenhuth EH: Potential effectiveness and safety of olanzapine in refractory panic disorder. Depress Anxiety. 2005, 21: 33-40.

  269. Hoge EA, Worthington JJ, Kaufman RE, Delong HR, Pollack MH, Simon NM: Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectr. 2008, 13: 522-527.

  270. Sepede G, De Berardis D, Gambi F, Campanella D, La Rovere R, D’Amico M, Cicconetti A, Penna L, Peca S, Carano A, et al: Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. J Clin Psychopharmacol. 2006, 26: 45-49.

  271. Simon NM, Hoge EA, Fischmann D, Worthington JJ, Christian KM, Kinrys G, Pollack MH: An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry. 2006, 67: 381-385.

  272. Baetz M, Bowen RC: Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can J Psychiatry. 1998, 43: 73-77.

  273. Keck PE, Taylor VE, Tugrul KC, McElroy SL, Bennett JA: Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry. 1993, 33: 542-546.

  274. Woodman CL, Noyes R: Panic disorder: treatment with valproate. J Clin Psychiatry. 1994, 55: 134-136.

  275. Primeau F, Fontaine R, Beauclair L: Valproic acid and panic disorder. Can J Psychiatry. 1990, 35: 248-250.

  276. Papp LA: Safety and efficacy of levetiracetam for patients with panic disorder: results of an open-label, fixed-flexible dose study. J Clin Psychiatry. 2006, 67: 1573-1576.

  277. Pande AC, Pollack MH, Crockatt J, Greiner M, Chouinard G, Lydiard RB, Taylor CB, Dager SR, Shiovitz T: Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol. 2000, 20: 467-471.

  278. Zwanzger P, Eser D, Nothdurfter C, Baghai TC, Moller HJ, Padberg F, Rupprecht R: Effects of the GABA-reuptake inhibitor tiagabine on panic and anxiety in patients with panic disorder. Pharmacopsychiatry. 2009, 42: 266-269.

  279. Sheehan DV, Sheehan KH, Raj BA, Janavs J: An open-label study of tiagabine in panic disorder. Psychopharmacol Bull. 2007, 40: 32-40.

  280. Uhde TW, Stein MB, Post RM: Lack of efficacy of carbamazepine in the treatment of panic disorder. Am J Psychiatry. 1988, 145: 1104-1109.

  281. Perugi G, Frare F, Toni C, Tusini G, Vannucchi G, Akiskal HS: Adjunctive valproate in panic disorder patients with comorbid bipolar disorder or otherwise resistant to standard antidepressants: a 3-year “open” follow-up study. Eur Arch Psychiatry Clin Neurosci. 2010, 260: 553-560.

  282. Sheehan DV, Raj AB, Sheehan KH, Soto S: Is buspirone effective for panic disorder?. J Clin Psychopharmacol. 1990, 10: 3-11.

  283. Charney DS, Woods SW, Goodman WK, Rifkin B, Kinch M, Aiken B, Quadrino LM, Heninger GR: Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone. J Clin Psychiatry. 1986, 47: 580-586.

  284. Munjack DJ, Crocker B, Cabe D, Brown R, Usigli R, Zulueta A, McManus M, McDowell D, Palmer R, Leonard M: Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. J Clin Psychopharmacol. 1989, 9: 22-27.

  285. Ravaris CL, Friedman MJ, Hauri PJ, McHugo GJ: A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients. J Clin Psychopharmacol. 1991, 11: 344-350.

  286. Hirschmann S, Dannon PN, Iancu I, Dolberg OT, Zohar J, Grunhaus L: Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2000, 20: 556-559.

  287. Lepola UM, Wade AG, Leinonen EV, Koponen HJ, Frazer J, Sjodin I, Penttinen JT, Pedersen T, Lehto HJ: A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry. 1998, 59: 528-534.

  288. Dannon PN, Iancu I, Lowengrub K, Gonopolsky Y, Musin E, Grunhaus L, Kotler M: A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder. Clin Neuropharmacol. 2007, 30: 326-334.

  289. Lecrubier Y, Judge R: Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand. 1997, 95: 153-160.

  290. Nardi AE, Freire RC, Mochcovitch MD, Amrein R, Levitan MN, King AL, Valenca AM, Veras AB, Paes F, Sardinha A, et al: A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine. J Clin Psychopharmacol. 2012, 32: 120-126.

  291. Curtis GC, Massana J, Udina C, Ayuso JL, Cassano GB, Perugi G: Maintenance drug therapy of panic disorder. J Psychiatr Res. 1993, 27 (Suppl 1): 127-142.

  292. Mavissakalian M, Perel JM: Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry. 1992, 49: 318-323.

  293. Rickels K, Schweizer E: Panic disorder: long-term pharmacotherapy and discontinuation. J Clin Psychopharmacol. 1998, 18: 12S-18S.

  294. Ferguson JM, Khan A, Mangano R, Entsuah R, Tzanis E: Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release. J Clin Psychiatry. 2007, 68: 58-68.

  295. Mavissakalian MR, Perel JM: Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry. 1999, 56: 821-827.

  296. Nardi AE, Freire RC, Valenca AM, Amrein R, de Cerqueira AC, Lopes FL, Nascimento I, Mezzasalma MA, Veras AB, Sardinha A, et al: Tapering clonazepam in patients with panic disorder after at least 3 years of treatment. J Clin Psychopharmacol. 2010, 30: 290-293.

  297. Mannu P, Rinaldi S, Fontani V, Castagna A, Margotti ML: Noninvasive brain stimulation by radioelectric asymmetric conveyor in the treatment of agoraphobia: open-label, naturalistic study. Patient Prefer Adherence. 2011, 5: 575-580.

  298. Mannu P, Rinaldi S, Fontani V, Castagna A, Margotti ML: Radio electric treatment vs. escitalopram in the treatment of panic disorders associated with major depression: an open-label, naturalistic study. Acupunct Electrother Res. 2009, 34: 135-149.

  299. Mantovani A, Lisanby SH, Pieraccini F, Ulivelli M, Castrogiovanni P, Rossi S: Repetitive transcranial magnetic stimulation (rTMS) in the treatment of panic disorder (PD) with comorbid major depression. J Affect Disord. 2007, 102: 277-280.

  300. Prasko J, Zalesky R, Bares M, Horacek J, Kopecek M, Novak T, Paskova B: The effect of repetitive transcranial magnetic stimulation (rTMS) add on serotonin reuptake inhibitors in patients with panic disorder: a randomized, double blind sham controlled study. Neuro Endocrinol Lett. 2007, 28: 33-38.

  301. Meuret AE, Rosenfield D, Seidel A, Bhaskara L, Hofmann SG: Respiratory and cognitive mediators of treatment change in panic disorder: evidence for intervention specificity. J Consult Clin Psychol. 2010, 78: 691-704.

  302. Wollburg E, Roth WT, Kim S: Effects of breathing training on voluntary hypo- and hyperventilation in patients with panic disorder and episodic anxiety. Appl Psychophysiol Biofeedback. 2011, 36: 81-91.

  303. Wedekind D, Broocks A, Weiss N, Engel K, Neubert K, Bandelow B: A randomized, controlled trial of aerobic exercise in combination with paroxetine in the treatment of panic disorder. World J Biol Psychiatry. 2010, 11: 904-913.

  304. Strohle A, Graetz B, Scheel M, Wittmann A, Feller C, Heinz A, Dimeo F: The acute antipanic and anxiolytic activity of aerobic exercise in patients with panic disorder and healthy control subjects. J Psychiatr Res. 2009, 43: 1013-1017.

  305. Stinson FS, Dawson DA, Patricia Chou S, Smith S, Goldstein RB, June Ruan W, Grant BF: The epidemiology of DSM-IV specific phobia in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 2007, 37: 1047-1059.

  306. LeBeau RT, Glenn D, Liao B, Wittchen HU, Beesdo-Baum K, Ollendick T, Craske MG: Specific phobia: a review of DSM-IV specific phobia and preliminary recommendations for DSM-V. Depress Anxiety. 2010, 27: 148-167.

  307. Becker ES, Rinck M, Turke V, Kause P, Goodwin R, Neumer S, Margraf J: Epidemiology of specific phobia subtypes: findings from the Dresden Mental Health Study. Eur Psychiatry. 2007, 22: 69-74.

  308. Benjet C, Borges G, Stein D, Mendez E, Medina-Mora M: Epidemiology of fears and specific phobia in adolescence: results from the Mexican Adolescent Mental Health Survey. J Clin Psychiatry. 2012, 73: 152-158.

  309. Trumpf J, Margraf J, Vriends N, Meyer AH, Becker ES: Specific phobia predicts psychopathology in young women. Soc Psychiatry Psychiatr Epidemiol. 2010, 45: 1161-1166.

  310. Choy Y, Fyer AJ, Goodwin RD: Specific phobia and comorbid depression: a closer look at the National Comorbidity Survey data. Compr Psychiatry. 2007, 48: 132-136.

  311. Hood H, Antony M: Evidence-based assessment and treatment of specific phobias in adults, Chapt.2. Intensive one-session treatment of specific phobias. Edited by: Davis T, Ollendick T, Öst L-G. 2012, New York: Springer, 19-42. Autism and Child Psychopathology Series

  312. Parsons TD, Rizzo AA: Affective outcomes of virtual reality exposure therapy for anxiety and specific phobias: a meta-analysis. J Behav Ther Exp Psychiatry. 2008, 39: 250-261.

  313. Ollendick TH, Ost LG, Reuterskiold L, Costa N, Cederlund R, Sirbu C, Davis TE, Jarrett MA: One-session treatment of specific phobias in youth: a randomized clinical trial in the United States and Sweden. J Consult Clin Psychol. 2009, 77: 504-516.

  314. Craske MG, Kircanski K, Zelikowsky M, Mystkowski J, Chowdhury N, Baker A: Optimizing inhibitory learning during exposure therapy. Behav Res Ther. 2008, 46: 5-27.

  315. Öst L-G, Fellenius J, Sterner U: Applied tension, exposure in vivo, and tension-only in the treatment of blood phobia. Behav Res Ther. 1991, 29: 561-574.

  316. Hellstrom K, Fellenius J, Öst L-G: One versus five sessions of applied tension in the treatment of blood phobia. Behav Res Ther. 1996, 34: 101-112.

  317. Kettwich SC, Sibbitt WL, Brandt JR, Johnson CR, Wong CS, Bankhurst AD: Needle phobia and stress-reducing medical devices in pediatric and adult chemotherapy patients. J Pediatr Oncol Nurs. 2007, 24: 20-28.

  318. Vika M, Skaret E, Raadal M, Ost LG, Kvale G: One- vs. five-session treatment of intra-oral injection phobia: a randomized clinical study. Eur J Oral Sci. 2009, 117: 279-285.

  319. Krijn M, Emmelkamp PM, Olafsson RP, Bouwman M, van Gerwen LJ, Spinhoven P, Schuemie MJ, van der Mast CA: Fear of flying treatment methods: virtual reality exposure vs. cognitive behavioral therapy. Aviat Space Environ Med. 2007, 78: 121-128.

  320. Van Gerwen LJ, Spinhoven P, Van Dyck R: Behavioral and cognitive group treatment for fear of flying: a randomized controlled trial. J Behav Ther Exp Psychiatry. 2006, 37: 358-371.

  321. Wiederhold BK, Jang DP, Gevirtz RG, Kim SI, Kim IY, Wiederhold MD: The treatment of fear of flying: a controlled study of imaginal and virtual reality graded exposure therapy. IEEE Trans Inf Technol Biomed. 2002, 6: 218-223.

  322. Rothbaum BO, Hodges L, Smith S, Lee JH, Price L: A controlled study of virtual reality exposure therapy for the fear of flying. J Consult Clin Psychol. 2000, 68: 1020-1026.

  323. Tortella-Feliu M, Botella C, Llabres J, Breton-Lopez JM, del Amo AR, Banos RM, Gelabert JM: Virtual reality versus computer-aided exposure treatments for fear of flying. Behav Modif. 2011, 35: 3-30.

  324. Rothbaum BO, Anderson P, Zimand E, Hodges L, Lang D, Wilson J: Virtual reality exposure therapy and standard (in vivo) exposure therapy in the treatment of fear of flying. Behav Ther. 2006, 37: 80-90.

  325. Kim S, Palin F, Anderson P, Edwards S, Lindner G, Rothbaum BO: Use of skills learned in CBT for fear of flying: managing flying anxiety after September 11th. J Anxiety Disord. 2008, 22: 301-309.

  326. Anderson P, Jacobs CH, Lindner GK, Edwards S, Zimand E, Hodges L, Rothbaum BO: Cognitive behavior therapy for fear of flying: sustainability of treatment gains after September 11. Behav Ther. 2006, 37: 91-97.

  327. Emmelkamp PM, Krijn M, Hulsbosch AM, de Vries S, Schuemie MJ, van der Mast CA: Virtual reality treatment versus exposure in vivo: a comparative evaluation in acrophobia. Behav Res Ther. 2002, 40: 509-516.

  328. Rothbaum BO, Hodges LF, Kooper R, Opdyke D, Williford JS, North M: Effectiveness of computer-generated (virtual reality) graded exposure in the treatment of acrophobia. Am J Psychiatry. 1995, 152: 626-628.

  329. Krijn M, Emmelkamp PM, Olafsson RP, Schuemie MJ, van der Mast CA: Do self-statements enhance the effectiveness of virtual reality exposure therapy? A comparative evaluation in acrophobia. Cyberpsychol Behav. 2007, 10: 362-370.

  330. Malbos E, Mestre DR, Note ID, Gellato C: Virtual reality and claustrophobia: multiple components therapy involving game editor virtual environments exposure. Cyberpsychol Behav. 2008, 11: 695-697.

  331. Michaliszyn D, Marchand A, Bouchard S, Martel MO, Poirier-Bisson J: A randomized, controlled clinical trial of in virtuo and in vivo exposure for spider phobia. Cyberpsychol Behav Soc Netw. 2010, 13: 689-695.

  332. Bouchard S, Cote S, St-Jacques J, Robillard G, Renaud P: Effectiveness of virtual reality exposure in the treatment of arachnophobia using 3D games. Technol Health Care. 2006, 14: 19-27.

  333. Granado LC, Ranvaud R, Pelaez JR: A spiderless arachnophobia therapy: comparison between placebo and treatment groups and six-month follow-up study. Neural Plast. 2007, 2007: 10241-

  334. Andersson G, Waara J, Jonsson U, Malmaeus F, Carlbring P, Ost LG: Internet-based self-help versus one-session exposure in the treatment of spider phobia: a randomized controlled trial. Cogn Behav Ther. 2009, 38: 114-120.

  335. Muller BH, Kull S, Wilhelm FH, Michael T: One-session computer-based exposure treatment for spider-fearful individuals–efficacy of a minimal self-help intervention in a randomised controlled trial. J Behav Ther Exp Psychiatry. 2011, 42: 179-184.

  336. Botella C, Quero S, Banos RM, Garcia-Palacios A, Breton-Lopez J, Alcaniz M, Fabregat S: Telepsychology and self-help: the treatment of phobias using the internet. Cyberpsychol Behav. 2008, 11: 659-664.

  337. Botella C, Breton-Lopez J, Quero S, Banos R, Garcia-Palacios A: Treating cockroach phobia with augmented reality. Behav Ther. 2010, 41: 401-413.

  338. Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, Hodges L, Davis M: Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry. 2004, 61: 1136-1144.

  339. Guastella AJ, Dadds MR, Lovibond PF, Mitchell P, Richardson R: A randomized controlled trial of the effect of d-cycloserine on exposure therapy for spider fear. J Psychiatr Res. 2007, 41: 466-471.

  340. de Quervain DJ, Bentz D, Michael T, Bolt OC, Wiederhold BK, Margraf J, Wilhelm FH: Glucocorticoids enhance extinction-based psychotherapy. Proc Natl Acad Sci U S A. 2011, 108: 6621-6625.

  341. Soravia LM, Heinrichs M, Aerni A, Maroni C, Schelling G, Ehlert U, Roozendaal B, de Quervain DJ: Glucocorticoids reduce phobic fear in humans. Proc Natl Acad Sci U S A. 2006, 103: 5585-5590.

  342. Meyerbroeker K, Powers MB, van Stegeren A, Emmelkamp PM: Does yohimbine hydrochloride facilitate fear extinction in virtual reality treatment of fear of flying? A randomized placebo-controlled trial. Psychother Psychosom. 2012, 81: 29-37.

  343. Powers MB, Smits JA, Otto MW, Sanders C, Emmelkamp PM: Facilitation of fear extinction in phobic participants with a novel cognitive enhancer: a randomized placebo controlled trial of yohimbine augmentation. J Anxiety Disord. 2009, 23: 350-356.

  344. Kozak AT, Spates CR, McChargue DE, Bailey KC, Schneider KL, Liepman MR: Naltrexone renders one-session exposure therapy less effective: a controlled pilot study. J Anxiety Disord. 2007, 21: 142-152.

  345. Benjamin J, Ben-Zion I, Karbofsky E, Dannon P: Double-blind placebo-controlled pilot study of paroxetine for specific phobia. Psychopharmacology (Berl). 2000, 149: 194-196.

  346. Alamy S, Wei Z, Varia I, Davidson JR, Connor KM: Escitalopram in specific phobia: results of a placebo-controlled pilot trial. J Psychopharmacol. 2008, 22: 157-161.

  347. Abene MV, Hamilton JD: Resolution of fear of flying with fluoxetine treatment. J Anxiety Disord. 1998, 12: 599-603.

  348. Balon R: Fluvoxamine for phobia of storms. Acta Psychiatr Scand. 1999, 100: 244-245. discussion 245-246

  349. Choy Y, Fyer AJ, Lipsitz JD: Treatment of specific phobia in adults. Clin Psychol Rev. 2007, 27: 266-286.

  350. Wilhelm FH, Roth WT: Acute and delayed effects of alprazolam on flight phobics during exposure. Behav Res Ther. 1997, 35: 831-841.

  351. Johren P, Jackowski J, Gangler P, Sartory G, Thom A: Fear reduction in patients with dental treatment phobia. Br J Oral Maxillofac Surg. 2000, 38: 612-616.

  352. Tschirch FT, Suter K, Froehlich JM, Studler U, Nidecker A, Eckhardt B, Beranek-Chiu J, Surber C, Weishaupt D: Multicenter trial: comparison of two different formulations and application systems of low-dose nasal midazolam for routine magnetic resonance imaging of claustrophobic patients. J Magn Reson Imaging. 2008, 28: 866-872.

  353. Tschirch FT, Gopfert K, Frohlich JM, Brunner G, Weishaupt D: Low-dose intranasal versus oral midazolam for routine body MRI of claustrophobic patients. Eur Radiol. 2007, 17: 1403-1410.

  354. Mather AA, Stein MB, Sareen J: Social anxiety disorder and social fears in the Canadian military: prevalence, comorbidity, impairment, and treatment-seeking. J Psychiatr Res. 2010, 44: 887-893.

  355. Beesdo K, Bittner A, Pine DS, Stein MB, Hofler M, Lieb R, Wittchen HU: Incidence of social anxiety disorder and the consistent risk for secondary depression in the first three decades of life. Arch Gen Psychiatry. 2007, 64: 903-912.

  356. Shields M: Social anxiety disorder–beyond shyness. Health Rep. 2004, 15 (Suppl): 45-61.

  357. Magee W, Eaton W, Wittchen H, McGonagle K, Kessler R: Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry. 1996, 53: 159-168.

  358. Stein M, Walker J, Forde D: Setting diagnostic thresholds for social phobia: considerations from a community survey of social anxiety. Am J Psychiatry. 1994, 151: 408-412.

  359. Schneier F, Johnson J, Hornig C, Liebowitz M, Weissman M: Social phobia. Comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry. 1992, 49: 282-288.

  360. Ohayon MM, Schatzberg AF: Social phobia and depression: prevalence and comorbidity. J Psychosom Res. 2010, 68: 235-243.

  361. Stein DJ, Ruscio AM, Lee S, Petukhova M, Alonso J, Andrade LH, Benjet C, Bromet E, Demyttenaere K, Florescu S, et al: Subtyping social anxiety disorder in developed and developing countries. Depress Anxiety. 2010, 27: 390-403.

  362. Ramsawh HJ, Raffa SD, Edelen MO, Rende R, Keller MB: Anxiety in middle adulthood: effects of age and time on the 14-year course of panic disorder, social phobia and generalized anxiety disorder. Psychol Med. 2009, 39: 615-624.

  363. Ruscio AM, Brown TA, Chiu WT, Sareen J, Stein MB, Kessler RC: Social fears and social phobia in the USA: results from the National Comorbidity Survey Replication. Psychol Med. 2008, 38: 15-28.

  364. Acarturk C, Smit F, de Graaf R, van Straten A, ten Have M, Cuijpers P: Incidence of social phobia and identification of its risk indicators: a model for prevention. Acta Psychiatr Scand. 2009, 119: 62-70.

  365. Kessler R, Stein M, Berglund P: Social phobia subtypes in the National Comorbidity Survey. Am J Psychiatry. 1998, 155: 613-619.

  366. Wong N, Sarver DE, Beidel DC: Quality of life impairments among adults with social phobia: the impact of subtype. J Anxiety Disord. 2012, 26: 50-57.

  367. Aderka IM, Hofmann SG, Nickerson A, Hermesh H, Gilboa-Schechtman E, Marom S: Functional impairment in social anxiety disorder. J Anxiety Disord. 2012, 26: 393-400.

  368. Tolman RM, Himle J, Bybee D, Abelson JL, Hoffman J, Van Etten-Lee M: Impact of social anxiety disorder on employment among women receiving welfare benefits. Psychiatr Serv. 2009, 60: 61-66.

  369. Moitra E, Beard C, Weisberg RB, Keller MB: Occupational impairment and social anxiety disorder in a sample of primary care patients. J Affect Disord. 2011, 130: 209-212.

  370. Acarturk C, Smit F, de Graaf R, van Straten A, Ten Have M, Cuijpers P: Economic costs of social phobia: a population-based study. J Affect Disord. 2009, 115: 421-429.

  371. Smit F, Cuijpers P, Oostenbrink J, Batelaan N, de Graaf R, Beekman A: Costs of nine common mental disorders: implications for curative and preventive psychiatry. J Ment Health Policy Econ. 2006, 9: 193-200.

  372. Filho AS, Hetem LA, Ferrari MC, Trzesniak C, Martin-Santos R, Borduqui T, de Lima Osorio F, Loureiro SR, Busatto Filho G, Zuardi AW, Crippa JA: Social anxiety disorder: what are we losing with the current diagnostic criteria?. Acta Psychiatr Scand. 2010, 121: 216-226.

  373. Cox BJ, Turnbull DL, Robinson JA, Grant BF, Stein MB: The effect of avoidant personality disorder on the persistence of generalized social anxiety disorder in the general population: results from a longitudinal, nationally representative mental health survey. Depress Anxiety. 2011, 28: 250-255.

  374. Kelly MM, Walters C, Phillips KA: Social anxiety and its relationship to functional impairment in body dysmorphic disorder. Behav Ther. 2010, 41: 143-153.

  375. Coles ME, Phillips KA, Menard W, Pagano ME, Fay C, Weisberg RB, Stout RL: Body dysmorphic disorder and social phobia: cross-sectional and prospective data. Depress Anxiety. 2006, 23: 26-33.

  376. Book SW, Thomas SE, Randall PK, Randall CL: Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder. J Anxiety Disord. 2008, 22: 310-318.

  377. Bernardi S, Faraone SV, Cortese S, Kerridge BT, Pallanti S, Wang S, Blanco C: The lifetime impact of attention deficit hyperactivity disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Psychol Med. 2012, 42: 875-887.

  378. Van Ameringen M, Mancini C, Simpson W, Patterson B: Adult attention deficit hyperactivity disorder in an anxiety disorders population. CNS Neurosci Ther. 2011, 17: 221-226.

  379. Stern RG, Petti TA, Bopp K, Tobia A: Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: an open-label cross-taper study. J Clin Psychopharmacol. 2009, 29: 206-209.

  380. Bogels SM, Alden L, Beidel DC, Clark LA, Pine DS, Stein MB, Voncken M: Social anxiety disorder: questions and answers for the DSM-V. Depress Anxiety. 2010, 27: 168-189.

  381. Taylor S: Meta-analysis of cognitive-behavioral treatments for social phobia. J Behav Ther Exp Psychiatry. 1996, 27: 1-9.

  382. Clark DM, Ehlers A, McManus F, Hackmann A, Fennell M, Campbell H, Flower T, Davenport C, Louis B: Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol. 2003, 71: 1058-1067.

  383. Clark D, Agras W: The assessment and treatment of performance anxiety in musicians. Am J Psychiatry. 1991, 148: 598-605.

  384. Heimberg R, Liebowitz M, Hope D, Schneier F, Holt C, Welkowitz L, Juster H, Campeas R, Bruch M, Cloitre M, et al: Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry. 1998, 55: 1133-1141.

  385. Otto M, Pollack M, Gould R, Worthington J, McArdle E, Rosenbaum J: A comparison of the efficacy of clonazepam and cognitive-behavioral group therapy for the treatment of social phobia. J Anxiety Disord. 2000, 14: 345-358.

  386. Gelernter C, Uhde T, Cimbolic P, Arnkoff D, Vittone B, Tancer M, Bartko J: Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. Arch Gen Psychiatry. 1991, 48: 938-945.

  387. Davidson JR, Foa EB, Huppert JD, Keefe FJ, Franklin ME, Compton JS, Zhao N, Connor KM, Lynch TR, Gadde KM: Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry. 2004, 61: 1005-1013.

  388. Liebowitz M, Heimberg R, Schneier F, Hope D, Davies S, Holt C, Goetz D, Juster H, Lin S, Bruch M, et al: Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome. Depress Anxiety. 1999, 10: 89-98.

  389. Haug T, Blomhoff S, Hellstrom K, Holme I, Humble M, Madsbu H, Wold J: Exposure therapy and sertraline in social phobia: I-year follow-up of a randomised controlled trial. Br J Psychiatry. 2003, 182: 312-318.

  390. Stangier U, Heidenreich T, Peitz M, Lauterbach W, Clark DM: Cognitive therapy for social phobia: individual versus group treatment. Behav Res Ther. 2003, 41: 991-1007.

  391. Mortberg E, Clark DM, Sundin O, Aberg Wistedt A: Intensive group cognitive treatment and individual cognitive therapy vs. treatment as usual in social phobia: a randomized controlled trial. Acta Psychiatr Scand. 2007, 115: 142-154.

  392. Hofmann SG: Cognitive mediation of treatment change in social phobia. J Consult Clin Psychol. 2004, 72: 393-399.

  393. Salaberria K, Echeburua E: Long-term outcome of cognitive therapy’s contribution to self-exposure in vivo to the treatment of generalized social phobia. Behav Modif. 1998, 22: 262-284.

  394. Clark DM, Ehlers A, Hackmann A, McManus F, Fennell M, Grey N, Waddington L, Wild J: Cognitive therapy versus exposure and applied relaxation in social phobia: a randomized controlled trial. J Consult Clin Psychol. 2006, 74: 568-578.

  395. Borgeat F, Stankovic M, Khazaal Y, Rouget BW, Baumann MC, Riquier F, O’Connor K, Jermann F, Zullino D, Bondolfi G: Does the form or the amount of exposure make a difference in the cognitive-behavioral therapy treatment of social phobia?. J Nerv Ment Dis. 2009, 197: 507-513.

  396. Smits JA, Powers MB, Buxkamper R, Telch MJ: The efficacy of videotape feedback for enhancing the effects of exposure-based treatment for social anxiety disorder: a controlled investigation. Behav Res Ther. 2006, 44: 1773-1785.

  397. Alden LE, Taylor CT: Relational treatment strategies increase social approach behaviors in patients with generalized social anxiety disorder. J Anxiety Disord. 2011, 25: 309-318.

  398. Lipsitz JD, Gur M, Vermes D, Petkova E, Cheng J, Miller N, Laino J, Liebowitz MR, Fyer AJ: A randomized trial of interpersonal therapy versus supportive therapy for social anxiety disorder. Depress Anxiety. 2008, 25: 542-553.

  399. Stangier U, Schramm E, Heidenreich T, Berger M, Clark DM: Cognitive therapy vs interpersonal psychotherapy in social anxiety disorder: a randomized controlled trial. Arch Gen Psychiatry. 2011, 68: 692-700.

  400. Borge FM, Hoffart A, Sexton H, Clark DM, Markowitz JC, McManus F: Residential cognitive therapy versus residential interpersonal therapy for social phobia: a randomized clinical trial. J Anxiety Disord. 2008, 22: 991-1010.

  401. Koszycki D, Benger M, Shlik J, Bradwejn J: Randomized trial of a meditation-based stress reduction program and cognitive behavior therapy in generalized social anxiety disorder. Behav Res Ther. 2007, 45: 2518-2526.

  402. Schmidt NB, Richey JA, Buckner JD, Timpano KR: Attention training for generalized social anxiety disorder. J Abnorm Psychol. 2009, 118: 5-14.

  403. Li S, Tan J, Qian M, Liu X: Continual training of attentional bias in social anxiety. Behav Res Ther. 2008, 46: 905-912.

  404. Berger T, Hohl E, Caspar F: Internet-based treatment for social phobia: a randomized controlled trial. J Clin Psychol. 2009, 65: 1021-1035.

  405. Carlbring P, Gunnarsdottir M, Hedensjo L, Andersson G, Ekselius L, Furmark T: Treatment of social phobia: randomised trial of internet-delivered cognitive-behavioural therapy with telephone support. Br J Psychiatry. 2007, 190: 123-128.

  406. Titov N, Andrews G, Choi I, Schwencke G, Mahoney A: Shyness 3: randomized controlled trial of guided versus unguided Internet-based CBT for social phobia. Aust N Z J Psychiatry. 2008, 42: 1030-1040.

  407. Titov N, Andrews G, Schwencke G: Shyness 2: treating social phobia online: replication and extension. Aust N Z J Psychiatry. 2008, 42: 595-605.

  408. Titov N, Andrews G, Schwencke G, Drobny J, Einstein D: Shyness 1: distance treatment of social phobia over the Internet. Aust N Z J Psychiatry. 2008, 42: 585-594.

  409. Andersson G, Carlbring P, Holmstrom A, Sparthan E, Furmark T, Nilsson-Ihrfelt E, Buhrman M, Ekselius L: Internet-based self-help with therapist feedback and in vivo group exposure for social phobia: a randomized controlled trial. J Consult Clin Psychol. 2006, 74: 677-686.

  410. Furmark T, Carlbring P, Hedman E, Sonnenstein A, Clevberger P, Bohman B, Eriksson A, Hallen A, Frykman M, Holmstrom A, et al: Guided and unguided self-help for social anxiety disorder: randomised controlled trial. Br J Psychiatry. 2009, 195: 440-447.

  411. Berger T, Caspar F, Richardson R, Kneubuhler B, Sutter D, Andersson G: Internet-based treatment of social phobia: a randomized controlled trial comparing unguided with two types of guided self-help. Behav Res Ther. 2011, 49: 158-169.

  412. Rapee RM, Abbott MJ, Baillie AJ, Gaston JE: Treatment of social phobia through pure self-help and therapist-augmented self-help. Br J Psychiatry. 2007, 191: 246-252.

  413. Tillfors M, Carlbring P, Furmark T, Lewenhaupt S, Spak M, Eriksson A, Westling BE, Andersson G: Treating university students with social phobia and public speaking fears: Internet delivered self-help with or without live group exposure sessions. Depress Anxiety. 2008, 25: 708-717.

  414. Hedman E, Andersson G, Ljotsson B, Andersson E, Ruck C, Mortberg E, Lindefors N: Internet-based cognitive behavior therapy vs. cognitive behavioral group therapy for social anxiety disorder: a randomized controlled non-inferiority trial. PLoS One. 2011, 6: e18001-

  415. Andrews G, Davies M, Titov N: Effectiveness randomized controlled trial of face to face versus Internet cognitive behaviour therapy for social phobia. Aust N Z J Psychiatry. 2011, 45: 337-340.

  416. Hedman E, Andersson E, Ljotsson B, Andersson G, Ruck C, Lindefors N: Cost-effectiveness of Internet-based cognitive behavior therapy vs. cognitive behavioral group therapy for social anxiety disorder: results from a randomized controlled trial. Behav Res Ther. 2011, 49: 729-736.

  417. Prasko J, Dockery C, Horacek J, Houbova P, Kosova J, Klaschka J, Paskova B, Praskova H, Seifertova D, Zalesky R, Hoschl C: Moclobemide and cognitive behavioral therapy in the treatment of social phobia. A six-month controlled study and 24 months follow up. Neuro Endocrinol Lett. 2006, 27: 473-481.

  418. Blanco C, Heimberg RG, Schneier FR, Fresco DM, Chen H, Turk CL, Vermes D, Erwin BA, Schmidt AB, Juster HR, et al: A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry. 2010, 67: 286-295.

  419. Guastella AJ, Richardson R, Lovibond PF, Rapee RM, Gaston JE, Mitchell P, Dadds MR: A randomized controlled trial of d-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry. 2008, 63: 544-549.

  420. Hofmann SG, Meuret AE, Smits JA, Simon NM, Pollack MH, Eisenmenger K, Shiekh M, Otto MW: Augmentation of exposure therapy with d-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006, 63: 298-304.

  421. Knijnik DZ, Blanco C, Salum GA, Moraes CU, Mombach C, Almeida E, Pereira M, Strapasson A, Manfro GG, Eizirik CL: A pilot study of clonazepam versus psychodynamic group therapy plus clonazepam in the treatment of generalized social anxiety disorder. Eur Psychiatry. 2008, 23: 567-574.

  422. Watanabe N, Furukawa TA, Chen J, Kinoshita Y, Nakano Y, Ogawa S, Funayama T, Ietsugu T, Noda Y: Change in quality of life and their predictors in the long-term follow-up after group cognitive behavioral therapy for social anxiety disorder: a prospective cohort study. BMC Psychiatry. 2010, 10: 81-

  423. Carlbring P, Nordgren LB, Furmark T, Andersson G: Long-term outcome of Internet-delivered cognitive-behavioural therapy for social phobia: a 30-month follow-up. Behav Res Ther. 2009, 47: 848-850.

  424. Hedman E, Furmark T, Carlbring P, Ljotsson B, Ruck C, Lindefors N, Andersson G: A 5-year follow-up of internet-based cognitive behavior therapy for social anxiety disorder. J Med Internet Res. 2011, 13: e39-

  425. Mortberg E, Clark DM, Bejerot S: Intensive group cognitive therapy and individual cognitive therapy for social phobia: sustained improvement at 5-year follow-up. J Anxiety Disord. 2011, 25: 994-1000.

  426. van der Linden G, Stein D, van Balkom A: The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomized controlled trials. Int Clin Psychopharmacol. 2000, 15 (Suppl 2): S15-23.

  427. Canton J, Scott KM, Glue P: Optimal treatment of social phobia: systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2012, 8: 203-215.

  428. Stein DJ, Ipser JC, Balkom AJ: Pharmacotherapy for social phobia. Cochrane Database Syst Rev. 2004, : CD001206-

  429. Hedges DW, Brown BL, Shwalb DA, Godfrey K, Larcher AM: The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials. J Psychopharmacol. 2007, 21: 102-111.

  430. Kasper S, Stein D, Loft H, Nil R: Escitalopram in the treatment of social anxiety disorder: Randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry. 2005, 186: 222-226.

  431. Lader M, Stender K, Burger V, Nil R: Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety. 2004, 19: 241-248.

  432. Pallanti S, Quercioli L: Resistant social anxiety disorder response to escitalopram. Clin Pract Epidemiol Ment Health. 2006, 2: 35-

  433. van Vliet I, den Boer J, Westenberg H: Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology (Berl). 1994, 115: 128-134.

  434. Stein M, Fyer A, Davidson J, Pollack M, Wiita B: Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry. 1999, 156: 756-760.

  435. Asakura S, Tajima O, Koyama T: Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2007, 10: 263-274.

  436. Davidson J, Yaryura-Tobias J, Du Pont R, Stallings L, Barbato L, van dHR, Li D: Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol. 2004, 24: 118-125.

  437. Westenberg H, Stein D, Yang H, Li D, Barbato L: A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol. 2004, 24: 49-55.

  438. Allgulander C: Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand. 1999, 100: 193-198.

  439. Allgulander C, Mangano R, Zhang J, Dahl AA, Lepola U, Sjodin I, Emilien G: Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol. 2004, 19: 387-396.

  440. Baldwin D, Bobes J, Stein D, Scharwachter I, Faure M: Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry. 1999, 175: 120-126.

  441. Liebowitz M, Gelenberg A, Munjack D: Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry. 2005, 62: 190-198.

  442. Liebowitz M, Stein M, Tancer M, Carpenter D, Oakes R, Pitts C: A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry. 2002, 63: 66-74.

  443. Stein D, Berk M, Els C, Emsley R, Gittelson L, Wilson D, Oakes R, Hunter B: A double-blind placebo-controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa. S Afr Med J. 1999, 89: 402-406.

  444. Stein M, Liebowitz M, Lydiard R, Pitts C, Bushnell W, Gergel I: Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA. 1998, 280: 708-713.

  445. Katzelnick D, Kobak K, Greist J, Jefferson J, Mantle J, Serlin R: Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry. 1995, 152: 1368-1371.

  446. Liebowitz M, De Martinis N, Weihs K, Londborg P, Smith W, Chung H, Fayyad R, Clary C: Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry. 2003, 64: 785-792.

  447. Van Ameringen M, Lane R, Walker J, Bowen R, Chokka P, Goldner E, Johnston D, Lavallee Y, Nandy S, Pecknold J, et al: Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry. 2001, 158: 275-281.

  448. Blomhoff S, Haug T, Hellstrom K, Holme I, Humble M, Madsbu H, Wold J: Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry. 2001, 179: 23-30.

  449. Kobak K, Greist J, Jefferson J, Katzelnick D: Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol. 2002, 22: 257-262.

  450. Atmaca M, Kuloglu M, Tezcan E, Unal A: Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002, 17: 401-405.

  451. Furmark T, Appel L, Michelgard A, Wahlstedt K, Ahs F, Zancan S, Jacobsson E, Flyckt K, Grohp M, Bergstrom M, et al: Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry. 2005, 58: 132-142.

  452. Lepola U, Bergtholdt B, St Lambert J, Davy KL, Ruggiero L: Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J Clin Psychiatry. 2004, 65: 222-229.

  453. Schutters S, van Megen H, Van Veen J, Schruers K, Westenberg H: Paroxetine augmentation in patients with generalised social anxiety disorder, non-responsive to mirtazapine or placebo. Hum Psychopharmacol Clin Exp. 2011, 26: 72-76.

  454. Liebowitz M, Mangano R, Bradwejn J, Asnis G: A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry. 2005, 66: 238-247.

  455. Rickels K, Mangano R, Khan A: A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol. 2004, 24: 488-496.

  456. Stein M, Pollack M, Bystritsky A, Kelsey J, Mangano R: Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl). 2005, 177: 280-288.

  457. Simon NM, Worthington JJ, Moshier SJ, Marks EH, Hoge EA, Brandes M, Delong H, Pollack MH: Duloxetine for the treatment of generalized social anxiety disorder: a preliminary randomized trial of increased dose to optimize response. CNS Spectr. 2010, 15: 367-373.

  458. Gringras M: An uncontrolled trial of clomipramine (Anafranil) in the treatment of phobic and obsessional states in general practice. J Int Med Res. 1977, 5 (Suppl 5): 111-115.

  459. Beaumont G: A large open multicentre trial of clomipramine (Anafranil) in the management of phobic disorders. J Int Med Res. 1977, 5 (Suppl 5): 116-123.

  460. Simpson H, Schneier F, Campeas R, Marshall R, Fallon B, Davies S, Klein D, Liebowitz M: Imipramine in the treatment of social phobia. J Clin Psychopharmacol. 1998, 18: 132-135.

  461. Liebowitz M, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, Gorman J, Papp L, Davies S, Gully R, et al: Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry. 1992, 49: 290-300.

  462. Versiani M, Nardi A, Mundim F, Alves A, Liebowitz M, Amrein R: Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry. 1992, 161: 353-360.

  463. International Multicenter Clinical Trial Group on Moclobemide in Social Phobia: Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci. 1997, 247: 71-80.

  464. Stein D, Cameron A, Amrein R, Montgomery S: Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. Int Clin Psychopharmacol. 2002, 17: 161-170.

  465. Noyes R, Moroz G, Davidson J, Liebowitz M, Davidson A, Siegel J, Bell J, Cain J, Curlik S, Kent T, et al: Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol. 1997, 17: 247-254.

  466. Schneier F, Goetz D, Campeas R, Fallon B, Marshall R, Liebowitz M: Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry. 1998, 172: 70-77.

  467. Schutters SI, Van Megen HJ, Van Veen JF, Denys DA, Westenberg HG: Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 2010, 25: 302-304.

  468. Muehlbacher M, Nickel MK, Nickel C, Kettler C, Lahmann C, Pedrosa Gil F, Leiberich PK, Rother N, Bachler E, Fartacek R, et al: Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2005, 25: 580-583.

  469. Emmanuel NP, Brawman-Mintzer O, Morton WA, Book SW, Johnson MR, Lorberbaum JP, Ballenger JC, Lydiard RB: Bupropion-SR in treatment of social phobia. Depress Anxiety. 2000, 12: 111-113.

  470. Davidson J, Potts N, Richichi E, Krishnan R, Ford S, Smith R, Wilson W: Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol. 1993, 13: 423-428.

  471. Munjack D, Baltazar P, Bohn P, Cabe D, Appleton A: Clonazepam in the treatment of social phobia: a pilot study. J Clin Psychiatry. 1990, 51 (Suppl): 35-40. discussion 50-33

  472. Versiani M, Nardi A, Figuera I, Marques C: Double-blind placebo controlled trial with bromazepam in social phobia. J Bras Psiquiatr. 1997, 46: 167-171.

  473. Seedat S, Stein M: Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry. 2004, 65: 244-248.

  474. Pande A, Feltner D, Jefferson J, Davidson J, Pollack M, Stein M, Lydiard R, Futterer R, Robinson P, Slomkowski M, et al: Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol. 2004, 24: 141-149.

  475. Feltner DE, Liu-Dumaw M, Schweizer E, Bielski R: Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. Int Clin Psychopharmacol. 2011, 26: 213-220.

  476. Pande A, Davidson J, Jefferson J, Janney C, Katzelnick D, Weisler R, Greist J, Sutherland S: Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol. 1999, 19: 341-348.

  477. Urbano MR, Spiegel DR, Laguerta N, Shrader CJ, Rowe DF, Hategan LF: Gabapentin and tiagabine for social anxiety: a randomized, double-blind, crossover study of 8 adults [Letter]. Prim Care Companion J Clin Psychiatry. 2009, 11: 123-

  478. Zhang W, Connor KM, Davidson JR: Levetiracetam in social phobia: a placebo controlled pilot study. J Psychopharmacol. 2005, 19: 551-553.

  479. Simon NM, Worthington JJ, Doyle AC, Hoge EA, Kinrys G, Fischmann D, Link N, Pollack MH: An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry. 2004, 65: 1219-1222.

  480. Stein MB, Ravindran LN, Simon NM, Liebowitz MR, Khan A, Brawman-Mintzer O, Lydiard RB, Pollack MH: Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. J Clin Psychiatry. 2010, 71: 627-631.

  481. Kinrys G, Pollack MH, Simon NM, Worthington JJ, Nardi AE, Versiani M: Valproic acid for the treatment of social anxiety disorder. Int Clin Psychopharmacol. 2003, 18: 169-172.

  482. Dunlop BW, Papp L, Garlow SJ, Weiss PS, Knight BT, Ninan PT: Tiagabine for social anxiety disorder. Hum Psychopharmacol. 2007, 22: 241-244.

  483. Van Ameringen M, Mancini C, Pipe B, Oakman J, Bennett M: An open trial of topiramate in the treatment of generalized social phobia. J Clin Psychiatry. 2004, 65: 1674-1678.

  484. Turner SM, Beidel DC, Jacob RG: Social phobia: a comparison of behavior therapy and atenolol. J Consult Clin Psychol. 1994, 62: 350-358.

  485. van Vliet I, den Boer J, Westenberg H, Pian K: Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. J Clin Psychiatry. 1997, 58: 164-168.

  486. Ravindran LN, Kim DS, Letamendi AM, Stein MB: A randomized controlled trial of atomoxetine in generalized social anxiety disorder. J Clin Psychopharmacol. 2009, 29: 561-564.

  487. Adler LA, Liebowitz M, Kronenberger W, Qiao M, Rubin R, Hollandbeck M, Deldar A, Schuh K, Durell T: Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety. 2009, 26: 212-221.

  488. Falloon IR, Lloyd GG, Harpin RE: The treatment of social phobia. Real-life rehearsal with nonprofessional therapists. J Nerv Ment Dis. 1981, 169: 180-184.

  489. Simpson HB, Schneier FR, Marshall RD, Campeas RB, Vermes D, Silvestre J, Davies S, Liebowitz MR: Low dose selegiline (L-Deprenyl) in social phobia. Depress Anxiety. 1998, 7: 126-129.

  490. Villarreal G, Johnson MR, Rubey R, Lydiard RB, Ballanger JC: Treatment of social phobia with the dopamine agonist pergolide. Depress Anxiety. 2000, 11: 45-47.

  491. Van Ameringen M, Mancini C, Wilson C: Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord. 1996, 39: 115-121.

  492. Stein M, Sareen J, Hami S, Chao J: Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry. 2001, 158: 1725-1727.

  493. Barnett S, Kramer M, Casat C, Connor K, Davidson J: Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol. 2002, 16: 365-368.

  494. Schutters SI, van Megen HJ, Westenberg HG: Efficacy of quetiapine in generalized social anxiety disorder: results from an open-label study [Letter]. J Clin Psychiatry. 2005, 66: 540-542.

  495. Vaishnavi S, Alamy S, Zhang W, Connor KM, Davidson JR: Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 2007, 31: 1464-1469.

  496. Worthington J, Kinrys G, Wygant L, Pollack M: Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol. 2005, 20: 9-11.

  497. Donovan MR, Glue P, Kolluri S, Emir B: Comparative efficacy of antidepressants in preventing relapse in anxiety disorders – a meta-analysis. J Affect Disord. 2010, 123: 9-16.

  498. Greist JH, Liu-Dumaw M, Schweizer E, Feltner D: Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study. Int Clin Psychopharmacol. 2011, 26: 243-251.

  499. Stein D, Westenberg H, Yang H, Li D, Barbato L: Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. Int J Neuropsychopharmacol. 2003, 6: 317-323.

  500. Versiani M, Amrein R, Montgomery S: Social phobia: long-term treatment outcome and prediction of response–a moclobemide study. Int Clin Psychopharmacol. 1997, 12: 239-254.

  501. Fontani V, Mannu P, Castagna A, Rinaldi S: Social anxiety disorder: radio electric asymmetric conveyor brain stimulation versus sertraline. Patient Prefer Adherence. 2011, 5: 581-586.

  502. Kobak K, Taylor L, Warner G, Futterer R: St. John’s wort versus placebo in social phobia: results from a placebo-controlled pilot study. J Clin Psychopharmacol. 2005, 25: 51-58.

  503. Gwynn RC, McQuistion HL, McVeigh KH, Garg RK, Frieden TR, Thorpe LE: Prevalence, diagnosis, and treatment of depression and generalized anxiety disorder in a diverse urban community. Psychiatr Serv. 2008, 59: 641-647.

  504. Asnaani A, Richey JA, Dimaite R, Hinton DE, Hofmann SG: A cross-ethnic comparison of lifetime prevalence rates of anxiety disorders. J Nerv Ment Dis. 2010, 198: 551-555.

  505. Grant BF, Hasin DS, Stinson FS, Dawson DA, June Ruan W, Goldstein RB, Smith SM, Saha TD, Huang B: Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 2005, 35: 1747-1759.

  506. Albano A, Chorpita B, Barlow D: Childhood anxiety disorders. Child psychopathology. Edited by: Mash E, Barkley R. 2003, New York, NY: Guilford, 279-329. 2

  507. Beesdo K, Pine DS, Lieb R, Wittchen HU: Incidence and risk patterns of anxiety and depressive disorders and categorization of generalized anxiety disorder. Arch Gen Psychiatry. 2010, 67: 47-57.

  508. Ansseau M, Fischler B, Dierick M, Albert A, Leyman S, Mignon A: Socioeconomic correlates of generalized anxiety disorder and major depression in primary care: the GADIS II study (Generalized Anxiety and Depression Impact Survey II). Depress Anxiety. 2008, 25: 506-513.

  509. Byers AL, Yaffe K, Covinsky KE, Friedman MB, Bruce ML: High occurrence of mood and anxiety disorders among older adults: the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2010, 67: 489-496.

  510. Mackenzie CS, Reynolds K, Chou KL, Pagura J, Sareen J: Prevalence and correlates of generalized anxiety disorder in a national sample of older adults. Am J Geriatr Psychiatry. 2011, 19: 305-315.

  511. Revicki DA, Travers K, Wyrwich KW, Svedsater H, Locklear J, Mattera MS, Sheehan DV, Montgomery S: Humanistic and economic burden of generalized anxiety disorder in North America and Europe. J Affect Disord. 2012, 140: 103-112.

  512. Baldwin DS, Allgulander C, Bandelow B, Ferre F, Pallanti S: An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder. World J Biol Psychiatry. 2012, 13: 510-516.

  513. Weisberg RB, Beard C, Pagano ME, Maki KM, Culpepper L, Keller MB: Impairment and functioning in a sample of primary care patients with generalized anxiety disorder: results from the primary care anxiety project. Prim Care Companion J Clin Psychiatry. 2010, 12: doi 10.4088/PCC.4009m00890blu

  514. Zhu B, Zhao Z, Ye W, Marciniak MD, Swindle R: The cost of comorbid depression and pain for individuals diagnosed with generalized anxiety disorder. J Nerv Ment Dis. 2009, 197: 136-139.

  515. Romera I, Fernandez-Perez S, Montejo AL, Caballero F, Caballero L, Arbesu JA, Delgado-Cohen H, Desaiah D, Polavieja P, Gilaberte I: Generalized anxiety disorder, with or without co-morbid major depressive disorder, in primary care: prevalence of painful somatic symptoms, functioning and health status. J Affect Disord. 2010, 127: 160-168.

  516. Garcia-Campayo J, Caballero F, Perez M, Lopez V: Pain related factors in newly diagnosed generalized anxiety disorder patients. Actas Esp Psiquiatr. 2012, 40: 177-186.

  517. Beesdo K, Hoyer J, Jacobi F, Low NC, Hofler M, Wittchen HU: Association between generalized anxiety levels and pain in a community sample: evidence for diagnostic specificity. J Anxiety Disord. 2009, 23: 684-693.

  518. Martens EJ, de Jonge P, Na B, Cohen BE, Lett H, Whooley MA: Scared to death? Generalized anxiety disorder and cardiovascular events in patients with stable coronary heart disease:The Heart and Soul Study. Arch Gen Psychiatry. 2010, 67: 750-758.

  519. Tyrer P, Seivewright H, Johnson T: The Nottingham Study of Neurotic Disorder: predictors of 12-year outcome of dysthymic, panic and generalized anxiety disorder. Psychol Med. 2004, 34: 1385-1394.

  520. Covin R, Ouimet AJ, Seeds PM, Dozois DJ: A meta-analysis of CBT for pathological worry among clients with GAD. J Anxiety Disord. 2008, 22: 108-116.

  521. Linden M, Zubraegel D, Baer T, Franke U, Schlattmann P: Efficacy of cognitive behaviour therapy in generalized anxiety disorders. Results of a controlled clinical trial (Berlin CBT-GAD Study). Psychother Psychosom. 2005, 74: 36-42.

  522. Borkovec T, Newman M, Pincus A, Lytle R: A component analysis of cognitive-behavioral therapy for generalized anxiety disorder and the role of interpersonal problems. J Consult Clin Psychol. 2002, 70: 288-298.

  523. Ferrero A, Piero A, Fassina S, Massola T, Lanteri A, Daga GA, Fassino S: A 12-month comparison of brief psychodynamic psychotherapy and pharmacotherapy treatment in subjects with generalised anxiety disorders in a community setting. Eur Psychiatry. 2007, 22: 530-539.

  524. Robinson E, Titov N, Andrews G, McIntyre K, Schwencke G, Solley K: Internet treatment for generalized anxiety disorder: a randomized controlled trial comparing clinician vs. technician assistance. PLoS One. 2010, 5: e10942-

  525. Paxling B, Almlov J, Dahlin M, Carlbring P, Breitholtz E, Eriksson T, Andersson G: Guided internet-delivered cognitive behavior therapy for generalized anxiety disorder: a randomized controlled trial. Cogn Behav Ther. 2011, 40: 159-173.

  526. Gorini A, Pallavicini F, Algeri D, Repetto C, Gaggioli A, Riva G: Virtual reality in the treatment of generalized anxiety disorders. Stud Health Technol Inform. 2010, 154: 39-43.

  527. den Boer PC, Wiersma D, Ten Vaarwerk I, Span MM, Stant AD, Van den Bosch RJ: Cognitive self-therapy for chronic depression and anxiety: a multi-centre randomized controlled study. Psychol Med. 2007, 37: 329-339.

  528. Wells A, Welford M, King P, Papageorgiou C, Wisely J, Mendel E: A pilot randomized trial of metacognitive therapy vs applied relaxation in the treatment of adults with generalized anxiety disorder. Behav Res Ther. 2010, 48: 429-434.

  529. Conrad A, Isaac L, Roth WT: The psychophysiology of generalized anxiety disorder: 2. Effects of applied relaxation. Psychophysiology. 2008, 45: 377-388.

  530. Dugas MJ, Brillon P, Savard P, Turcotte J, Gaudet A, Ladouceur R, Leblanc R, Gervais NJ: A randomized clinical trial of cognitive-behavioral therapy and applied relaxation for adults with generalized anxiety disorder. Behav Ther. 2010, 41: 46-58.

  531. Dubois O, Salamon R, Germain C, Poirier MF, Vaugeois C, Banwarth B, Mouaffak F, Galinowski A, Olie JP: Balneotherapy versus paroxetine in the treatment of generalized anxiety disorder. Complement Ther Med. 2010, 18: 1-7.

  532. Dugas MJ, Marchand A, Ladouceur R: Further validation of a cognitive-behavioral model of generalized anxiety disorder: diagnostic and symptom specificity. J Anxiety Disord. 2005, 19: 329-343.

  533. Roemer L, Orsillo SM, Salters-Pedneault K: Efficacy of an acceptance-based behavior therapy for generalized anxiety disorder: evaluation in a randomized controlled trial. J Consult Clin Psychol. 2008, 76: 1083-1089.

  534. van der Heiden C, Muris P, van der Molen HT: Randomized controlled trial on the effectiveness of metacognitive therapy and intolerance-of-uncertainty therapy for generalized anxiety disorder. Behav Res Ther. 2012, 50: 100-109.

  535. Hoyer J, Beesdo K, Gloster AT, Runge J, Hofler M, Becker ES: Worry exposure versus applied relaxation in the treatment of generalized anxiety disorder. Psychother Psychosom. 2009, 78: 106-115.

  536. Riskind JH, Williams NL, Joiner TE: The looming cognitive style: A cognitive vulnerability for anxiety disorders. J Social Clin Psychol. 2006, 25: 779-801.

  537. Leichsenring F, Salzer S, Jaeger U, Kachele H, Kreische R, Leweke F, Ruger U, Winkelbach C, Leibing E: Short-term psychodynamic psychotherapy and cognitive-behavioral therapy in generalized anxiety disorder: a randomized, controlled trial. Am J Psychiatry. 2009, 166: 875-881.

  538. Newman MG, Castonguay LG, Borkovec TD, Fisher AJ, Boswell JF, Szkodny LE, Nordberg SS: A randomized controlled trial of cognitive-behavioral therapy for generalized anxiety disorder with integrated techniques from emotion-focused and interpersonal therapies. J Consult Clin Psychol. 2011, 79: 171-181.

  539. Aviram A, Westra HA: The impact of motivational interviewing on resistance in cognitive behavioural therapy for generalized anxiety disorder. Psychother Res. 2011, 21: 698-708.

  540. Westra HA, Arkowitz H, Dozois DJ: Adding a motivational interviewing pretreatment to cognitive behavioral therapy for generalized anxiety disorder: a preliminary randomized controlled trial. J Anxiety Disord. 2009, 23: 1106-1117.

  541. Crits-Christoph P, Newman MG, Rickels K, Gallop R, Gibbons MB, Hamilton JL, Ring-Kurtz S, Pastva AM: Combined medication and cognitive therapy for generalized anxiety disorder. J Anxiety Disord. 2011, 25: 1087-1094.

  542. Gosselin P, Ladouceur R, Morin CM, Dugas MJ, Baillargeon L: Benzodiazepine discontinuation among adults with GAD: A randomized trial of cognitive-behavioral therapy. J Consult Clin Psychol. 2006, 74: 908-919.

  543. Salzer S, Winkelbach C, Leweke F, Leibing E, Leichsenring F: Long-term effects of short-term psychodynamic psychotherapy and cognitive-behavioural therapy in generalized anxiety disorder: 12-month follow-up. Can J Psychiatry. 2011, 56: 503-508.

  544. Davidson J, Bose A, Korotzer A, Zheng H: Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety. 2004, 19: 234-240.

  545. Goodman WK, Bose A, Wang Q: Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord. 2005, 87: 161-167.

  546. Bielski RJ, Bose A, Chang CC: A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry. 2005, 17: 65-69.

  547. Baldwin DS, Huusom AK, Maehlum E: Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Br J Psychiatry. 2006, 189: 264-272.

  548. Bose A, Korotzer A, Gommoll C, Li D: Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder. Depress Anxiety. 2008, 25: 854-861.

  549. Bystritsky A, Kerwin L, Feusner JD, Vapnik T: A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder. Psychopharmacol Bull. 2008, 41: 46-51.

  550. Lenze EJ, Rollman BL, Shear MK, Dew MA, Pollock BG, Ciliberti C, Costantino M, Snyder S, Shi P, Spitznagel E, et al: Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial. JAMA. 2009, 301: 295-303.

  551. Merideth C, Cutler AJ, She F, Eriksson H: Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study. Int Clin Psychopharmacol. 2012, 27: 40-54.

  552. Coric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC, Wu X, Gentile KA, Huang SP, Emison E, et al: Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress Anxiety. 2010, 27: 417-425.

  553. Kapczinski F, Lima MS, Souza JS, Schmitt R: Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev. 2003, CD003592-

  554. Rickels K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D: Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2003, 160: 749-756.

  555. Pollack M, Zaninelli R, Goddard A, McCafferty J, Bellew K, Burnham D, Iyengar M: Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001, 62: 350-357.

  556. Ball S, Kuhn A, Wall D, Shekhar A, Goddard A: Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. J Clin Psychiatry. 2005, 66: 94-99.

  557. Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, Eriksson H: Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol. 2010, 13: 305-320.

  558. Kim TS, Pae CU, Yoon SJ, Bahk WM, Jun TY, Rhee WI, Chae JH: Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder. Psychiatry Clin Neurosci. 2006, 60: 347-351.

  559. Allgulander C, Dahl A, Austin C, Morris P, Sogaard J, Fayyad R, Kutcher S, Clary C: Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry. 2004, 161: 1642-1649.

  560. Brawman-Mintzer O, Knapp RG, Rynn M, Carter RE, Rickels K: Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006, 67: 874-881.

  561. Mokhber N, Azarpazhooh MR, Khajehdaluee M, Velayati A, Hopwood M: Randomized, single-blind, trial of sertraline and buspirone for treatment of elderly patients with generalized anxiety disorder. Psychiatry Clin Neurosci. 2010, 64: 128-133.

  562. Varia I, Rauscher F: Treatment of generalized anxiety disorder with citalopram. Int Clin Psychopharmacol. 2002, 17: 103-107.

  563. Simon NM, Zalta AK, Worthington JJ, Hoge EA, Christian KM, Stevens JC, Pollack MH: Preliminary support for gender differences in response to fluoxetine for generalized anxiety disorder. Depress Anxiety. 2006, 23: 373-376.

  564. Gross PK, Nourse R, Wasser TE, Krulewicz S: Effects of paroxetine CR on depressive and anxiety symptoms: in a community sample of adult Hispanic women with major depression or generalized anxiety disorder. Psychiatry (Edgmont). 2006, 3: 64-68.

  565. Simon NM, Connor KM, LeBeau RT, Hoge EA, Worthington JJ, Zhang W, Davidson JR, Pollack MH: Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berl). 2008, 197: 675-681.

  566. Rynn M, Russell J, Erickson J, Detke MJ, Ball S, Dinkel J, Rickels K, Raskin J: Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety. 2008, 25: 182-189.

  567. Koponen H, Allgulander C, Erickson J, Dunayevich E, Pritchett Y, Detke MJ, Ball SG, Russell JM: Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry. 2007, 9: 100-107.

  568. Wu WY, Wang G, Ball SG, Desaiah D, Ang QQ: Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China. Chin Med J (Engl). 2011, 124: 3260-3268.

  569. Allgulander C, Hartford J, Russell J, Ball S, Erickson J, Raskin J, Rynn M: Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials. Curr Med Res Opin. 2007, 23: 1245-1252.

  570. Hartford J, Kornstein S, Liebowitz M, Pigott T, Russell J, Detke M, Walker D, Ball S, Dunayevich E, Dinkel J, Erickson J: Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol. 2007, 22: 167-174.

  571. Allgulander C, Nutt D, Detke M, Erickson J, Spann M, Walker D, Ball SG, Russell JM: A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder. J Psychopharmacol. 2008, 22: 417-425.

  572. Davidson J, Du Pont R, Hedges D, Haskins J: Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry. 1999, 60: 528-535.

  573. Nimatoudis I, Zissis N, Kogeorgos J, Theodoropoulou S, Vidalis A, Kaprinis G: Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study. Int Clin Psychopharmacol. 2004, 19: 331-336.

  574. Rickels K, Pollack M, Sheehan D, Haskins J: Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry. 2000, 157: 968-974.

  575. Katz I, Reynolds C, Alexopoulos G, Hackett D: Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials. J Am Geriatr Soc. 2002, 50: 18-25.

  576. Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC: Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry. 2006, 67: 771-782.

  577. Kasper S, Herman B, Nivoli G, Van Ameringen M, Petralia A, Mandel FS, Baldinetti F, Bandelow B: Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol. 2009, 24: 87-96.

  578. Allgulander C, Hackett D, Salinas E: Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry. 2001, 179: 15-22.

  579. Gelenberg A, Lydiard R, Rudolph R, Aguiar L, Haskins J, Salinas E: Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA. 2000, 283: 3082-3088.

  580. Lenox-Smith AJ, Reynolds A: A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care. Br J Gen Pract. 2003, 53: 772-777.

  581. Hoehn-Saric R, McLeod D, Zimmerli W: Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry. 1988, 49: 293-301.

  582. Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L: Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand. 1997, 95: 444-450.

  583. Rickels K, Downing R, Schweizer E, Hassman H: Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry. 1993, 50: 884-895.

  584. Stein DJ, Ahokas AA, de Bodinat C: Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008, 28: 561-566.

  585. Stein D, Marquez M, Hoschl C, Ahokas A, Oh K-S, Jarema M, Avedisova A, Vavrusova L, Olivier V: Efficacy and tolerability of agomelatine in generalized anxiety disorder: A randomised double blind placebo controlled trial with escitalopram as active control [poster]. 28th CINP Congress; Jun 3-7; Stockholm, Sweden. 2012

  586. Rothschild AJ, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV: Vortioxetine (Lu AA21004) 5mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. Eur Neuropsychopharmacol. 2012, 22: 858-866.

  587. Bidzan L, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV: Vortioxetine (Lu AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial. Eur Neuropsychopharmacol. 2012, 22: 847-857.

  588. Gambi F, De Berardis D, Campanella D, Carano A, Sepede G, Salini G, Mezzano D, Cicconetti A, Penna L, Salerno RM, Ferro FM: Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study. J Psychopharmacol. 2005, 19: 483-487.

  589. Mitte K, Noack P, Steil R, Hautzinger M: A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. J Clin Psychopharmacol. 2005, 25: 141-150.

  590. Lydiard R, Ballenger J, Rickels K: A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group. J Clin Psychiatry. 1997, 58 (Suppl 11): 11-18.

  591. Moller H, Volz H, Reimann I, Stoll K: Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol. 2001, 21: 59-65.

  592. Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, Tobias K, Brock JD, Zornberg GL, Pande AC: Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005, 62: 1022-1030.

  593. Lydiard RB, Rickels K, Herman B, Feltner DE: Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol. 2010, 13: 229-241.

  594. Llorca P, Spadone C, Sol O, Danniau A, Bougerol T, Corruble E, Faruch M, Macher J, Sermet E, Servant D: Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. J Clin Psychiatry. 2002, 63: 1020-1027.

  595. Rickels K, Schweizer E, De Martinis N, Mandos L, Mercer C: Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial. J Clin Psychopharmacol. 1997, 17: 272-277.

  596. Rickels K, DeMartinis N, Aufdembrinke B: A double-blind, placebo-controlled trial of abecarnil and diazepam in the treatment of patients with generalized anxiety disorder. J Clin Psychopharmacol. 2000, 20: 12-18.

  597. Feltner D, Crockatt J, Dubovsky S, Cohn C, Shrivastava R, Targum S, Liu-Dumaw M, Carter C, Pande A: A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2003, 23: 240-249.

  598. Laakmann G, Schule C, Lorkowski G, Baghai T, Kuhn K, Ehrentraut S: Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacology (Berl). 1998, 136: 357-366.

  599. Fresquet A, Sust M, Lloret A, Murphy M, Carter F, Campbell G, Marion-Landais G: Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder. Ann Pharmacother. 2000, 34: 147-153.

  600. Woelk H, Schlafke S: A multi-center, double-blind, randomised study of the lavender oil preparation Silexan in comparison to lorazepam for generalized anxiety disorder. Phytomedicine. 2010, 17: 94-99.

  601. Herrera-Arellano A, Jimenez-Ferrer E, Zamilpa A, Morales-Valdez M, Garcia-Valencia CE, Tortoriello J: Efficacy and tolerability of a standardized herbal product from galphimia glauca on generalized anxiety disorder. A randomized, double-blind clinical trial controlled with lorazepam. Planta Med. 2007, 73: 713-717.

  602. Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H: A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2011, 31: 418-428.

  603. Stein DJ, Bandelow B, Merideth C, Olausson B, Szamosi J, Eriksson H: Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies. Hum Psychopharmacol. 2011, 26: 614-628.

  604. Katzman MA, Vermani M, Jacobs L, Marcus M, Kong B, Lessard S, Galarraga W, Struzik L, Gendron A: Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. J Anxiety Disord. 2008, 22: 1480-1486.

  605. Altamura AC, Serati M, Buoli M, Dell’Osso B: Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder: a randomized, placebo-controlled study. Int Clin Psychopharmacol. 2011, 26: 201-205.

  606. Brawman-Mintzer O, Knapp RG, Nietert PJ: Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2005, 66: 1321-1325.

  607. Pandina GJ, Canuso CM, Turkoz I, Kujawa M, Mahmoud RA: Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial. Psychopharmacol Bull. 2007, 40: 41-57.

  608. Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, Kinrys G, Oppenheimer J: Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006, 59: 211-215.

  609. Menza MA, Dobkin RD, Marin H: An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder [Letter]. J Clin Psychopharmacol. 2007, 27: 207-210.

  610. Gabriel A: The extended-release formulation of quetiapine fumarate (quetiapine XR) adjunctive treatment in partially responsive generalized anxiety disorder (GAD): An open label naturalistic study. Clin Ter. 2011, 162: 113-118.

  611. Lohoff FW, Etemad B, Mandos LA, Gallop R, Rickels K: Ziprasidone treatment of refractory generalized anxiety disorder: a placebo-controlled, double-blind study. J Clin Psychopharmacol. 2010, 30: 185-189.

  612. Snyderman SH, Rynn MA, Rickels K: Open-label pilot study of ziprasidone for refractory generalized anxiety disorder [Letter]. J Clin Psychopharmacol. 2005, 25: 497-499.

  613. Pohl R, Feltner D, Fieve R, Pande A: Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol. 2005, 25: 151-158.

  614. Aliyev NA, Aliyev ZN: Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled study. Eur Psychiatry. 2008, 23: 109-114.

  615. Pollack MH, Tiller J, Xie F, Trivedi MH: Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. J Clin Psychopharmacol. 2008, 28: 308-316.

  616. Rosenthal M: Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry. 2003, 64: 1245-1249.

  617. Rickels K, Shiovitz TM, Ramey TS, Weaver JJ, Knapp LE, Miceli JJ: Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. Int Clin Psychopharmacol. 2012, 27: 142-150.

  618. Pollack M, Worthington J, Manfro G, Otto M, Zucker B: Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone. J Clin Psychiatry. 1997, 58 (Suppl 11): 19-23.

  619. Lader M, Scotto J: A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology (Berl). 1998, 139: 402-406.

  620. Guaiana G, Barbui C, Cipriani A: Hydroxyzine for generalised anxiety disorder. Cochrane Database Syst Rev. 2010, CD006815-

  621. Meibach RC, Dunner D, Wilson LG, Ishiki D, Dager SR: Comparative efficacy of propranolol, chlordiazepoxide, and placebo in the treatment of anxiety: a double-blind trial. J Clin Psychiatry. 1987, 48: 355-358.

  622. Feusner JD, Kerwin L, Saxena S, Bystritsky A: Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacol Bull. 2009, 42: 81-93.

  623. Baldwin DS, Nutt DJ: On assessing potential efficacy for vortioxetine in generalized anxiety disorder. Eur Neuropsychopharmacol. 2012, 22: 841-843.

  624. Davidson JR, Wittchen HU, Llorca PM, Erickson J, Detke M, Ball SG, Russell JM: Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol. 2008, 18: 673-681.

  625. Allgulander C, Florea I, Huusom AK: Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol. 2006, 9: 495-505.

  626. Stocchi F, Nordera G, Jokinen R, Lepola U, Hewett K, Bryson H, Iyengar M: Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry. 2003, 64: 250-258.

  627. Rickels K, Etemad B, Khalid-Khan S, Lohoff FW, Rynn MA, Gallop RJ: Time to relapse after 6 and 12 months’ treatment of generalized anxiety disorder with venlafaxine extended release. Arch Gen Psychiatry. 2010, 67: 1274-1281.

  628. Feltner D, Wittchen HU, Kavoussi R, Brock J, Baldinetti F, Pande AC: Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol. 2008, 23: 18-28.

  629. Katzman MA, Brawman-Mintzer O, Reyes EB, Olausson B, Liu S, Eriksson H: Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2011, 26: 11-24.

  630. Bystritsky A, Kaplan JT, Feusner JD, Kerwin LE, Wadekar M, Burock M, Wu AD, Iacoboni M: A preliminary study of fMRI-guided rTMS in the treatment of generalized anxiety disorder. J Clin Psychiatry. 2008, 69: 1092-1098.

  631. Bystritsky A, Kerwin LE, Feusner JD: A preliminary study of fMRI-guided rTMS in the treatment of generalized anxiety disorder: 6-month follow-up [Letter]. J Clin Psychiatry. 2009, 70: 431-432.

  632. Kasper S, Gastpar M, Muller WE, Volz HP, Moller HJ, Dienel A, Schlafke S: Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of ‘subsyndromal’ anxiety disorder: a randomized, double-blind, placebo controlled trial. Int Clin Psychopharmacol. 2010, 25: 277-287.

  633. Miyasaka LS, Atallah AN, Soares BG: Passiflora for anxiety disorder. Cochrane Database Syst Rev. 2007, CD004518-

  634. Andreatini R, Sartori VA, Seabra ML, Leite JR: Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother Res. 2002, 16: 650-654.

  635. Miyasaka LS, Atallah AN, Soares BG: Valerian for anxiety disorders. Cochrane Database Syst Rev. 2006, CD004515-

  636. Herring MP, Jacob ML, Suveg C, Dishman RK, O’Connor PJ: Feasibility of exercise training for the short-term treatment of generalized anxiety disorder: a randomized controlled trial. Psychother Psychosom. 2012, 81: 21-28.

  637. Pilkington K, Kirkwood G, Rampes H, Cummings M, Richardson J: Acupuncture for anxiety and anxiety disorders–a systematic literature review. Acupunct Med. 2007, 25: 1-10.

  638. Lu CF, Smith LN, Gau CH: Exploring the zen meditation experiences of patients with generalized anxiety disorder: a focus-group approach. J Nurs Res. 2012, 20: 43-52.

  639. Katzman MA, Vermani M, Gerbarg PL, Brown RP, Iorio C, Davis M, Cameron C, Tsirgielis D: A multicomponent yoga-based, breath intervention program as an adjunctive treatment in patients suffering from generalized anxiety disorder with or without comorbidities. Int J Yoga. 2012, 5: 57-65.

  640. Youngstedt SD, Kline CE, Ginsberg JP, Zielinski MR, Hardin JW: Bright light treatment for high-anxious young adults: a randomized controlled pilot study. Depress Anxiety. 2011, 28: 324-332.

  641. Ruscio AM, Stein DJ, Chiu WT, Kessler RC: The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry. 2010, 15: 53-63.

  642. Adam Y, Meinlschmidt G, Gloster AT, Lieb R: Obsessive-compulsive disorder in the community: 12-month prevalence, comorbidity and impairment. Soc Psychiatry Psychiatr Epidemiol. 2012, 47: 339-349.

  643. Rosario-Campos MC, Leckman JF, Mercadante MT, Shavitt RG, Prado HS, Sada P, Zamignani D, Miguel EC: Adults with early-onset obsessive-compulsive disorder. Am J Psychiatry. 2001, 158: 1899-1903.

  644. Veldhuis J, Dieleman JP, Wohlfarth T, Storosum JG, van Den Brink W, Sturkenboom MC, Denys D: Incidence and prevalence of “diagnosed OCD” in a primary care, treatment seeking, population. Int J Psychiatry Clin Pract. 2012, 16: 85-92.

  645. Torres AR, Prince MJ, Bebbington PE, Bhugra D, Brugha TS, Farrell M, Jenkins R, Lewis G, Meltzer H, Singleton N: Obsessive-compulsive disorder: prevalence, comorbidity, impact, and help-seeking in the British National Psychiatric Morbidity Survey of 2000. Am J Psychiatry. 2006, 163: 1978-1985.

  646. Grisham JR, Fullana MA, Mataix-Cols D, Moffitt TE, Caspi A, Poulton R: Risk factors prospectively associated with adult obsessive-compulsive symptom dimensions and obsessive-compulsive disorder. Psychol Med. 2011, : 1-12.

  647. Hauschildt M, Jelinek L, Randjbar S, Hottenrott B, Moritz S: Generic and illness-specific quality of life in obsessive-compulsive disorder. Behav Cogn Psychother. 2010, 38: 417-436.

  648. Eisen JL, Mancebo MA, Pinto A, Coles ME, Pagano ME, Stout R, Rasmussen SA: Impact of obsessive-compulsive disorder on quality of life. Compr Psychiatry. 2006, 47: 270-275.

  649. Vikas A, Avasthi A, Sharan P: Psychosocial impact of obsessive-compulsive disorder on patients and their caregivers: a comparative study with depressive disorder. Int J Soc Psychiatry. 2011, 57: 45-56.

  650. Rampacher F, Lennertz L, Vogeley A, Schulze-Rauschenbach S, Kathmann N, Falkai P, Wagner M: ation processing in patients with OCD compared to patients with unipolar depresEvidence for specific cognitive deficits in visual informsion. Prog Neuropsychopharmacol Biol Psychiatry. 2010, 34: 984-991.

  651. Aigner M, Sachs G, Bruckmuller E, Winklbaur B, Zitterl W, Kryspin-Exner I, Gur R, Katschnig H: Cognitive and emotion recognition deficits in obsessive-compulsive disorder. Psychiatry Res. 2007, 149: 121-128.

  652. Torres AR, Ramos-Cerqueira AT, Ferrao YA, Fontenelle LF, do Rosario MC, Miguel EC: Suicidality in obsessive-compulsive disorder: prevalence and relation to symptom dimensions and comorbid conditions. J Clin Psychiatry. 2011, 72: 17-26. quiz 119-120

  653. Eaton WW, Martins SS, Nestadt G, Bienvenu OJ, Clarke D, Alexandre P: The burden of mental disorders. Epidemiol Rev. 2008, 30: 1-14.

  654. Leckman JF, Denys D, Simpson HB, Mataix-Cols D, Hollander E, Saxena S, Miguel EC, Rauch SL, Goodman WK, Phillips KA, Stein DJ: Obsessive-compulsive disorder: a review of the diagnostic criteria and possible subtypes and dimensional specifiers for DSM-V. Depress Anxiety. 2010, 27: 507-527.

  655. Abramowitz JS: Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol. 1997, 65: 44-52.

  656. Eddy K, Dutra L, Bradley R, Westen D: A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev. 2004, 24: 1011-1030.

  657. Noordik E, van der Klink JJ, Klingen EF, Nieuwenhuijsen K, van Dijk FJ: Exposure-in-vivo containing interventions to improve work functioning of workers with anxiety disorder: a systematic review. BMC Public Health. 2010, 10: 598-

  658. Foa E, Liebowitz M, Kozak M, Davies S, Campeas R, Franklin M, Huppert J, Kjernisted K, Rowan V, Schmidt A, et al: Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry. 2005, 162: 151-161.

  659. Sousa MB, Isolan LR, Oliveira RR, Manfro GG, Cordioli AV: A randomized clinical trial of cognitive-behavioral group therapy and sertraline in the treatment of obsessive-compulsive disorder. J Clin Psychiatry. 2006, 67: 1133-1139.

  660. Belotto-Silva C, Diniz JB, Malavazzi DM, Valerio C, Fossaluza V, Borcato S, Seixas AA, Morelli D, Miguel EC, Shavitt RG: Group cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: a practical clinical trial. J Anxiety Disord. 2012, 26: 25-31.

  661. Jones MK, Menzies RG: Danger ideation reduction therapy (DIRT) for obsessive-compulsive washers. A controlled trial. Behav Res Ther. 1998, 36: 959-970.

  662. Krochmalik A, Jones MK, Menzies RG, Kirkby K: The superiority of danger ideation reduction therapy (DIRT) over exposure and response prevention (ERP) in treating compulsive washing. Behaviour Change. 2004, 21: 251-268.

  663. Jonsson H, Hougaard E, Bennedsen BE: Randomized comparative study of group versus individual cognitive behavioural therapy for obsessive compulsive disorder. Acta Psychiatr Scand. 2011, 123: 387-397.

  664. Jaurrieta N, Jimenez-Murcia S, Alonso P, Granero R, Segalas C, Labad J, Menchon JM: Individual versus group cognitive behavioral treatment for obsessive-compulsive disorder: follow up. Psychiatry Clin Neurosci. 2008, 62: 697-704.

  665. O’Connor K, Freeston MH, Gareau D, Careau Y, Dufour MJ, Aardema F, Todorov C: Group versus individual treatment in obsessions without compulsions. Clin Psychol Psychother. 2005, 12: 87-96.

  666. Belloch A, Cabedo E, Carrio C, Fernandez-Alvarez H, Garcia F, Larsson C: Group versus individual cognitive treatment for obsessive-compulsive disorder: changes in non-OCD symptoms and cognitions at post-treatment and one-year follow-up. Psychiatry Res. 2011, 187: 174-179.

  667. Cabedo E, Belloch A, Carrio C, Larsson C, Fernandez-Alvarez H, Garcia F: Group versus individual cognitive treatment for obsessive-compulsive disorder: changes in severity at post-treatment and one-year follow-up. Behav Cogn Psychother. 2010, 38: 227-232.

  668. Kozak M, Foa E: Mastery of obsessive–compulsive disorder: A cognitive–behavioral approach. 1997, San Antonio, TX: The Psychological Corporation

  669. Abramowitz JS, Foa EB, Franklin ME: Exposure and ritual prevention for obsessive-compulsive disorder: effects of intensive versus twice-weekly sessions. J Consult Clin Psychol. 2003, 71: 394-398.

  670. Tolin DF, Diefenbach GJ, Gilliam CM: Stepped care versus standard cognitive-behavioral therapy for obsessive-compulsive disorder: a preliminary study of efficacy and costs. Depress Anxiety. 2011, 28: 314-323.

  671. Twohig MP, Hayes SC, Plumb JC, Pruitt LD, Collins AB, Hazlett-Stevens H, Woidneck MR: A randomized clinical trial of acceptance and commitment therapy versus progressive relaxation training for obsessive-compulsive disorder. J Consult Clin Psychol. 2010, 78: 705-716.

  672. Wilhelm S, Steketee G, Fama JM, Buhlmann U, Teachman BA, Golan E: Modular cognitive therapy for obsessive-compulsive disorder: a wait-list controlled trial. J Cogn Psychother. 2009, 23: 294-305.

  673. Freeston MH, Ladouceur R, Gagnon F, Thibodeau N, Rheaume J, Letarte H, Bujold A: Cognitive-behavioral treatment of obsessive thoughts: a controlled study. J Consult Clin Psychol. 1997, 65: 405-413.

  674. O’Connor KP, Aardema F, Bouthillier D, Fournier S, Guay S, Robillard S, Pelissier MC, Landry P, Todorov C, Tremblay M, Pitre D: Evaluation of an inference-based approach to treating obsessive-compulsive disorder. Cogn Behav Ther. 2005, 34: 148-163.

  675. Park HS, Shin YW, Ha TH, Shin MS, Kim YY, Lee YH, Kwon JS: Effect of cognitive training focusing on organizational strategies in patients with obsessive-compulsive disorder. Psychiatry Clin Neurosci. 2006, 60: 718-726.

  676. Buhlmann U, Deckersbach T, Engelhard I, Cook LM, Rauch SL, Kathmann N, Wilhelm S, Savage CR: Cognitive retraining for organizational impairment in obsessive-compulsive disorder. Psychiatry Res. 2006, 144: 109-116.

  677. Hanstede M, Gidron Y, Nyklicek I: The effects of a mindfulness intervention on obsessive-compulsive symptoms in a non-clinical student population. J Nerv Ment Dis. 2008, 196: 776-779.

  678. Simpson HB, Zuckoff AM, Maher MJ, Page JR, Franklin ME, Foa EB, Schmidt AB, Wang Y: Challenges using motivational interviewing as an adjunct to exposure therapy for obsessive-compulsive disorder. Behav Res Ther. 2010, 48: 941-948.

  679. Meyer E, Souza F, Heldt E, Knapp P, Cordioli A, Shavitt RG, Leukefeld C: A randomized clinical trial to examine enhancing cognitive-behavioral group therapy for obsessive-compulsive disorder with motivational interviewing and thought mapping. Behav Cogn Psychother. 2010, 38: 319-336.

  680. Nazari H, Momeni N, Jariani M, Tarrahi MJ: Comparison of eye movement desensitization and reprocessing with citalopram in treatment of obsessive-compulsive disorder. Int J Psychiatry Clin Pract. 2011, 15: 270-274.

  681. Tolin DF, Hannan S, Maltby N, Diefenbach GJ, Worhunsky P, Brady RE: A randomized controlled trial of self-directed versus therapist-directed cognitive-behavioral therapy for obsessive-compulsive disorder patients with prior medication trials. Behav Ther. 2007, 38: 179-191.

  682. Lovell K, Cox D, Haddock G, Jones C, Raines D, Garvey R, Roberts C, Hadley S: Telephone administered cognitive behaviour therapy for treatment of obsessive compulsive disorder: randomised controlled non-inferiority trial. BMJ. 2006, 333: 883-

  683. Moritz S, Jelinek L, Hauschildt M, Naber D: How to treat the untreated: effectiveness of a self-help metacognitive training program (myMCT) for obsessive-compulsive disorder. Dialogues Clin Neurosci. 2010, 12: 209-220.

  684. Moritz S, Jelinek L: Further evidence for the efficacy of association splitting as a self-help technique for reducing obsessive thoughts. Depress Anxiety. 2011, 28: 574-581.

  685. Andersson E, Enander J, Andren P, Hedman E, Ljotsson B, Hursti T, Bergstrom J, Kaldo V, Lindefors N, Andersson G, Ruck C: Internet-based cognitive behaviour therapy for obsessive-compulsive disorder: a randomized controlled trial. Psychol Med. 2012, 1-11.

  686. Tumur I, Kaltenthaler E, Ferriter M, Beverley C, Parry G: Computerised cognitive behaviour therapy for obsessive-compulsive disorder: a systematic review. Psychother Psychosom. 2007, 76: 196-202.

  687. Greist JH, Marks IM, Baer L, Kobak KA, Wenzel KW, Hirsch MJ, Mantle JM, Clary CM: Behavior therapy for obsessive-compulsive disorder guided by a computer or by a clinician compared with relaxation as a control. J Clin Psychiatry. 2002, 63: 138-145.

  688. Kenwright M, Marks I, Graham C, Franses A, Mataix-Cols D: Brief scheduled phone support from a clinician to enhance computer-aided self-help for obsessive-compulsive disorder: randomized controlled trial. J Clin Psychol. 2005, 61: 1499-1508.

  689. Lebowitz ER, Panza KE, Su J, Bloch MH: Family accommodation in obsessive-compulsive disorder. Expert Rev Neurother. 2012, 12: 229-238.

  690. Rachman S, Elliott CM, Shafran R, Radomsky AS: Separating hoarding from OCD. Behav Res Ther. 2009, 47: 520-522.

  691. Muroff J, Steketee G, Bratiotis C, Ross A: Group cognitive and behavioral therapy and bibliotherapy for hoarding: a pilot trial. Depress Anxiety. 2012, 29: 597-604.

  692. Foa EB, Franklin ME, Moser J: Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination?. Biol Psychiatry. 2002, 52: 987-997.

  693. Simpson HB, Foa EB, Liebowitz MR, Ledley DR, Huppert JD, Cahill S, Vermes D, Schmidt AB, Hembree E, Franklin M, et al: A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. Am J Psychiatry. 2008, 165: 621-630.

  694. Simpson HB, Liebowitz MR, Foa EB, Kozak MJ, Schmidt AB, Rowan V, Petkova E, Kjernisted K, Huppert JD, Franklin ME, et al: Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder. Depress Anxiety. 2004, 19: 225-233.

  695. van Oppen P, van Balkom AJ, de Haan E, van Dyck R: Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5-year follow-up. J Clin Psychiatry. 2005, 66: 1415-1422.

  696. O’Connor KP, Aardema F, Robillard S, Guay S, Pelissier MC, Todorov C, Borgeat F, Leblanc V, Grenier S, Doucet P: Cognitive behaviour therapy and medication in the treatment of obsessive-compulsive disorder. Acta Psychiatr Scand. 2006, 113: 408-419.

  697. Kordon A, Kahl KG, Broocks A, Voderholzer U, Rasche-Rauchle H, Hohagen F: Clinical outcome in patients with obsessive-compulsive disorder after discontinuation of SRI treatment: results from a two-year follow-up. Eur Arch Psychiatry Clin Neurosci. 2005, 255: 48-50.

  698. Chasson GS, Buhlmann U, Tolin DF, Rao SR, Reese HE, Rowley T, Welsh KS, Wilhelm S: Need for speed: evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine. Behav Res Ther. 2010, 48: 675-679.

  699. Kushner MG, Kim SW, Donahue C, Thuras P, Adson D, Kotlyar M, McCabe J, Peterson J, Foa EB: D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry. 2007, 62: 835-838.

  700. Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, Reese HE, Cannistraro P, Jenike MA, Rauch SL: Augmentation of behavior therapy with d-cycloserine for obsessive-compulsive disorder. Am J Psychiatry. 2008, 165: 335-341. quiz 409

  701. Storch EA, Merlo LJ, Bengtson M, Murphy TK, Lewis MH, Yang MC, Jacob ML, Larson M, Hirsh A, Fernandez M, et al: D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2007, 22: 230-237.

  702. Braga DT, Manfro GG, Niederauer K, Cordioli AV: Full remission and relapse of obsessive-compulsive symptoms after cognitive-behavioral group therapy: a two-year follow-up. Rev Bras Psiquiatr. 2010, 32: 164-168.

  703. Whittal ML, Robichaud M, Thordarson DS, McLean PD: Group and individual treatment of obsessive-compulsive disorder using cognitive therapy and exposure plus response prevention: a 2-year follow-up of two randomized trials. J Consult Clin Psychol. 2008, 76: 1003-1014.

  704. Anand N, Sudhir PM, Math SB, Thennarasu K, Janardhan Reddy YC: Cognitive behavior therapy in medication non-responders with obsessive-compulsive disorder: a prospective 1-year follow-up study. J Anxiety Disord. 2011, 25: 939-945.

  705. Stein DJ, Andersen EW, Tonnoir B, Fineberg N: Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr Med Res Opin. 2007, 23: 701-711.

  706. Khan MN, Hotiana UA, Ahmad S: Escitalopram in the treatment of obsessive-compulsive disorder: a double blind placebo control trial. J Ayub Med Coll Abbottabad. 2007, 19: 58-63.

  707. Shim G, Park HY, Jang JH, Kim E, Hwang JY, Kim SN, Jang GE, Kwon JS: What is the optimal dose of escitalopram for the treatment of obsessive-compulsive disorder? A naturalistic open-label study. Int Clin Psychopharmacol. 2011, 26: 284-290.

  708. Dougherty DD, Jameson M, Deckersbach T, Loh R, Thompson-Hollands J, Jenike M, Keuthen NJ: Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 2009, 24: 306-311.

  709. Rabinowitz I, Baruch Y, Barak Y: High-dose escitalopram for the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 2008, 23: 49-53.

  710. Bergeron R, Ravindran A, Chaput Y, Goldner E, Swinson R, van AM, Austin C, Hadrava V: Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study. J Clin Psychopharmacol. 2002, 22: 148-154.

  711. Piccinelli M, Pini S, Bellantuono C, Wilkinson G: Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry. 1995, 166: 424-443.

  712. Zitterl W, Meszaros K, Hornik K, Twaroch T, Dossenbach M, Zitterl-Eglseer K, Zapotoczky HG: Efficacy of fluoxetine in Austrian patients with obsessive-compulsive disorder. Wien Klin Wochenschr. 1999, 111: 439-442.

  713. Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC: Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch Gen Psychiatry. 1995, 52: 53-60.

  714. Ackerman DL, Greenland S: Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol. 2002, 22: 309-317.

  715. Sayyah M, Boostani H, Pakseresht S, Malayeri A: Comparison of silybum marianum (L.) gaertn. with fluoxetine in the treatment of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2010, 34: 362-365.

  716. Lopez-Ibor JJ, Saiz J, Cottraux J, Note I, Vinas R, Bourgeois M, Hernandez M, Gomez-Perez JC: Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder. Eur Neuropsychopharmacol. 1996, 6: 111-118.

  717. Mundo E, Maina G, Uslenghi C: Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 2000, 15: 69-76.

  718. Mundo E, Rouillon F, Figuera M, Stigler M: Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine. Hum Psychopharmacol. 2001, 16: 461-468.

  719. Hollander E, Koran LM, Goodman WK, Greist JH, Ninan PT, Yang H, Li D, Barbato LM: A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry. 2003, 64: 640-647.

  720. Zohar J, Judge R: Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. Br J Psychiatry. 1996, 169: 468-474.

  721. Denys D, van der Wee N, van Megen HJ, Westenberg HG: A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol. 2003, 23: 568-575.

  722. Hollander E, Allen A, Steiner M, Wheadon DE, Oakes R, Burnham DB: Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatry. 2003, 64: 1113-1121.

  723. Hoehn-Saric R, Ninan P, Black D, Stahl S, Greist J, Lydiard B, McElroy S, Zajecka J, Chapman D, Clary C, Harrison W: Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry. 2000, 57: 76-82.

  724. Bisserbe J, Lane R, Flament M: A double-blind comparison of sertraline and clomipramine in outpatients with obsessive compulsive disorder. Eur Psychiatry. 1997, 12: 82-93.

  725. Ninan PT, Koran LM, Kiev A, Davidson JR, Rasmussen SA, Zajecka JM, Robinson DG, Crits-Christoph P, Mandel FS, Austin C: High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry. 2006, 67: 15-22.

  726. Montgomery S, Kasper S, Stein D, Bang Hedegaard K, Lemming O: Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2001, 16: 75-86.

  727. Pallanti S, Quercioli L, Bruscoli M: Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J Clin Psychiatry. 2004, 65: 1394-1399.

  728. Vulink NC, Denys D, Fluitman SB, Meinardi JC, Westenberg HG: Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. J Clin Psychiatry. 2009, 70: 1001-1008.

  729. Pallanti S, Quercioli L, Koran LM: Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J Clin Psychiatry. 2002, 63: 796-801.

  730. Marazziti D, Golia F, Consoli G, Presta S, Pfanner C, Carlini M, Mungai F, Catena Dell’osso M: Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients. CNS Spectr. 2008, 13: 971-976.

  731. Albert U, Aguglia E, Maina G, Bogetto F: Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J Clin Psychiatry. 2002, 63: 1004-1009.

  732. Yaryura-Tobias JA, Neziroglu FA: Venlafaxine in obsessive-compulsive disorder [Letter]. Arch Gen Psychiatry. 1996, 53: 653-654.

  733. Denys D, van Megen HJ, van der Wee N, Westenberg HG: A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J Clin Psychiatry. 2004, 65: 37-43.

  734. Dell’osso B, Mundo E, Marazziti D, Altamura AC: Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series. J Psychopharmacol. 2008, 22: 210-213.

  735. Blay S, Black DW: A case of obsessive-compulsive disorder responding to duloxetine. Prim Care Companion J Clin Psychiatry. 2007, 9: 234-235.

  736. Yeh YW, Chen CH, Kuo SC, Wang SC, Chen CK, Feng HM: High-dose duloxetine for treatment-resistant obsessive-compulsive disorder: a case report with sustained full remission. Clin Neuropharmacol. 2009, 32: 174-176.

  737. Vallejo J, Olivares J, Marcos T, Bulbena A, Menchon JM: Clomipramine versus phenelzine in obsessive-compulsive disorder. A controlled clinical trial. Br J Psychiatry. 1992, 161: 665-670.

  738. Jenike MA, Baer L, Minichiello WE, Rauch SL, Buttolph ML: Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am J Psychiatry. 1997, 154: 1261-1264.

  739. Joffe R, Swinson R: Tranylcypromine in primary obsessive-compulsive disorder. J Anxiety Disord. 1990, 4: 365-367.

  740. Stein DJ, Spadaccini E, Hollander E: Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacol. 1995, 10: 11-18.

  741. Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ, Henk HJ: Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis. Psychopharmacology (Berl). 1998, 136: 205-216.

  742. Fallon BA, Liebowitz MR, Campeas R, Schneier FR, Marshall R, Davies S, Goetz D, Klein DF: Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study. Arch Gen Psychiatry. 1998, 55: 918-924.

  743. Koran LM, Sallee FR, Pallanti S: Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Am J Psychiatry. 1997, 154: 396-401.

  744. Koran LM, Aboujaoude E, Ward H, Shapira NA, Sallee FR, Gamel N, Elliott M: Pulse-loaded intravenous clomipramine in treatment-resistant obsessive-compulsive disorder. J Clin Psychopharmacol. 2006, 26: 79-83.

  745. Goodman WK, Price LH, Delgado PL, Palumbo J, Krystal JH, Nagy LM, Rasmussen SA, Heninger GR, Charney DS: Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry. 1990, 47: 577-585.

  746. Diniz JB, Shavitt RG, Pereira CA, Hounie AG, Pimentel I, Koran LM, Dainesi SM, Miguel EC: Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial. J Psychopharmacol. 2010, 24: 297-307.

  747. Diniz JB, Shavitt RG, Fossaluza V, Koran L, Pereira CA, Miguel EC: A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder. J Clin Psychopharmacol. 2011, 31: 763-768.

  748. Koran L, Gamel N, Choung H, Smith E, Aboujaoude E: Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychiatry. 2005, 66: 515-520.

  749. Vulink NC, Denys D, Westenberg HG: Bupropion for patients with obsessive-compulsive disorder: an open-label, fixed-dose study. J Clin Psychiatry. 2005, 66: 228-230.

  750. Muscatello MR, Bruno A, Pandolfo G, Mico U, Scimeca G, Romeo VM, Santoro V, Settineri S, Spina E, Zoccali RA: Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2011, 31: 174-179.

  751. Pessina E, Albert U, Bogetto F, Maina G: Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study. Int Clin Psychopharmacol. 2009, 24: 265-269.

  752. Ak M, Bulut SD, Bozkurt A, Ozsahin A: Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study. Adv Ther. 2011, 28: 341-348.

  753. Delle Chiaie R, Scarciglia P, Pasquini M, Caredda M, Biondi M: Aripiprazole augmentation in patients with resistant obsessive compulsive disorder: a pilot study. Clin Pract Epidemiol Ment Health. 2011, 7: 107-111.

  754. Sayyah M, Boostani H, Ghaffari SM, Hoseini A: Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial). Depress Anxiety. 2012, 29: 850-854.

  755. Selvi Y, Atli A, Aydin A, Besiroglu L, Ozdemir P, Ozdemir O: The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study. Hum Psychopharmacol. 2011, 26: 51-57.

  756. McDougle C, Epperson C, Pelton G, Wasylink S, Price L: A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000, 57: 794-801.

  757. Hollander E, Baldini Rossi N, Sood E, Pallanti S: Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2003, 6: 397-401.

  758. Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR: Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry. 2005, 66: 736-743.

  759. Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L: Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol. 2005, 15: 69-74.

  760. Maina G, Pessina E, Albert U, Bogetto F: 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2008, 18: 364-372.

  761. Simpson HB, Foa EB, Liebowitz MR, Huppert JD, Cahill S, Maher MJ, McLean CP, Bender J, Marcus SM, Williams MT, et al: Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry. 2013, 70: 1190-1199.

  762. Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S: Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry. 2004, 65: 565-568.

  763. Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MC, Blier P, Goodman WK: A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry. 2004, 55: 553-555.

  764. Fineberg NA, Sivakumaran T, Roberts A, Gale T: Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int Clin Psychopharmacol. 2005, 20: 223-226.

  765. Carey PD, Vythilingum B, Seedat S, Muller JE, van Ameringen M, Stein DJ: Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study. BMC Psychiatry. 2005, 5: 5-

  766. Denys D, de Geus F, van Megen H, Westenberg H: A double blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry. 2004, 65: 1040-1048.

  767. Savas HA, Yumru M, Ozen ME: Quetiapine and ziprasidone as adjuncts in treatment-resistant obsessive-compulsive disorder: a retrospective comparative study. Clin Drug Investig. 2008, 28: 439-442.

  768. Kordon A, Wahl K, Koch N, Zurowski B, Anlauf M, Vielhaber K, Kahl KG, Broocks A, Voderholzer U, Hohagen F: Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol. 2008, 28: 550-554.

  769. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH: Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994, 51: 302-308.

  770. Metin O, Yazici K, Tot S, Yazici AE: Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial. Hum Psychopharmacol. 2003, 18: 463-467.

  771. Hollander E, Kaplan A, Stahl SM: A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder. World J Biol Psychiatry. 2003, 4: 30-34.

  772. Crockett BA, Churchill E, Davidson JR: A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder. Ann Clin Psychiatry. 2004, 16: 127-132.

  773. Hewlett WA, Vinogradov S, Agras WS: Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol. 1992, 12: 420-430.

  774. Dannon P, Sasson Y, Hirschmann S, Iancu I, Grunhaus L, Zohar J: Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial. Eur Neuropsychopharmacol. 2000, 10: 165-169.

  775. Mundo E, Guglielmo E, Bellodi L: Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study. Int Clin Psychopharmacol. 1998, 13: 219-224.

  776. Blier P, Bergeron R: Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: preliminary findings. Int Clin Psychopharmacol. 1996, 11: 37-44.

  777. Sayyah M, Boostani H, Pakseresht S, Malayeri A: A preliminary randomized double-blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive-compulsive disorder. Psychiatry Res. 2011, 189: 403-406.

  778. Askari N, Moin M, Sanati M, Tajdini M, Hosseini SM, Modabbernia A, Najand B, Salimi S, Tabrizi M, Ashrafi M, et al: Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2012, 26: 883-892.

  779. Rodriguez CI, Kegeles LS, Levinson A, Feng T, Marcus SM, Vermes D, Flood P, Simpson HB: Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology. 2013, 38: 2475-2483.

  780. Bloch MH, Wasylink S, Landeros-Weisenberger A, Panza KE, Billingslea E, Leckman JF, Krystal JH, Bhagwagar Z, Sanacora G, Pittenger C: Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol Psychiatry. 2012, 72: 964-970.

  781. Aboujaoude E, Barry JJ, Gamel N: Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol. 2009, 29: 51-55.

  782. Stewart SE, Jenike EA, Hezel DM, Stack DE, Dodman NH, Shuster L, Jenike MA: A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol. 2010, 30: 34-39.

  783. Ghaleiha A, Entezari N, Modabbernia A, Najand B, Askari N, Tabrizi M, Ashrafi M, Hajiaghaee R, Akhondzadeh S: Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res. 2013, 47: 175-180.

  784. Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E: Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. CNS Drugs. 2009, 23: 1047-1055.

  785. Soltani F, Sayyah M, Feizy F, Malayeri A, Siahpoosh A, Motlagh I: A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. Hum Psychopharmacol. 2010, 25: 509-513.

  786. Afshar H, Roohafza H, Mohammad-Beigi H, Haghighi M, Jahangard L, Shokouh P, Sadeghi M, Hafezian H: N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2012, 32: 797-803.

  787. Van Ameringen M, Patterson B, Simpson W, Turna J: N-acetylcysteine augmentation in treatment resistant obsessive compulsive disorder: A case series. J Obsess Compul Rel Dis. 2013, 2: 48-52.

  788. Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, et al: Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry. 2005, 58: 424-428.

  789. Pittenger C, Kelmendi B, Wasylink S, Bloch MH, Coric V: Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a series of 13 cases, with long-term follow-up. J Clin Psychopharmacol. 2008, 28: 363-367.

  790. McDougle CJ, Price LH, Goodman WK, Charney DS, Heninger GR: A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol. 1991, 11: 175-184.

  791. Pigott TA, Pato MT, L’Heureux F, Hill JL, Grover GN, Bernstein SE, Murphy DL: A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol. 1991, 11: 242-248.

  792. Jenike MA, Baer L, Buttolph L: Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder. J Clin Psychiatry. 1991, 52: 13-14.

  793. Pigott TA, L’Heureux F, Hill JL, Bihari K, Bernstein SE, Murphy DL: A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol. 1992, 12: 11-18.

  794. Rodriguez CI, Bender J, Marcus SM, Snape M, Rynn M, Simpson HB: Minocycline augmentation of pharmacotherapy in obsessive-compulsive disorder: an open-label trial [Letter]. J Clin Psychiatry. 2010, 71: 1247-1249.

  795. Rubio G, Jimenez-Arriero MA, Martinez-Gras I, Manzanares J, Palomo T: The effects of topiramate adjunctive treatment added to antidepressants in patients with resistant obsessive-compulsive disorder. J Clin Psychopharmacol. 2006, 26: 341-344.

  796. Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, Hollander E: Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2011, 72: 716-721.

  797. Mowla A, Khajeian AM, Sahraian A, Chohedri AH, Kashkoli F: Topiramate augmentation in resistant OCD: a double-blind placebo-controlled clinical trial. CNS Spectr. 2010, 15: 613-617.

  798. Van Ameringen M, Mancini C, Patterson B, Bennett M: Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series. Depress Anxiety. 2006, 23: 1-5.

  799. Bruno A, Mico U, Pandolfo G, Mallamace D, Abenavoli E, Di Nardo F, D’Arrigo C, Spina E, Zoccali RA, Muscatello MR: Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Psychopharmacol. 2012, 26: 1456-1462.

  800. Kumar TC, Khanna S: Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder. Aust N Z J Psychiatry. 2000, 34: 527-528.

  801. Di Nicola M, Tedeschi D, Martinotti G, De Vita O, Monetta M, Pozzi G, Janiri L: Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder: a 16-week case series. J Clin Psychopharmacol. 2011, 31: 675-677.

  802. Oulis P, Mourikis I, Konstantakopoulos G: Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder. Int Clin Psychopharmacol. 2011, 26: 221-224.

  803. Onder E, Tural U, Gokbakan M: Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder?. Eur Arch Psychiatry Clin Neurosci. 2008, 258: 319-323.

  804. Cora-Locatelli G, Greenberg BD, Martin J, Murphy DL: Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder [Letter]. J Clin Psychiatry. 1998, 59: 480-481.

  805. Goldsmith TB, Shapira NA, Keck PE: Rapid remission of OCD with tramadol hydrochloride [Letter]. Am J Psychiatry. 1999, 156: 660-661.

  806. Shapira NA, Keck PE, Goldsmith TD, McConville BJ, Eis M, McElroy SL: Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder. Depress Anxiety. 1997, 6: 170-173.

  807. Amiaz R, Fostick L, Gershon A, Zohar J: Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study. Eur Neuropsychopharmacol. 2008, 18: 455-461.

  808. Koran LM, Aboujaoude E, Bullock KD, Franz B, Gamel N, Elliott M: Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2005, 66: 353-359.

  809. Soomro GM, Altman D, Rajagopal S, Oakley-Browne M: Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev. 2008, CD001765-

  810. Stein DJ, Andersen EW, Overo KF: Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo. Rev Bras Psiquiatr. 2007, 29: 303-307.

  811. Stein DJ, Carey PD, Lochner C, Seedat S, Fineberg N, Andersen EW: Escitalopram in obsessive-compulsive disorder: response of symptom dimensions to pharmacotherapy. CNS Spectr. 2008, 13: 492-498.

  812. Landeros-Weisenberger A, Bloch MH, Kelmendi B, Wegner R, Nudel J, Dombrowski P, Pittenger C, Krystal JH, Goodman WK, Leckman JF, Coric V: Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder. J Affect Disord. 2010, 121: 175-179.

  813. Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB: Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry. 2007, 164: 5-53.

  814. Decloedt EH, Stein DJ: Current trends in drug treatment of obsessive-compulsive disorder. Neuropsychiatr Dis Treat. 2010, 6: 233-242.

  815. Ipser JC, Carey P, Dhansay Y, Fakier N, Seedat S, Stein DJ: Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database Syst Rev. 2006, CD005473-

  816. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF: A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006, 11: 622-632.

  817. Komossa K, Depping AM, Meyer M, Kissling W, Leucht S: Second-generation antipsychotics for obsessive compulsive disorder. Cochrane Database Syst Rev. 2010, CD008141-

  818. Fineberg NA, Tonnoir B, Lemming O, Stein DJ: Escitalopram prevents relapse of obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2007, 17: 430-439.

  819. Koran LM, Hackett E, Rubin A, Wolkow R, Robinson D: Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. Am J Psychiatry. 2002, 159: 88-95.

  820. Romano S, Goodman W, Tamura R, Gonzales J: Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. J Clin Psychopharmacol. 2001, 21: 46-52.

  821. Katz RJ, DeVeaugh-Geiss J, Landau P: Clomipramine in obsessive-compulsive disorder. Biol Psychiatry. 1990, 28: 401-414.

  822. Rasmussen S, Hackett E, DuBoff E, Greist J, Halaris A, Koran LM, Liebowitz M, Lydiard RB, McElroy S, Mendels J, O’Connor K: A 2-year study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 1997, 12: 309-316.

  823. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G: Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs). Psychopharmacol Bull. 1996, 32: 167-173.

  824. Koran LM, Bromberg D, Hornfeldt CS, Shepski JC, Wang S, Hollander E: Extended-release fluvoxamine and improvements in quality of life in patients with obsessive-compulsive disorder. Compr Psychiatry. 2010, 51: 373-379.

  825. Mantovani A, Lisanby SH, Pieraccini F, Ulivelli M, Castrogiovanni P, Rossi S: Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette’s syndrome (TS). Int J Neuropsychopharmacol. 2006, 9: 95-100.

  826. Kumar N, Chadda RK: Augmentation effect of repetitive transcranial magnetic stimulation over the supplementary motor cortex in treatment refractory patients with obsessive compulsive disorder. Indian J Psychiatry. 2011, 53: 340-342.

  827. Mantovani A, Simpson HB, Fallon BA, Rossi S, Lisanby SH: Randomized sham-controlled trial of repetitive transcranial magnetic stimulation in treatment-resistant obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2010, 13: 217-227.

  828. Ruffini C, Locatelli M, Lucca A, Benedetti F, Insacco C, Smeraldi E: Augmentation effect of repetitive transcranial magnetic stimulation over the orbitofrontal cortex in drug-resistant obsessive-compulsive disorder patients: a controlled investigation. Prim Care Companion J Clin Psychiatry. 2009, 11: 226-230.

  829. Sachdev PS, Loo CK, Mitchell PB, McFarquhar TF, Malhi GS: Repetitive transcranial magnetic stimulation for the treatment of obsessive compulsive disorder: a double-blind controlled investigation. Psychol Med. 2007, 37: 1645-1649.

  830. Sarkhel S, Sinha VK, Praharaj SK: Adjunctive high-frequency right prefrontal repetitive transcranial magnetic stimulation (rTMS) was not effective in obsessive-compulsive disorder but improved secondary depression. J Anxiety Disord. 2010, 24: 535-539.

  831. Prasko J, Paskova B, Zalesky R, Novak T, Kopecek M, Bares M, Horacek J: The effect of repetitive transcranial magnetic stimulation (rTMS) on symptoms in obsessive compulsive disorder. A randomized, double blind, sham controlled study. Neuro Endocrinol Lett. 2006, 27: 327-332.

  832. Greenberg BD, Gabriels LA, Malone DA, Rezai AR, Friehs GM, Okun MS, Shapira NA, Foote KD, Cosyns PR, Kubu CS, et al: Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience. Mol Psychiatry. 2010, 15: 64-79.

  833. Goodman WK, Foote KD, Greenberg BD, Ricciuti N, Bauer R, Ward H, Shapira NA, Wu SS, Hill CL, Rasmussen SA, Okun MS: Deep brain stimulation for intractable obsessive compulsive disorder: pilot study using a blinded, staggered-onset design. Biol Psychiatry. 2010, 67: 535-542.

  834. Abelson JL, Curtis GC, Sagher O, Albucher RC, Harrigan M, Taylor SF, Martis B, Giordani B: Deep brain stimulation for refractory obsessive-compulsive disorder. Biol Psychiatry. 2005, 57: 510-516.

  835. Liu K, Zhang H, Liu C, Guan Y, Lang L, Cheng Y, Sun B, Wang H, Zuo C, Pan L, et al: Stereotactic treatment of refractory obsessive compulsive disorder by bilateral capsulotomy with 3 years follow-up. J Clin Neurosci. 2008, 15: 622-629.

  836. Ruck C, Karlsson A, Steele JD, Edman G, Meyerson BA, Ericson K, Nyman H, Asberg M, Svanborg P: Capsulotomy for obsessive-compulsive disorder: long-term follow-up of 25 patients. Arch Gen Psychiatry. 2008, 65: 914-921.

  837. Lopes AC, Greenberg BD, Noren G, Canteras MM, Busatto GF, de Mathis ME, Taub A, D’Alcante CC, Hoexter MQ, Gouvea FS, et al: Treatment of resistant obsessive-compulsive disorder with ventral capsular/ventral striatal gamma capsulotomy: a pilot prospective study. J Neuropsychiatry Clin Neurosci. 2009, 21: 381-392.

  838. Csigo K, Harsanyi A, Demeter G, Rajkai C, Nemeth A, Racsmany M: Long-term follow-up of patients with obsessive-compulsive disorder treated by anterior capsulotomy: a neuropsychological study. J Affect Disord. 2010, 126: 198-205.

  839. Ruck C, Larsson KJ, Mataix-Cols D: Predictors of medium and long-term outcome following capsulotomy for obsessive-compulsive disorder: one site may not fit all. Eur Neuropsychopharmacol. 2012, 22: 406-414.

  840. Jung HH, Kim CH, Chang JH, Park YG, Chung SS, Chang JW: Bilateral anterior cingulotomy for refractory obsessive-compulsive disorder: Long-term follow-up results. Stereotact Funct Neurosurg. 2006, 84: 184-189.

  841. Dougherty DD, Baer L, Cosgrove GR, Cassem EH, Price BH, Nierenberg AA, Jenike MA, Rauch SL: Prospective long-term follow-up of 44 patients who received cingulotomy for treatment-refractory obsessive-compulsive disorder. Am J Psychiatry. 2002, 159: 269-275.

  842. Kim CH, Chang JW, Koo MS, Kim JW, Suh HS, Park IH, Lee HS: Anterior cingulotomy for refractory obsessive-compulsive disorder. Acta Psychiatr Scand. 2003, 107: 283-290.

  843. Krisanaprakornkit T, Krisanaprakornkit W, Piyavhatkul N, Laopaiboon M: Meditation therapy for anxiety disorders. Cochrane Database Syst Rev. 2006, CD004998-

  844. Abrantes AM, Strong DR, Cohn A, Cameron AY, Greenberg BD, Mancebo MC, Brown RA: Acute changes in obsessions and compulsions following moderate-intensity aerobic exercise among patients with obsessive-compulsive disorder. J Anxiety Disord. 2009, 23: 923-927.

  845. Brown RA, Abrantes AM, Strong DR, Mancebo MC, Menard J, Rasmussen SA, Greenberg BD: A pilot study of moderate-intensity aerobic exercise for obsessive compulsive disorder. J Nerv Ment Dis. 2007, 195: 514-520.

  846. Pakseresht S, Boostani H, Sayyah M: Extract of valerian root (Valeriana officinalis L.) vs. placebo in treatment of obsessive-compulsive disorder: a randomized double-blind study. J Complement Integr Med. 2011, 8: 10.2202/1553-3840.1465

  847. Taylor LH, Kobak KA: An open-label trial of St. John’s Wort (Hypericum perforatum) in obsessive-compulsive disorder. J Clin Psychiatry. 2000, 61: 575-578.

  848. Van Ameringen M, Mancini C, Patterson B, Boyle MH: Post-traumatic stress disorder in Canada. CNS Neurosci Ther. 2008, 14: 171-181.

  849. Pietrzak RH, Goldstein RB, Southwick SM, Grant BF: Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. J Anxiety Disord. 2011, 25: 456-465.

  850. Darves-Bornoz JM, Alonso J, de Girolamo G, de Graaf R, Haro JM, Kovess-Masfety V, Lepine JP, Nachbaur G, Negre-Pages L, Vilagut G, Gasquet I: Main traumatic events in Europe: PTSD in the European study of the epidemiology of mental disorders survey. J Trauma Stress. 2008, 21: 455-462.

  851. Stein MB, Walker JR, Hazen AL, Forde DR: Full and partial posttraumatic stress disorder: findings from a community survey. Am J Psychiatry. 1997, 154: 1114-1119.

  852. Bravo-Mehmedbasic A, Kucukalic A, Kulenovic AD, Suljic E: Impact of chronic posttraumatic stress disorder on the quality of life of war survivors. Psychiatr Danub. 2010, 22: 430-435.

  853. Pietrzak RH, Goldstein MB, Malley JC, Johnson DC, Southwick SM: Subsyndromal posttraumatic stress disorder is associated with health and psychosocial difficulties in veterans of Operations Enduring Freedom and Iraqi Freedom. Depress Anxiety. 2009, 26: 739-744.

  854. Westphal M, Olfson M, Gameroff MJ, Wickramaratne P, Pilowsky DJ, Neugebauer R, Lantigua R, Shea S, Neria Y: Functional impairment in adults with past posttraumatic stress disorder: findings from primary care. Depress Anxiety. 2011, 28: 686-695.

  855. Rona RJ, Jones M, Iversen A, Hull L, Greenberg N, Fear NT, Hotopf M, Wessely S: The impact of posttraumatic stress disorder on impairment in the UK military at the time of the Iraq war. J Psychiatr Res. 2009, 43: 649-655.

  856. Asmundson GJ, Wright KD, Stein MB: Pain and PTSD symptoms in female veterans. Eur J Pain. 2004, 8: 345-350.

  857. Poundja J, Fikretoglu D, Guay S, Brunet A: Validation of the French version of the brief pain inventory in Canadian veterans suffering from traumatic stress. J Pain Symptom Manage. 2007, 33: 720-726.

  858. Villano CL, Rosenblum A, Magura S, Fong C, Cleland C, Betzler TF: Prevalence and correlates of posttraumatic stress disorder and chronic severe pain in psychiatric outpatients. J Rehabil Res Dev. 2007, 44: 167-178.

  859. Lowe B, Kroenke K, Spitzer RL, Williams JB, Mussell M, Rose M, Wingenfeld K, Sauer N, Spitzer C: Trauma exposure and posttraumatic stress disorder in primary care patients: cross-sectional criterion standard study. J Clin Psychiatry. 2011, 72: 304-312.

  860. Babson K, Feldner M, Badour C, Trainor C, Blumenthal H, Sachs-Ericsson N, Schmidt N: Posttraumatic stress and sleep: differential relations across types of symptoms and sleep problems. J Anxiety Disord. 2011, 25: 706-713.

  861. Hirsch KA: Sexual dysfunction in male Operation Enduring Freedom/Operation Iraqi Freedom patients with severe post-traumatic stress disorder. Mil Med. 2009, 174: 520-522.

  862. Lagarde G, Doyon J, Brunet A: Memory and executive dysfunctions associated with acute posttraumatic stress disorder. Psychiatry Res. 2010, 177: 144-149.

  863. Reinhard MJ, Wolf G, Cozolino L: Using the MMPI to assess reported cognitive disturbances and somatization as a core feature of complex PTSD. J Trauma Dissociation. 2010, 11: 57-72.

  864. Frewen PA, Dozois DJ, Neufeld RW, Lanius RA: Meta-analysis of alexithymia in posttraumatic stress disorder. J Trauma Stress. 2008, 21: 243-246.

  865. Sareen J, Houlahan T, Cox BJ, Asmundson GJ: Anxiety disorders associated with suicidal ideation and suicide attempts in the National Comorbidity Survey. J Nerv Ment Dis. 2005, 193: 450-454.

  866. Kartha A, Brower V, Saitz R, Samet JH, Keane TM, Liebschutz J: The impact of trauma exposure and post-traumatic stress disorder on healthcare utilization among primary care patients. Med Care. 2008, 46: 388-393.

  867. Fikretoglu D, Brunet A, Guay S, Pedlar D: Mental health treatment seeking by military members with posttraumatic stress disorder: findings on rates, characteristics, and predictors from a nationally representative Canadian military sample. Can J Psychiatry. 2007, 52: 103-110.

  868. Sareen J, Belik SL, Stein MB, Asmundson GJ: Correlates of perceived need for mental health care among active military personnel. Psychiatr Serv. 2010, 61: 50-57.

  869. Nacasch N, Fostick L, Zohar J: High prevalence of obsessive-compulsive disorder among posttraumatic stress disorder patients. Eur Neuropsychopharmacol. 2011, 21: 876-879.

  870. Cougle JR, Feldner MT, Keough ME, Hawkins KA, Fitch KE: Comorbid panic attacks among individuals with posttraumatic stress disorder: associations with traumatic event exposure history, symptoms, and impairment. J Anxiety Disord. 2010, 24: 183-188.

  871. Ginzburg K, Ein-Dor T, Solomon Z: Comorbidity of posttraumatic stress disorder, anxiety and depression: a 20-year longitudinal study of war veterans. J Affect Disord. 2010, 123: 249-257.

  872. Post LM, Zoellner LA, Youngstrom E, Feeny NC: Understanding the relationship between co-occurring PTSD and MDD: symptom severity and affect. J Anxiety Disord. 2011, 25: 1123-1130.

  873. Fetzner MG, McMillan KA, Sareen J, Asmundson GJ: What is the association between traumatic life events and alcohol abuse/dependence in people with and without PTSD? Findings from a nationally representative sample. Depress Anxiety. 2011, 28: 632-638.

  874. Pagura J, Stein MB, Bolton JM, Cox BJ, Grant B, Sareen J: Comorbidity of borderline personality disorder and posttraumatic stress disorder in the U.S. population. J Psychiatr Res. 2010, 44: 1190-1198.

  875. Friedman MJ, Resick PA, Bryant RA, Brewin CR: Considering PTSD for DSM-5. Depress Anxiety. 2011, 28: 750-769.

  876. Rose S, Bisson J, Churchill R, Wessely S: Psychological debriefing for preventing post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2002, CD000560-

  877. van Emmerik AA, Kamphuis JH, Hulsbosch AM, Emmelkamp PM: Single session debriefing after psychological trauma: a meta-analysis. Lancet. 2002, 360: 766-771.

  878. Roberts NP, Kitchiner NJ, Kenardy J, Bisson J: Multiple session early psychological interventions for the prevention of post-traumatic stress disorder. Cochrane Database Syst Rev. 2009, CD006869-

  879. Kornor H, Winje D, Ekeberg O, Weisaeth L, Kirkehei I, Johansen K, Steiro A: Early trauma-focused cognitive-behavioural therapy to prevent chronic post-traumatic stress disorder and related symptoms: a systematic review and meta-analysis. BMC Psychiatry. 2008, 8: 81-

  880. Roberts NP, Kitchiner NJ, Kenardy J, Bisson JI: Early psychological interventions to treat acute traumatic stress symptoms. Cochrane Database Syst Rev. 2010, CD007944-

  881. Gelpin E, Bonne O, Peri T, Brandes D, Shalev A: Treatment of recent trauma survivors with benzodiazepines: a prospective study. J Clin Psychiatry. 1996, 57: 390-394.

  882. Mellman TA, Bustamante V, David D, Fins AI: Hypnotic medication in the aftermath of trauma [letter]. J Clin Psychiatry. 2002, 63: 1183-1184.

  883. Fowler M, Garza TH, Slater TM, Maani CV, McGhee LL: The relationship between gabapentin and pregabalin and posttraumatic stress disorder in burned servicemembers. J Burn Care Res. 2012, 33: 612-618.

  884. Vaiva G, Ducrocq F, Jezequel K, Averland B, Lestavel P, Brunet A, Marmar C: Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma. Biol Psychiatry. 2003, 54: 947-949.

  885. Tarsitani L, De Santis V, Mistretta M, Parmigiani G, Zampetti G, Roselli V, Vitale D, Tritapepe L, Biondi M, Picardi A: Treatment with beta-blockers and incidence of post-traumatic stress disorder after cardiac surgery: a prospective observational study. J Cardiothorac Vasc Anesth. 2011, 26: 265-269.

  886. Sharp S, Thomas C, Rosenberg L, Rosenberg M, Meyer W: Propranolol does not reduce risk for acute stress disorder in pediatric burn trauma. J Trauma. 2010, 68: 193-197.

  887. Pastrana Jimenez JI, Catalina Romero C, Garcia Dieguez N, Lopez-Ibor Alino JJ: Pharmacological treatment of acute stress disorder with propranolol and hypnotics. Actas Esp Psiquiatr. 2007, 35: 351-358.

  888. McGhee LL, Maani CV, Garza TH, Desocio PA, Gaylord KM, Black IH: The effect of propranolol on posttraumatic stress disorder in burned service members. J Burn Care Res. 2009, 30: 92-97.

  889. Pitman R, Sanders K, Zusman R, Healy A, Cheema F, Lasko N, Cahill L, Orr S: Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry. 2002, 51: 189-192.

  890. Stoddard FJ, Luthra R, Sorrentino EA, Saxe GN, Drake J, Chang Y, Levine JB, Chedekel DS, Sheridan RL: A randomized controlled trial of sertraline to prevent posttraumatic stress disorder in burned children. J Child Adolesc Psychopharmacol. 2011, 21: 469-477.

  891. Bryant RA, Creamer M, O’Donnell M, Silove D, McFarlane AC: A study of the protective function of acute morphine administration on subsequent posttraumatic stress disorder. Biol Psychiatry. 2009, 65: 438-440.

  892. Stoddard FJ, Sorrentino EA, Ceranoglu TA, Saxe G, Murphy JM, Drake JE, Ronfeldt H, White GW, Kagan J, Snidman N, et al: Preliminary evidence for the effects of morphine on posttraumatic stress disorder symptoms in one- to four-year-olds with burns. J Burn Care Res. 2009, 30: 836-843.

  893. Saxe G, Geary M, Bedard K, Bosquet M, Miller A, Koenen K, Stoddard F, Moulton S: Separation anxiety as a mediator between acute morphine administration and PTSD symptoms in injured children. Ann N Y Acad Sci. 2006, 1071: 41-45.

  894. Holbrook TL, Galarneau MR, Dye JL, Quinn K, Dougherty AL: Morphine use after combat injury in Iraq and post-traumatic stress disorder. N Engl J Med. 2010, 362: 110-117.

  895. Stewart CL, Wrobel TA: Evaluation of the efficacy of pharmacotherapy and psychotherapy in treatment of combat-related post-traumatic stress disorder: a meta-analytic review of outcome studies. Mil Med. 2009, 174: 460-469.

  896. Nijdam MJ, Gersons BP, Reitsma JB, de Jongh A, Olff M: Brief eclectic psychotherapy v. eye movement desensitisation and reprocessing therapy for post-traumatic stress disorder: randomised controlled trial. Br J Psychiatry. 2012, 200: 224-231.

  897. Resick PA, Nishith P, Weaver TL, Astin MC, Feuer CA: A comparison of cognitive-processing therapy with prolonged exposure and a waiting condition for the treatment of chronic posttraumatic stress disorder in female rape victims. J Consult Clin Psychol. 2002, 70: 867-879.

  898. Foa EB, Dancu CV, Hembree EA, Jaycox LH, Meadows EA, Street GP: A comparison of exposure therapy, stress inoculation training, and their combination for reducing posttraumatic stress disorder in female assault victims. J Consult Clin Psychol. 1999, 67: 194-200.

  899. Resick PA, Galovski TE, O’Brien Uhlmansiek M, Scher CD, Clum GA, Young-Xu Y: A randomized clinical trial to dismantle components of cognitive processing therapy for posttraumatic stress disorder in female victims of interpersonal violence. J Consult Clin Psychol. 2008, 76: 243-258.

  900. Galovski TE, Monson C, Bruce SE, Resick PA: Does cognitive-behavioral therapy for PTSD improve perceived health and sleep impairment?. J Trauma Stress. 2009, 22: 197-204.

  901. Resick PA, Williams LF, Suvak MK, Monson CM, Gradus JL: Long-term outcomes of cognitive-behavioral treatments for posttraumatic stress disorder among female rape survivors. J Consult Clin Psychol. 2012, 80: 201-210.

  902. Bryant RA, Moulds ML, Guthrie RM, Dang ST, Nixon RD: Imaginal exposure alone and imaginal exposure with cognitive restructuring in treatment of posttraumatic stress disorder. J Consult Clin Psychol. 2003, 71: 706-712.

  903. Ehlers A, Clark D, Hackmann A, McManus F, Fennell M, Herbert C, Mayou R: A randomized controlled trial of cognitive therapy, a self-help booklet, and repeated assessments as early interventions for posttraumatic stress disorder. Arch Gen Psychiatry. 2003, 60: 1024-1032.

  904. Zoellner T, Rabe S, Karl A, Maercker A: Post-traumatic growth as outcome of a cognitive-behavioural therapy trial for motor vehicle accident survivors with PTSD. Psychol Psychother. 2011, 84: 201-213.

  905. Kemp M, Drummond P, McDermott B: A wait-list controlled pilot study of eye movement desensitization and reprocessing (EMDR) for children with post-traumatic stress disorder (PTSD) symptoms from motor vehicle accidents. Clinical child psychology and psychiatry. 2010, 15: 5-25.

  906. Beck JG, Coffey SF, Foy DW, Keane TM, Blanchard EB: Group cognitive behavior therapy for chronic posttraumatic stress disorder: an initial randomized pilot study. Behav Ther. 2009, 40: 82-92.

  907. Basoglu M, Salcioglu E, Livanou M: A randomized controlled study of single-session behavioural treatment of earthquake-related post-traumatic stress disorder using an earthquake simulator. Psychol Med. 2007, 37: 203-213.

  908. Hogberg G, Pagani M, Sundin O, Soares J, Aberg-Wistedt A, Tarnell B, Hallstrom T: On treatment with eye movement desensitization and reprocessing of chronic post-traumatic stress disorder in public transportation workers–a randomized controlled trial. Nord J Psychiatry. 2007, 61: 54-61.

  909. Keane TM, Zimering RT, Caddell JM: Implosive (flooding) therapy reduces symptoms of PTSD in Vietnam combat veterans. Behav Ther. 1989, 20: 245-260.

  910. Forbes D, Lloyd D, Nixon RD, Elliott P, Varker T, Perry D, Bryant RA, Creamer M: A multisite randomized controlled effectiveness trial of cognitive processing therapy for military-related posttraumatic stress disorder. J Anxiety Disord. 2012, 26: 442-452.

  911. Alvarez J, McLean C, Harris AH, Rosen CS, Ruzek JI, Kimerling R: The comparative effectiveness of cognitive processing therapy for male veterans treated in a VHA posttraumatic stress disorder residential rehabilitation program. J Consult Clin Psychol. 2011, 79: 590-599.

  912. Macdonald A, Monson CM, Doron-Lamarca S, Resick PA, Palfai TP: Identifying patterns of symptom change during a randomized controlled trial of cognitive processing therapy for military-related posttraumatic stress disorder. J Trauma Stress. 2011, 24: 268-276.

  913. Monson CM, Schnurr PP, Resick PA, Friedman MJ, Young-Xu Y, Stevens SP: Cognitive processing therapy for veterans with military-related posttraumatic stress disorder. J Consult Clin Psychol. 2006, 74: 898-907.

  914. Gros DF, Yoder M, Tuerk PW, Lozano BE, Acierno R: Exposure therapy for PTSD delivered to veterans via telehealth: predictors of treatment completion and outcome and comparison to treatment delivered in person. Behav Ther. 2011, 42: 276-283.

  915. van Minnen A, Foa EB: The effect of imaginal exposure length on outcome of treatment for PTSD. J Trauma Stress. 2006, 19: 427-438.

  916. Bryant RA, Moulds ML, Guthrie RM, Dang ST, Mastrodomenico J, Nixon RD, Felmingham KL, Hopwood S, Creamer M: A randomized controlled trial of exposure therapy and cognitive restructuring for posttraumatic stress disorder. J Consult Clin Psychol. 2008, 76: 695-703.

  917. Foa EB, Hembree EA, Cahill SP, Rauch SA, Riggs DS, Feeny NC, Yadin E: Randomized trial of prolonged exposure for posttraumatic stress disorder with and without cognitive restructuring: outcome at academic and community clinics. J Consult Clin Psychol. 2005, 73: 953-964.

  918. Paunovic N, Öst L-G: Cognitive-behavior therapy vs exposure therapy in the treatment of PTSD in refugees. Behav Res Ther. 2001, 39: 1183-1197.

  919. Moser JS, Cahill SP, Foa EB: Evidence for poorer outcome in patients with severe negative trauma-related cognitions receiving prolonged exposure plus cognitive restructuring: implications for treatment matching in posttraumatic stress disorder. J Nerv Ment Dis. 2010, 198: 72-75.

  920. Grunert BK, Weis JM, Smucker MR, Christianson HF: Imagery rescripting and reprocessing therapy after failed prolonged exposure for post-traumatic stress disorder following industrial injury. J Behav Ther Exp Psychiatry. 2007, 38: 317-328.

  921. Arntz A, Tiesema M, Kindt M: Treatment of PTSD: a comparison of imaginal exposure with and without imagery rescripting. J Behav Ther Exp Psychiatry. 2007, 38: 345-370.

  922. Beidel DC, Frueh BC, Uhde TW, Wong N, Mentrikoski JM: Multicomponent behavioral treatment for chronic combat-related posttraumatic stress disorder: a randomized controlled trial. J Anxiety Disord. 2011, 25: 224-231.

  923. Bradley R, Greene J, Russ E, Dutra L, Westen D: A multidimensional meta-analysis of psychotherapy for PTSD. Am J Psychiatry. 2005, 162: 214-227.

  924. Kar N: Cognitive behavioral therapy for the treatment of post-traumatic stress disorder: a review. Neuropsychiatr Dis Treat. 2011, 7: 167-181.

  925. Schottenbauer MA, Glass CR, Arnkoff DB, Tendick V, Gray SH: Nonresponse and dropout rates in outcome studies on PTSD: review and methodological considerations. Psychiatry. 2008, 71: 134-168.

  926. van der Kolk BA, Roth S, Pelcovitz D, Sunday S, Spinazzola J: Disorders of extreme stress: The empirical foundation of a complex adaptation to trauma. J Trauma Stress. 2005, 18: 389-399.

  927. Najavits LM: Expanding the boundaries of PTSD treatment. JAMA. 2012, 308: 714-716.

  928. Steil R, Dyer A, Priebe K, Kleindienst N, Bohus M: Dialectical behavior therapy for posttraumatic stress disorder related to childhood sexual abuse: a pilot study of an intensive residential treatment program. J Trauma Stress. 2011, 24: 102-106.

  929. Harned MS, Jackson SC, Comtois KA, Linehan MM: Dialectical behavior therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with borderline personality disorder. J Trauma Stress. 2010, 23: 421-429.

  930. Harned MS, Korslund KE, Foa EB, Linehan MM: Treating PTSD in suicidal and self-injuring women with borderline personality disorder: development and preliminary evaluation of a Dialectical Behavior Therapy Prolonged Exposure Protocol. Behav Res Ther. 2012, 50: 381-386.

  931. Mills KL, Teesson M, Back SE, Brady KT, Baker AL, Hopwood S, Sannibale C, Barrett EL, Merz S, Rosenfeld J, Ewer PL: Integrated exposure-based therapy for co-occurring posttraumatic stress disorder and substance dependence: a randomized controlled trial. JAMA. 2012, 308: 690-699.

  932. Cloitre M, Courtois CA, Charuvastra A, Carapezza R, Stolbach BC, Green BL: Treatment of complex PTSD: results of the ISTSS expert clinician survey on best practices. J Trauma Stress. 2011, 24: 615-627.

  933. Brunet A, Ashbaugh A, Hebert P: Internet use in the aftermath of trauma. 2010, Amsterdam: NATO Books, IOS Press

  934. Spence J, Titov N, Dear BF, Johnston L, Solley K, Lorian C, Wootton B, Zou J, Schwenke G: Randomized controlled trial of Internet-delivered cognitive behavioral therapy for posttraumatic stress disorder. Depress Anxiety. 2011, 28: 541-550.

  935. Litz BT, Engel CC, Bryant RA, Papa A: A randomized, controlled proof-of-concept trial of an internet-based, therapist-assisted self-management treatment for posttraumatic stress disorder. Am J Psychiatry. 2007, 164: 1676-1683.

  936. Knaevelsrud C, Maercker A: Internet-based treatment for PTSD reduces distress and facilitates the development of a strong therapeutic alliance: a randomized controlled clinical trial. BMC Psychiatry. 2007, 7: 13-

  937. Klein B, Mitchell J, Abbott J, Shandley K, Austin D, Gilson K, Kiropoulos L, Cannard G, Redman T: A therapist-assisted cognitive behavior therapy internet intervention for posttraumatic stress disorder: pre-, post- and 3-month follow-up results from an open trial. J Anxiety Disord. 2010, 24: 635-644.

  938. Knaevelsrud C, Liedl A, Maercker A: Posttraumatic growth, optimism and openness as outcomes of a cognitive-behavioural intervention for posttraumatic stress reactions. J Health Psychol. 2010, 15: 1030-1038.

  939. Lange A, van de Ven JP, Schrieken B, Emmelkamp PM: Interapy, treatment of posttraumatic stress through the Internet: a controlled trial. J Behav Ther Exp Psychiatry. 2001, 32: 73-90.

  940. Lange A, Rietdijk D, Hudcovicova M, van de Ven JP, Schrieken B, Emmelkamp PM: Interapy: a controlled randomized trial of the standardized treatment of posttraumatic stress through the internet. J Consult Clin Psychol. 2003, 71: 901-909.

  941. Rothbaum BO, Hodges LF, Ready D, Graap K, Alarcon RD: Virtual reality exposure therapy for Vietnam veterans with posttraumatic stress disorder. J Clin Psychiatry. 2001, 62: 617-622.

  942. Ready DJ, Gerardi RJ, Backscheider AG, Mascaro N, Rothbaum BO: Comparing virtual reality exposure therapy to present-centered therapy with 11 U.S. Vietnam veterans with PTSD. Cyberpsychol Behav Soc Netw. 2010, 13: 49-54.

  943. Difede J, Cukor J, Jayasinghe N, Patt I, Jedel S, Spielman L, Giosan C, Hoffman HG: Virtual reality exposure therapy for the treatment of posttraumatic stress disorder following September 11, 2001. J Clin Psychiatry. 2007, 68: 1639-1647.

  944. Germain V, Marchand A, Bouchard S, Drouin MS, Guay S: Effectiveness of cognitive behavioural therapy administered by videoconference for posttraumatic stress disorder. Cogn Behav Ther. 2009, 38: 42-53.

  945. Hetrick SE, Purcell R, Garner B, Parslow R: Combined pharmacotherapy and psychological therapies for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2010, CD007316-

  946. Cohen JA, Mannarino AP, Perel JM, Staron V: A pilot randomized controlled trial of combined trauma-focused CBT and sertraline for childhood PTSD symptoms. J Am Acad Child Adolesc Psychiatry. 2007, 46: 811-819.

  947. Simon NM, Connor KM, Lang AJ, Rauch S, Krulewicz S, LeBeau RT, Davidson JR, Stein MB, Otto MW, Foa EB, Pollack MH: Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. J Clin Psychiatry. 2008, 69: 400-405.

  948. Rothbaum BO, Cahill SP, Foa EB, Davidson JR, Compton J, Connor KM, Astin MC, Hahn CG: Augmentation of sertraline with prolonged exposure in the treatment of posttraumatic stress disorder. J Trauma Stress. 2006, 19: 625-638.

  949. Otto M, Hinton D, Korbly N, Chea A, Ba P, Gershuny B, Pollack M: Treatment of pharmacotherapy-refractory posttraumatic stress disorder among Cambodian refugees: a pilot study of combination treatment with cognitive-behavior therapy vs sertraline alone. Behav Res Ther. 2003, 41: 1271-1276.

  950. Schneier FR, Neria Y, Pavlicova M, Hembree E, Suh EJ, Amsel L, Marshall RD: Combined prolonged exposure therapy and paroxetine for PTSD related to the World Trade Center attack: a randomized controlled trial. Am J Psychiatry. 2012, 169: 80-88.

  951. Brunet A, Orr SP, Tremblay J, Robertson K, Nader K, Pitman RK: Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. J Psychiatr Res. 2008, 42: 503-506.

  952. Brunet A, Poundja J, Tremblay J, Bui E, Thomas E, Orr SP, Azzoug A, Birmes P, Pitman RK: Trauma reactivation under the influence of propranolol decreases posttraumatic stress symptoms and disorder: 3 open-label trials. J Clin Psychopharmacol. 2011, 31: 547-550.

  953. de Kleine RA, Hendriks GJ, Kusters WJ, Broekman TG, van Minnen A: A randomized placebo-controlled trial of D-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biol Psychiatry. 2012, 71: 962-968.

  954. Litz BT, Salters-Pedneault K, Steenkamp MM, Hermos JA, Bryant RA, Otto MW, Hofmann SG: A randomized placebo-controlled trial of d-cycloserine and exposure therapy for posttraumatic stress disorder. J Psychiatr Res. 2012, 46: 1184-1190.

  955. Van Etten M, Taylor S: Comparative efficacy of treatments for post-traumatic stress disorder: a meta-analysis. Clin Psychol Psychother. 1998, 5: 126-144.

  956. Edmond T, Rubin A: Assessing the long-term effects of EMDR: results from an 18-month follow-up study with adult female survivors of CSA. J Child Sex Abus. 2004, 13: 69-86.

  957. Wilson SA, Becker LA, Tinker RH: Fifteen-month follow-up of eye movement desensitization and reprocessing (EMDR) treatment for posttraumatic stress disorder and psychological trauma. J Consult Clin Psychol. 1997, 65: 1047-1056.

  958. Knaevelsrud C, Maercker A: Long-term effects of an internet-based treatment for posttraumatic stress. Cogn Behav Ther. 2010, 39: 72-77.

  959. Hogberg G, Pagani M, Sundin O, Soares J, Aberg-Wistedt A, Tarnell B, Hallstrom T: Treatment of post-traumatic stress disorder with eye movement desensitization and reprocessing: outcome is stable in 35-month follow-up. Psychiatry Res. 2008, 159: 101-108.

  960. van der Kolk B, Dreyfuss D, Michaels M, Shera D, Berkowitz R, Fisler R, Saxe G: Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry. 1994, 55: 517-522.

  961. Connor K, Sutherland S, Tupler L, Malik M, Davidson J: Fluoxetine in post-traumatic stress disorder. Randomised, double-blind study. Br J Psychiatry. 1999, 175: 17-22.

  962. Martenyi F, Brown E, Zhang H, Prakash A, Koke S: Fluoxetine versus placebo in posttraumatic stress disorder. J Clin Psychiatry. 2002, 63: 199-206.

  963. van der Kolk BA, Spinazzola J, Blaustein ME, Hopper JW, Hopper EK, Korn DL, Simpson WB: A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance. J Clin Psychiatry. 2007, 68: 37-46.

  964. Martenyi F, Brown EB, Caldwell CD: Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study. J Clin Psychopharmacol. 2007, 27: 166-170.

  965. Hertzberg MA, Feldman ME, Beckham JC, Kudler HS, Davidson JR: Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. Ann Clin Psychiatry. 2000, 12: 101-105.

  966. Tucker P, Zaninelli R, Yehuda R, Ruggiero L, Dillingham K, Pitts C: Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001, 62: 860-868.

  967. Marshall R, Beebe K, Oldham M, Zaninelli R: Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry. 2001, 158: 1982-1988.

  968. Stein D, Davidson J, Seedat S, Beebe K: Paroxetine in the treatment of post-traumatic stress disorder: pooled analysis of placebo-controlled studies. Expert Opin Pharmacother. 2003, 4: 1829-1838.

  969. Marshall RD, Lewis-Fernandez R, Blanco C, Simpson HB, Lin SH, Vermes D, Garcia W, Schneier F, Neria Y, Sanchez-Lacay A, Liebowitz MR: A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depress Anxiety. 2007, 24: 77-84.

  970. Petrakis IL, Ralevski E, Desai N, Trevisan L, Gueorguieva R, Rounsaville B, Krystal JH: Noradrenergic vs serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol dependence. Neuropsychopharmacology. 2012, 37: 996-1004.

  971. Davidson J, Rothbaum B, van der Kolk B, Sikes C, Farfel G: Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry. 2001, 58: 485-492.

  972. Brady K, Pearlstein T, Asnis G, Baker D, Rothbaum B, Sikes C, Farfel G: Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA. 2000, 283: 1837-1844.

  973. Zohar J, Amital D, Miodownik C, Kotler M, Bleich A, Lane R, Austin C: Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. J Clin Psychopharmacol. 2002, 22: 190-195.

  974. Tucker P, Potter-Kimball R, Wyatt D, Parker D, Burgin C, Jones D, Masters B: Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo. Psychopharmacol Bull. 2003, 37: 135-149.

  975. Davidson J, Rothbaum BO, Tucker P, Asnis G, Benattia I, Musgnung JJ: Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. J Clin Psychopharmacol. 2006, 26: 259-267.

  976. Stein DJ, van der Kolk BA, Austin C, Fayyad R, Clary C: Efficacy of sertraline in posttraumatic stress disorder secondary to interpersonal trauma or childhood abuse. Ann Clin Psychiatry. 2006, 18: 243-249.

  977. Friedman MJ, Marmar CR, Baker DG, Sikes CR, Farfel GM: Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. J Clin Psychiatry. 2007, 68: 711-720.

  978. Panahi Y, Moghaddam BR, Sahebkar A, Nazari MA, Beiraghdar F, Karami G, Saadat AR: A randomized, double-blind, placebo-controlled trial on the efficacy and tolerability of sertraline in Iranian veterans with post-traumatic stress disorder. Psychol Med. 2011, 41: 2159-2166.

  979. Marmar C, Schoenfeld F, Weiss D, Metzler T, Zatzick D, Wu R, Smiga S, Tecott L, Neylan T: Open trial of fluvoxamine treatment for combat-related posttraumatic stress disorder. J Clin Psychiatry. 1996, 57 (Suppl 8): 66-70. discussion 71-62

  980. Escalona R, Canive J, Calais L, Davidson J: Fluvoxamine treatment in veterans with combat-related post-traumatic stress disorder. Depress Anxiety. 2002, 15: 29-33.

  981. Tucker P, Smith K, Marx B, Jones D, Miranda R, Lensgraf J: Fluvoxamine reduces physiologic reactivity to trauma scripts in posttraumatic stress disorder. J Clin Psychopharmacol. 2000, 20: 367-372.

  982. Neylan T, Metzler T, Schoenfeld F, Weiss D, Lenoci M, Best S, Lipsey T, Marmar C: Fluvoxamine and sleep disturbances in posttraumatic stress disorder. J Trauma Stress. 2001, 14: 461-467.

  983. De Boer M, Op den Velde W, Falger P, Hovens J, De Groen J, Van Duijn H: Fluvoxamine treatment for chronic PTSD: a pilot study. Psychother Psychosom. 1992, 57: 158-163.

  984. Spivak B, Strous RD, Shaked G, Shabash E, Kotler M, Weizman A: Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial. J Clin Psychopharmacol. 2006, 26: 152-156.

  985. Robert S, Hamner MB, Ulmer HG, Lorberbaum JP, Durkalski VL: Open-label trial of escitalopram in the treatment of posttraumatic stress disorder. J Clin Psychiatry. 2006, 67: 1522-1526.

  986. Seedat S, Stein D, Emsley R: Open trial of citalopram in adults with post-traumatic stress disorder. Int J Neuropsychopharmacol. 2000, 3: 135-140.

  987. Seedat S, Stein D, Ziervogel C, Middleton T, Kaminer D, Emsley R, Rossouw W: Comparison of response to a selective serotonin reuptake inhibitor in children, adolescents, and adults with posttraumatic stress disorder. J Child Adolesc Psychopharmacol. 2002, 12: 37-46.

  988. English BA, Jewell M, Jewell G, Ambrose S, Davis LL: Treatment of chronic posttraumatic stress disorder in combat veterans with citalopram: an open trial. J Clin Psychopharmacol. 2006, 26: 84-88.

  989. Davidson J, Baldwin D, Stein DJ, Kuper E, Benattia I, Ahmed S, Pedersen R, Musgnung J: Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch Gen Psychiatry. 2006, 63: 1158-1165.

  990. Walderhaug E, Kasserman S, Aikins D, Vojvoda D, Nishimura C, Neumeister A: Effects of duloxetine in treatment-refractory men with posttraumatic stress disorder. Pharmacopsychiatry. 2010, 43: 45-49.

  991. Villarreal G, Canive JM, Calais LA, Toney G, Smith AK: Duloxetine in military posttraumatic stress disorder. Psychopharmacol Bull. 2010, 43: 26-34.

  992. Frank J, Kosten T, Giller E, Dan E: A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder. Am J Psychiatry. 1988, 145: 1289-1291.

  993. Kosten T, Frank J, Dan E, McDougle C, Giller E: Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis. 1991, 179: 366-370.

  994. Davidson J, Kudler H, Smith R, Mahorney S, Lipper S, Hammett E, Saunders W, Cavenar J: Treatment of posttraumatic stress disorder with amitriptyline and placebo. Arch Gen Psychiatry. 1990, 47: 259-266.

  995. Reist C, Kauffmann C, Haier R, Sangdahl C, De ME, Chicz-De MA, Nelson J: A controlled trial of desipramine in 18 men with posttraumatic stress disorder. Am J Psychiatry. 1989, 146: 513-516.

  996. Shestatzky M, Greenberg D, Lerer B: A controlled trial of phenelzine in posttraumatic stress disorder. Psychiatry Res. 1988, 24: 149-155.

  997. Onder E, Tural U, Aker T: A comparative study of fluoxetine, moclobemide, and tianeptine in the treatment of posttraumatic stress disorder following an earthquake. Eur Psychiatry. 2006, 21: 174-179.

  998. Neal L, Shapland W, Fox C: An open trial of moclobemide in the treatment of post-traumatic stress disorder. Int Clin Psychopharmacol. 1997, 12: 231-237.

  999. Connor K, Davidson J, Weisler R, Ahearn E: A pilot study of mirtazapine in post-traumatic stress disorder. Int Clin Psychopharmacol. 1999, 14: 29-31.

  1000. Davidson JR, Weisler RH, Butterfield MI, Casat CD, Connor KM, Barnett S, van Meter S: Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biol Psychiatry. 2003, 53: 188-191.

  1001. Chung M, Min K, Jun Y, Kim S, Kim W, Jun E: Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Hum Psychopharmacol. 2004, 19: 489-494.

  1002. Alderman CP, Condon JT, Gilbert AL: An open-label study of mirtazapine as treatment for combat-related PTSD. Ann Pharmacother. 2009, 43: 1220-1226.

  1003. Canive J, Clark R, Calais L, Qualls C, Tuason V: Bupropion treatment in veterans with posttraumatic stress disorder: an open study. J Clin Psychopharmacol. 1998, 18: 379-383.

  1004. Franciskovic T, Sukovic Z, Janovic S, Stevanovic A, Nemcic-Moro I, Roncevic-Grzeta I, Letica-Crepulja M: Tianeptine in the combined treatment of combat related posttraumatic stress disorder. Psychiatr Danub. 2011, 23: 257-263.

  1005. Becker ME, Hertzberg MA, Moore SD, Dennis MF, Bukenya DS, Beckham JC: A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder. J Clin Psychopharmacol. 2007, 27: 193-197.

  1006. Braun P, Greenberg D, Dasberg H, Lerer B: Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry. 1990, 51: 236-238.

  1007. Cates M, Bishop M, Davis L, Lowe J, Woolley T: Clonazepam for treatment of sleep disturbances associated with combat-related posttraumatic stress disorder. Ann Pharmacother. 2004, 38: 1395-1399.

  1008. Shalev A, Rogel-Fuchs Y: Auditory startle reflex in post-traumatic stress disorder patients treated with clonazepam. Isr J Psychiatry Relat Sci. 1992, 29: 1-6.

  1009. Tucker P, Trautman RP, Wyatt DB, Thompson J, Wu SC, Capece JA, Rosenthal NR: Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007, 68: 201-206.

  1010. Yeh MS, Mari JJ, Costa MC, Andreoli SB, Bressan RA, Mello MF: A double-blind randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSD. CNS Neurosci Ther. 2011, 17: 305-310.

  1011. Hertzberg M, Butterfield M, Feldman M, Beckham J, Sutherland S, Connor K, Davidson J: A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry. 1999, 45: 1226-1229.

  1012. Lipper S, Davidson J, Grady T, Edinger J, Hammett E, Mahorney S, Cavenar J: Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics. 1986, 27: 849-854.

  1013. Wolf M, Alavi A, Mosnaim A: Posttraumatic stress disorder in Vietnam veterans clinical and EEG findings; possible therapeutic effects of carbamazepine. Biol Psychiatry. 1988, 23: 642-644.

  1014. Fesler F: Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry. 1991, 52: 361-364.

  1015. Clark R, Canive J, Calais L, Qualls C, Tuason V: Divalproex in posttraumatic stress disorder: an open-label clinical trial. J Trauma Stress. 1999, 12: 395-401.

  1016. Davis LL, Davidson JR, Ward LC, Bartolucci A, Bowden CL, Petty F: Divalproex in the treatment of posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. J Clin Psychopharmacol. 2008, 28: 84-88.

  1017. Hamner MB, Faldowski RA, Robert S, Ulmer HG, Horner MD, Lorberbaum JP: A preliminary controlled trial of divalproex in posttraumatic stress disorder. Ann Clin Psychiatry. 2009, 21: 89-94.

  1018. Davidson JR, Brady K, Mellman TA, Stein MB, Pollack MH: The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J Clin Psychopharmacol. 2007, 27: 85-88.

  1019. Hamner M, Brodrick P, Labbate L: Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry. 2001, 13: 141-146.

  1020. Malek-Ahmadi P: Gabapentin and posttraumatic stress disorder. Ann Pharmacother. 2003, 37: 664-666.

  1021. Kinrys G, Wygant LE, Pardo TB, Melo M: Levetiracetam for treatment-refractory posttraumatic stress disorder. J Clin Psychiatry. 2006, 67: 211-214.

  1022. Pae CU, Marks DM, Han C, Masand PS, Patkar AA: Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open label pilot study. Int Clin Psychopharmacol. 2009, 24: 29-33.

  1023. Schwartz T: The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case series. Psychopharmacol Bull. 2002, 36: 53-57.

  1024. Taylor F: Tiagabine for posttraumatic stress disorder: a case series of 7 women. J Clin Psychiatry. 2003, 64: 1421-1425.

  1025. Berigan T: Treatment of posttraumatic stress disorder with tiagabine. Can J Psychiatry. 2002, 47: 788-

  1026. Berlant J: Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder. BMC Psychiatry. 2004, 4: 24-

  1027. Berlant J, van Kammen D: Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry. 2002, 63: 15-20.

  1028. Lindley SE, Carlson EB, Hill K: A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder. J Clin Psychopharmacol. 2007, 27: 677-681.

  1029. Alderman CP, McCarthy LC, Condon JT, Marwood AC, Fuller JR: Topiramate in combat-related posttraumatic stress disorder. Ann Pharmacother. 2009, 43: 635-641.

  1030. Padala PR, Madison J, Monnahan M, Marcil W, Price P, Ramaswamy S, Din AU, Wilson DR, Petty F: Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. Int Clin Psychopharmacol. 2006, 21: 275-280.

  1031. Villarreal G, Calais LA, Canive JM, Lundy SL, Pickard J, Toney G: Prospective study to evaluate the efficacy of aripiprazole as a monotherapy in patients with severe chronic posttraumatic stress disorder: an open trial. Psychopharmacol Bull. 2007, 40: 6-18.

  1032. Mello MF, Costa MC, Schoedl AF, Fiks JP: Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial. Rev Bras Psiquiatr. 2008, 30: 358-361.

  1033. Lambert MT: Aripiprazole in the management of post-traumatic stress disorder symptoms in returning global war on terrorism veterans. Int Clin Psychopharmacol. 2006, 21: 185-187.

  1034. Kozaric-Kovacic D, Pivac N: Quetiapine treatment in an open trial in combat-related post-traumatic stress disorder with psychotic features. Int J Neuropsychopharmacol. 2007, 10: 253-261.

  1035. Byers MG, Allison KM, Wendel CS, Lee JK: Prazosin versus quetiapine for nighttime posttraumatic stress disorder symptoms in veterans: an assessment of long-term comparative effectiveness and safety. J Clin Psychopharmacol. 2010, 30: 225-229.

  1036. Butterfield MI, Becker ME, Connor KM, Sutherland S, Churchill LE, Davidson JR: Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. Int Clin Psychopharmacol. 2001, 16: 197-203.

  1037. Pivac N, Kozaric-Kovacic D, Muck-Seler D: Olanzapine versus fluphenazine in an open trial in patients with psychotic combat-related post-traumatic stress disorder. Psychopharmacology (Berl). 2004, 175: 451-456.

  1038. Petty F, Brannan S, Casada J, Davis L, Gajewski V, Kramer G, Stone R, Teten A, Worchel J, Young K: Olanzapine treatment for post-traumatic stress disorder: an open-label study. Int Clin Psychopharmacol. 2001, 16: 331-337.

  1039. Hamner M, Faldowski R, Ulmer H, Frueh B, Huber M, Arana G: Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. Int Clin Psychopharmacol. 2003, 18: 1-8.

  1040. Monnelly E, Ciraulo D, Knapp C, Keane T: Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol. 2003, 23: 193-196.

  1041. Bartzokis G, Lu P, Turner J, Mintz J, Saunders C: Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol Psychiatry. 2005, 57: 474-479.

  1042. Reich D, Winternitz S, Hennen J, Watts T, Stanculescu C: A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. J Clin Psychiatry. 2004, 65: 1601-1606.

  1043. Krystal JH, Rosenheck RA, Cramer JA, Vessicchio JC, Jones KM, Vertrees JE, Horney RA, Huang GD, Stock C: Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. JAMA. 2011, 306: 493-502.

  1044. Rothbaum BO, Killeen TK, Davidson JR, Brady KT, Connor KM, Heekin MH: Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. J Clin Psychiatry. 2008, 69: 520-525.

  1045. Stein M, Kline N, Matloff J: Adjunctive olanzapine for SSRI-resistant combat-related PTSD: A double-blind, placebo-controlled study. Am J Psychiatry. 2002, 159: 1777-1779.

  1046. Robert S, Hamner MB, Durkalski VL, Brown MW, Ulmer HG: An open-label assessment of aripiprazole in the treatment of PTSD. Psychopharmacol Bull. 2009, 42: 69-80.

  1047. Richardson JD, Fikretoglu D, Liu A, McIntosh D: Aripiprazole augmentation in the treatment of military-related PTSD with major depression: a retrospective chart review. BMC Psychiatry. 2011, 11: 86-

  1048. Sokolski K, Denson T, Lee R, Reist C: Quetiapine for treatment of refractory symptoms of combat-related post-traumatic stress disorder. Mil Med. 2003, 168: 486-489.

  1049. Hamner M, Deitsch S, Brodrick P, Ulmer H, Lorberbaum J: Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacol. 2003, 23: 15-20.

  1050. Ahearn EP, Mussey M, Johnson C, Krohn A, Krahn D: Quetiapine as an adjunctive treatment for post-traumatic stress disorder: an 8-week open-label study. Int Clin Psychopharmacol. 2006, 21: 29-33.

  1051. Duffy J, Malloy P: Efficacy of buspirone in the treatment of posttraumatic stress disorder: an open trial. Ann Clin Psychiatry. 1994, 6: 33-37.

  1052. Wells B, Chu C, Johnson R, Nasdahl C, Ayubi M, Sewell E, Statham P: Buspirone in the treatment of posttraumatic stress disorder. Pharmacotherapy. 1991, 11: 340-343.

  1053. Hertzberg M, Feldman M, Beckham J, Davidson J: Trial of trazodone for posttraumatic stress disorder using a multiple baseline group design. J Clin Psychopharmacol. 1996, 16: 294-298.

  1054. Battista MA, Hierholzer R, Khouzam HR, Barlow A, O’Toole S: Pilot trial of memantine in the treatment of posttraumatic stress disorder. Psychiatry. 2007, 70: 167-174.

  1055. Pollack MH, Hoge EA, Worthington JJ, Moshier SJ, Wechsler RS, Brandes M, Simon NM: Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011, 72: 892-897.

  1056. Kinzie J, Leung P: Clonidine in Cambodian patients with posttraumatic stress disorder. J Nerv Ment Dis. 1989, 177: 546-550.

  1057. Neylan TC, Lenoci M, Samuelson KW, Metzler TJ, Henn-Haase C, Hierholzer RW, Lindley SE, Otte C, Schoenfeld FB, Yesavage JA, Marmar CR: No improvement of posttraumatic stress disorder symptoms with guanfacine treatment. Am J Psychiatry. 2006, 163: 2186-2188.

  1058. Davis LL, Ward C, Rasmusson A, Newell JM, Frazier E, Southwick SM: A placebo-controlled trial of guanfacine for the treatment of posttraumatic stress disorder in veterans. Psychopharmacol Bull. 2008, 41: 8-18.

  1059. Abramowitz EG, Barak Y, Ben-Avi I, Knobler HY: Hypnotherapy in the treatment of chronic combat-related PTSD patients suffering from insomnia: a randomized, zolpidem-controlled clinical trial. Int J Clin Exp Hypn. 2008, 56: 270-280.

  1060. Stein D, Seedat S, van dLG, Zungu-Dirwayi N: Selective serotonin reuptake inhibitors in the treatment of post-traumatic stress disorder: a meta-analysis of randomized controlled trials. Int Clin Psychopharmacol. 2000, 15 (Suppl 2): S31-39.

  1061. Pae CU, Lim HK, Peindl K, Ajwani N, Serretti A, Patkar AA, Lee C: The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Int Clin Psychopharmacol. 2008, 23: 1-8.

  1062. Raskind M, Peskind E, Kanter E, Petrie E, Radant A, Thompson C, Dobie D, Hoff D, Rein R, Straits-Troster K, et al: Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry. 2003, 160: 371-373.

  1063. Peskind E, Bonner L, Hoff D, Raskind M: Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder. J Geriatr Psychiatry Neurol. 2003, 16: 165-171.

  1064. Taylor F, Raskind M: The alpha1-adrenergic antagonist prazosin improves sleep and nightmares in civilian trauma posttraumatic stress disorder. J Clin Psychopharmacol. 2002, 22: 82-85.

  1065. Raskind MA, Peskind ER, Hoff DJ, Hart KL, Holmes HA, Warren D, Shofer J, O’Connell J, Taylor F, Gross C, et al: A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry. 2007, 61: 928-934.

  1066. Taylor FB, Martin P, Thompson C, Williams J, Mellman TA, Gross C, Peskind ER, Raskind MA: Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. Biol Psychiatry. 2008, 63: 629-632.

  1067. Lubin G, Weizman A, Shmushkevitz M, Valevski A: Short-term treatment of post-traumatic stress disorder with naltrexone: an open-label preliminary study. Hum Psychopharmacol. 2002, 17: 181-185.

  1068. Bohus MJ, Landwehrmeyer GB, Stiglmayr CE, Limberger MF, Bohme R, Schmahl CG: Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. J Clin Psychiatry. 1999, 60: 598-603.

  1069. Glover H: A preliminary trial of nalmefene for the treatment of emotional numbing in combat veterans with post-traumatic stress disorder. Isr J Psychiatry Relat Sci. 1993, 30: 255-263.

  1070. Bills LJ, Kreisler K: Treatment of flashbacks with naltrexone. Am J Psychiatry. 1993, 150: 1430-

  1071. Jacobs-Rebhun S, Schnurr PP, Friedman MJ, Peck R, Brophy M, Fuller D: Posttraumatic stress disorder and sleep difficulty [Letter]. Am J Psychiatry. 2000, 157: 1525-1526.

  1072. Davidson J, Connor K, Hertzberg M, Weisler R, Wilson W, Payne V: Maintenance therapy with fluoxetine in posttraumatic stress disorder: a placebo-controlled discontinuation study. J Clin Psychopharmacol. 2005, 25: 166-169.

  1073. Martenyi F, Brown E, Zhang H, Koke S, Prakash A: Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder. Br J Psychiatry. 2002, 181: 315-320.

  1074. Davidson J, Pearlstein T, Londborg P, Brady K, Rothbaum B, Bell J, Maddock R, Hegel M, Farfel G: Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry. 2001, 158: 1974-1981.

  1075. Connor KM, Davidson JR, Weisler RH, Zhang W, Abraham K: Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology. 2006, 184: 21-25.

  1076. Kim Y, Asukai N, Konishi T, Kato H, Hirotsune H, Maeda M, Inoue H, Narita H, Iwasaki M: Clinical evaluation of paroxetine in post-traumatic stress disorder (PTSD): 52-week, non-comparative open-label study for clinical use experience. Psychiatry Clin Neurosci. 2008, 62: 646-652.

  1077. Londborg P, Hegel M, Goldstein S, Goldstein D, Himmelhoch J, Maddock R, Patterson W, Rausch J, Farfel G: Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatment. J Clin Psychiatry. 2001, 62: 325-331.

  1078. Boggio PS, Rocha M, Oliveira MO, Fecteau S, Cohen RB, Campanha C, Ferreira-Santos E, Meleiro A, Corchs F, Zaghi S, et al: Noninvasive brain stimulation with high-frequency and low-intensity repetitive transcranial magnetic stimulation treatment for posttraumatic stress disorder. J Clin Psychiatry. 2010, 71: 992-999.

  1079. Watts BV, Landon B, Groft A, Young-Xu Y: A sham controlled study of repetitive transcranial magnetic stimulation for posttraumatic stress disorder. Brain Stimul. 2012, 5: 38-43.

  1080. Osuch EA, Benson BE, Luckenbaugh DA, Geraci M, Post RM, McCann U: Repetitive TMS combined with exposure therapy for PTSD: a preliminary study. J Anxiety Disord. 2009, 23: 54-59.

  1081. Margoob MA, Ali Z, Andrade C: Efficacy of ECT in chronic, severe, antidepressant- and CBT-refractory PTSD: an open, prospective study. Brain Stimul. 2010, 3: 28-35.

  1082. Watts BV: Electroconvulsive therapy for comorbid major depressive disorder and posttraumatic stress disorder. J ECT. 2007, 23: 93-95.

  1083. Hollifield M, Sinclair-Lian N, Warner TD, Hammerschlag R: Acupuncture for posttraumatic stress disorder: a randomized controlled pilot trial. J Nerv Ment Dis. 2007, 195: 504-513.

  1084. Bormann JE, Thorp S, Wetherell JL, Golshan S: A spiritually based group intervention for combat veterans with posttraumatic stress disorder: feasibility study. J Holist Nurs. 2008, 26: 109-116.

  1085. Rosenthal JZ, Grosswald S, Ross R, Rosenthal N: Effects of transcendental meditation in veterans of Operation Enduring Freedom and Operation Iraqi Freedom with posttraumatic stress disorder: a pilot study. Mil Med. 2011, 176: 626-630.

  1086. Vesga-Lopez O, Blanco C, Keyes K, Olfson M, Grant BF, Hasin DS: Psychiatric disorders in pregnant and postpartum women in the United States. Arch Gen Psychiatry. 2008, 65: 805-815.

  1087. Sutter-Dallay AL, Giaconne-Marcesche V, Glatigny-Dallay E, Verdoux H: Women with anxiety disorders during pregnancy are at increased risk of intense postnatal depressive symptoms: a prospective survey of the MATQUID cohort. Eur Psychiatry. 2004, 19: 459-463.

  1088. Buist A, Gotman N, Yonkers KA: Generalized anxiety disorder: course and risk factors in pregnancy. J Affect Disord. 2011, 131: 277-283.

  1089. Ross LE, McLean LM: Anxiety disorders during pregnancy and the postpartum period: A systematic review. J Clin Psychiatry. 2006, 67: 1285-1298.

  1090. Zambaldi CF, Cantilino A, Montenegro AC, Paes JA, de Albuquerque TL, Sougey EB: Postpartum obsessive-compulsive disorder: prevalence and clinical characteristics. Compr Psychiatry. 2009, 50: 503-509.

  1091. Alcorn KL, O’Donovan A, Patrick JC, Creedy D, Devilly GJ: A prospective longitudinal study of the prevalence of post-traumatic stress disorder resulting from childbirth events. Psychol Med. 2010, 40: 1849-1859.

  1092. Forray A, Mayes LC, Magriples U, Epperson CN: Prevalence of post-traumatic stress disorder in pregnant women with prior pregnancy complications. J Matern Fetal Neonatal Med. 2009, 22: 522-527.

  1093. Banhidy F, Acs N, Puho E, Czeizel AE: Association between maternal panic disorders and pregnancy complications and delivery outcomes. Eur J Obstet Gynecol Reprod Biol. 2006, 124: 47-52.

  1094. Lilliecreutz C, Sydsjo G, Josefsson A: Obstetric and perinatal outcomes among women with blood- and injection phobia during pregnancy. J Affect Disord. 2011, 129: 289-295.

  1095. Chen YH, Lin HC, Lee HC: Pregnancy outcomes among women with panic disorder – do panic attacks during pregnancy matter?. J Affect Disord. 2010, 120: 258-262.

  1096. Littleton HL, Breitkopf CR, Berenson AB: Correlates of anxiety symptoms during pregnancy and association with perinatal outcomes: a meta-analysis. Am J Obstet Gynecol. 2007, 196: 424-432.

  1097. Rogal SS, Poschman K, Belanger K, Howell HB, Smith MV, Medina J, Yonkers KA: Effects of posttraumatic stress disorder on pregnancy outcomes. J Affect Disord. 2007, 102: 137-143.

  1098. Newport DJ, Ji S, Long Q, Knight BT, Zach EB, Smith EN, Morris NJ, Stowe ZN: Maternal depression and anxiety differentially impact fetal exposures during pregnancy. J Clin Psychiatry. 2012, 73: 247-251.

  1099. Lee AM, Lam SK, Sze Mun Lau SM, Chong CS, Chui HW, Fong DY: Prevalence, course, and risk factors for antenatal anxiety and depression. Obstet Gynecol. 2007, 110: 1102-1112.

  1100. Challacombe F, Salkovskis P: A preliminary investigation of the impact of maternal obsessive-compulsive disorder and panic disorder on parenting and children. J Anxiety Disord. 2009, 23: 848-857.

  1101. Zelkowitz P, Na S, Wang T, Bardin C, Papageorgiou A: Early maternal anxiety predicts cognitive and behavioural outcomes of VLBW children at 24 months corrected age. Acta Paediatr. 2011, 100: 700-704.

  1102. O’Connor T, Heron J, Glover V: Antenatal anxiety predicts child behavioral/emotional problems independently of postnatal depression. J Am Acad Child Adolesc Psychiatry. 2002, 41: 1470-1477.

  1103. Martini J, Knappe S, Beesdo-Baum K, Lieb R, Wittchen HU: Anxiety disorders before birth and self-perceived distress during pregnancy: associations with maternal depression and obstetric, neonatal and early childhood outcomes. Early Hum Dev. 2010, 86: 305-310.

  1104. Seekles W, Cuijpers P, Kok R, Beekman A, van Marwijk H, van Straten A: Psychological treatment of anxiety in primary care: a meta-analysis. Psychol Med. 2012, : 1-11.

  1105. Lilliecreutz C, Josefsson A, Sydsjo G: An open trial with cognitive behavioral therapy for blood- and injection phobia in pregnant women-a group intervention program. Arch Womens Ment Health. 2010, 13: 259-265.

  1106. Challacombe FL, Salkovskis PM: Intensive cognitive-behavioural treatment for women with postnatal obsessive-compulsive disorder: a consecutive case series. Behav Res Ther. 2011, 49: 422-426.

  1107. Arch JJ, Dimidjian S, Chessick C: Are exposure-based cognitive behavioral therapies safe during pregnancy?. Arch Womens Ment Health. 2012, 15: 445-457.

  1108. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2008, 111: 1001-1020.

  1109. Law R, Bozzo P, Koren G, Einarson A: FDA pregnancy risk categories and the CPS: do they help or are they a hindrance?. Can Fam Physician. 2010, 56: 239-241.

  1110. Einarson A, Choi J, Einarson TR, Koren G: Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry. 2009, 54: 242-246.

  1111. Malm H, Artama M, Gissler M, Ritvanen A: Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol. 2011, 118: 111-120.

  1112. Bellantuono C, Migliarese G, Gentile S: Serotonin reuptake inhibitors in pregnancy and the risk of major malformations: a systematic review. Hum Psychopharmacol. 2007, 22: 121-128.

  1113. Grigoriadis S, Vonderporten EH, Mamisashvili L, Roerecke M, Rehm J, Dennis CL, Koren G, Steiner M, Mousmanis P, Cheung A, Ross LE: Antidepressant exposure during pregnancy and congenital malformations: is there an association? a systematic review and meta-analysis of the best evidence. J Clin Psychiatry. 2013, 74: e293-308.

  1114. Reis M, Kallen B: Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med. 2010, 40: 1723-1733.

  1115. Bar-Oz B, Einarson T, Einarson A, Boskovic R, O’Brien L, Malm H, Berard A, Koren G: Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther. 2007, 29: 918-926.

  1116. Wurst KE, Poole C, Ephross SA, Olshan AF: First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol. 2010, 88: 159-170.

  1117. Important safety information on Paxil (paroxetine) and increased risk of cardiac defects following exposure during first trimester of pregnancy. 2005, [http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2005/14173a-eng.php]

  1118. Ross LE, Grigoriadis S, Mamisashvili L, Vonderporten EH, Roerecke M, Rehm J, Dennis CL, Koren G, Steiner M, Mousmanis P, Cheung A: Selected pregnancy and delivery outcomes after exposure to antidepressant medication: A systematic review and meta-analysis. JAMA Psychiatry. 2013, 70: 436-443.

  1119. Hemels ME, Einarson A, Koren G, Lanctot KL, Einarson TR: Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. Ann Pharmacother. 2005, 39: 803-809.

  1120. Rahimi R, Nikfar S, Abdollahi M: Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials. Reprod Toxicol. 2006, 22: 571-575.

  1121. Grigoriadis S, Vonderporten EH, Mamisashvili L, Eady A, Tomlinson G, Dennis CL, Koren G, Steiner M, Mousmanis P, Cheung A, Ross LE: The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. J Clin Psychiatry. 2013, 74: e309-320.

  1122. Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Wisner KL: Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005, 293: 2372-2383.

  1123. Lattimore KA, Donn SM, Kaciroti N, Kemper AR, Neal CR, Vazquez DM: Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J Perinatol. 2005, 25: 595-604.

  1124. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA: Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006, 354: 579-587.

  1125. Kieler H, Artama M, Engeland A, Ericsson O, Furu K, Gissler M, Nielsen RB, Norgaard M, Stephansson O, Valdimarsdottir U, et al: Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ. 2012, 344: d8012-

  1126. Andrade SE, McPhillips H, Loren D, Raebel MA, Lane K, Livingston J, Boudreau DM, Smith DH, Davis RL, Willy ME, Platt R: Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf. 2009, 18: 246-252.

  1127. Wilson KL, Zelig CM, Harvey JP, Cunningham BS, Dolinsky BM, Napolitano PG: Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol. 2011, 28: 19-24.

  1128. Gentile S: Neurodevelopmental effects of prenatal exposure to psychotropic medications. Depress Anxiety. 2010, 27: 675-686.

  1129. Gentile S, Galbally M: Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: a systematic review. J Affect Disord. 2011, 128: 1-9.

  1130. Udechuku A, Nguyen T, Hill R, Szego K: Antidepressants in pregnancy: a systematic review. Aust N Z J Psychiatry. 2010, 44: 978-996.

  1131. Nulman I, Koren G, Rovet J, Barrera M, Pulver A, Streiner D, Feldman B: Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. Am J Psychiatry. 2012, 169: 1165-1174.

  1132. Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V: Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry. 2011, 68: 1104-1112.

  1133. Rai D, Lee BK, Dalman C, Golding J, Lewis G, Magnusson C: Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. BMJ. 2013, 346: f2059-

  1134. Figueroa R: Use of antidepressants during pregnancy and risk of attention-deficit/hyperactivity disorder in the offspring. J Dev Behav Pediatr. 2010, 31: 641-648.

  1135. Froehlich TE, Anixt JS, Loe IM, Chirdkiatgumchai V, Kuan L, Gilman RC: Update on environmental risk factors for attention-deficit/hyperactivity disorder. Current psychiatry reports. 2011, 13: 333-344.

  1136. Berle JO, Spigset O: Antidepressant use during breastfeeding. Curr Womens Health Rev. 2011, 7: 28-34.

  1137. Enato E, Moretti M, Koren G: The fetal safety of benzodiazepines: an updated meta-analysis. J Obstet Gynaecol Can. 2011, 33: 46-48.

  1138. Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J: Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry. 1996, 153: 592-606.

  1139. Eros E, Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J: A population-based case-control teratologic study of nitrazepam, medazepam, tofisopam, alprazolum and clonazepam treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2002, 101: 147-154.

  1140. Kelly LE, Poon S, Madadi P, Koren G: Neonatal benzodiazepines exposure during breastfeeding. J Pediatr. 2012, 161: 448-451.

  1141. Gentile S: Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull. 2010, 36: 518-544.

  1142. Einarson A, Boskovic R: Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract. 2009, 15: 183-192.

  1143. Oyebode F, Rastogi A, Berrisford G, Coccia F: Psychotropics in pregnancy: safety and other considerations. Pharmacol Ther. 2012, 135: 71-77.

  1144. Newham JJ, Thomas SH, MacRitchie K, McElhatton PR, McAllister-Williams RH: Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. Br J Psychiatry. 2008, 192: 333-337.

  1145. Diav-Citrin O, Shechtman S, Ornoy S, Arnon J, Schaefer C, Garbis H, Clementi M, Ornoy A: Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. J Clin Psychiatry. 2005, 66: 317-322.

  1146. McKenna K, Koren G, Tetelbaum M, Wilton L, Shakir S, Diav-Citrin O, Levinson A, Zipursky RB, Einarson A: Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry. 2005, 66: 444-449. quiz 546

  1147. Lin HC, Chen IJ, Chen YH, Lee HC, Wu FJ: Maternal schizophrenia and pregnancy outcome: does the use of antipsychotics make a difference?. Schizophr Res. 2010, 116: 55-60.

  1148. Hironaka M, Kotani T, Sumigama S, Tsuda H, Mano Y, Hayakawa H, Tanaka S, Ozaki N, Tamakoshi K, Kikkawa F: Maternal mental disorders and pregnancy outcomes: a clinical study in a Japanese population. J Obstet Gynaecol Res. 2011, 37: 1283-1289.

  1149. Wichman CL: Atypical antipsychotic use in pregnancy: a retrospective review. Arch Womens Ment Health. 2009, 12: 53-57.

  1150. Galbally M, Snellen M, Lewis AJ: A review of the use of psychotropic medication in pregnancy. Curr Opin Obstet Gynecol. 2011, 23: 408-414.

  1151. Antipsychotic drugs: class labeling change – treatment during pregnancy and potential risk to newborns. [http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm244175.htm]

  1152. FDA drug safety communication: antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. [http://www.fda.gov/Drugs/DrugSafety/ucm243903.htm]

  1153. Antipsychotic drugs: labelling update regarding the risk of abnormal muscle movements and withdrawal symptoms in newborns exposed during pregnancy. [http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2011/13616a-eng.php]

  1154. Gentile S: Infant safety with antipsychotic therapy in breast-feeding: a systematic review. J Clin Psychiatry. 2008, 69: 666-673.

  1155. Kessler RC, Avenevoli S, Costello EJ, Georgiades K, Green JG, Gruber MJ, He JP, Koretz D, McLaughlin KA, Petukhova M, et al: Prevalence, persistence, and sociodemographic correlates of DSM-IV disorders in the National Comorbidity Survey Replication Adolescent Supplement. Arch Gen Psychiatry. 2012, 69: 372-380.

  1156. Merikangas KR, He JP, Burstein M, Swanson SA, Avenevoli S, Cui L, Benjet C, Georgiades K, Swendsen J: Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication-Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry. 2010, 49: 980-989.

  1157. Meltzer H, Vostanis P, Dogra N, Doos L, Ford T, Goodman R: Children’s specific fears. Child Care Health Dev. 2009, 35: 781-789.

  1158. Heyman I, Fombonne E, Simmons H, Ford T, Meltzer H, Goodman R: Prevalence of obsessive-compulsive disorder in the British nationwide survey of child mental health. Int Rev Psychiatry. 2003, 15: 178-184.

  1159. Apter A, Fallon TJ, King RA, Ratzoni G, Zohar AH, Binder M, Weizman A, Leckman JF, Pauls DL, Kron S, Cohen DJ: Obsessive-compulsive characteristics: from symptoms to syndrome. J Am Acad Child Adolesc Psychiatry. 1996, 35: 907-912.

  1160. Flament MF, Whitaker A, Rapoport JL, Davies M, Berg CZ, Kalikow K, Sceery W, Shaffer D: Obsessive compulsive disorder in adolescence: an epidemiological study. J Am Acad Child Adolesc Psychiatry. 1988, 27: 764-771.

  1161. Albano AM, Kendall PC: Cognitive behavioural therapy for children and adolescents with anxiety disorders: Clinical research advances. Int Rev Psychiatry. 2002, 14: 129-134.

  1162. Kendall P, Brady E, Verduin T: Comorbidity in childhood anxiety disorders and treatment outcome. J Am Acad Child Adolesc Psychiatry. 2001, 40: 787-794.

  1163. Verduin T, Kendall P: Differential occurrence of comorbidity within childhood anxiety disorders. J Clin Child Adolesc Psychol. 2003, 32: 290-295.

  1164. Bernstein GA, Bernat DH, Davis AA, Layne AE: Symptom presentation and classroom functioning in a nonclinical sample of children with social phobia. Depress Anxiety. 2008, 25: 752-760.

  1165. Layne AE, Bernat DH, Victor AM, Bernstein GA: Generalized anxiety disorder in a nonclinical sample of children: symptom presentation and predictors of impairment. J Anxiety Disord. 2009, 23: 283-289.

  1166. Frojd S, Ranta K, Kaltiala-Heino R, Marttunen M: Associations of social phobia and general anxiety with alcohol and drug use in a community sample of adolescents. Alcohol Alcohol. 2011, 46: 192-199.

  1167. Low NC, Lee SS, Johnson JG, Williams JB, Harris ES: The association between anxiety and alcohol versus cannabis abuse disorders among adolescents in primary care settings. Fam Pract. 2008, 25: 321-327.

  1168. Reed PL, Anthony JC, Breslau N: Incidence of drug problems in young adults exposed to trauma and posttraumatic stress disorder: do early life experiences and predispositions matter?. Arch Gen Psychiatry. 2007, 64: 1435-1442.

  1169. Cornelius JR, Kirisci L, Reynolds M, Clark DB, Hayes J, Tarter R: PTSD contributes to teen and young adult cannabis use disorders. Addict Behav. 2010, 35: 91-94.

  1170. Forbes EE, Bertocci MA, Gregory AM, Ryan ND, Axelson DA, Birmaher B, Dahl RE: Objective sleep in pediatric anxiety disorders and major depressive disorder. J Am Acad Child Adolesc Psychiatry. 2008, 47: 148-155.

  1171. Alfano CA, Ginsburg GS, Kingery JN: Sleep-related problems among children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2007, 46: 224-232.

  1172. Alfano CA, Kim KL: Objective sleep patterns and severity of symptoms in pediatric obsessive compulsive disorder: a pilot investigation. J Anxiety Disord. 2011, 25: 835-839.

  1173. Storch EA, Murphy TK, Lack CW, Geffken GR, Jacob ML, Goodman WK: Sleep-related problems in pediatric obsessive-compulsive disorder. J Anxiety Disord. 2008, 22: 877-885.

  1174. Ginsburg GS, Riddle MA, Davies M: Somatic symptoms in children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2006, 45: 1179-1187.

  1175. Boden JM, Fergusson DM, Horwood LJ: Anxiety disorders and suicidal behaviours in adolescence and young adulthood: findings from a longitudinal study. Psychol Med. 2007, 37: 431-440.

  1176. Andres S, Boget T, Lazaro L, Penades R, Morer A, Salamero M, Castro-Fornieles J: Neuropsychological performance in children and adolescents with obsessive-compulsive disorder and influence of clinical variables. Biol Psychiatry. 2007, 61: 946-951.

  1177. Jacob ML, Morelen D, Suveg C, Brown Jacobsen AM, Whiteside SP: Emotional, behavioral, and cognitive factors that differentiate obsessive-compulsive disorder and other anxiety disorders in youth. Anxiety Stress Coping. 2012, 25: 229-237.

  1178. Hughes AA, Lourea-Waddell B, Kendall PC: Somatic complaints in children with anxiety disorders and their unique prediction of poorer academic performance. Child Psychiatry Hum Dev. 2008, 39: 211-220.

  1179. Grills-Taquechel AE, Fletcher JM, Vaughn SR, Denton CA, Taylor P: Anxiety and inattention as predictors of achievement in early elementary school children. Anxiety Stress Coping. 2013, 26: 391-410.

  1180. Tillfors M, Persson S, Willen M, Burk WJ: Prospective links between social anxiety and adolescent peer relations. J Adolesc. 2012, 35: 1255-1263.

  1181. Teubert D, Pinquart M: A meta-analytic review on the prevention of symptoms of anxiety in children and adolescents. J Anxiety Disord. 2011, 25: 1046-1059.

  1182. Barrett PM, Farrell LJ, Ollendick TH, Dadds M: Long-term outcomes of an Australian universal prevention trial of anxiety and depression symptoms in children and youth: an evaluation of the friends program. J Clin Child Adolesc Psychol. 2006, 35: 403-411.

  1183. Simon E, Bogels SM, Voncken JM: Efficacy of child-focused and parent-focused interventions in a child anxiety prevention study. J Clin Child Adolesc Psychol. 2011, 40: 204-219.

  1184. Manassis K, Wilansky-Traynor P, Farzan N, Kleiman V, Parker K, Sanford M: The feelings club: randomized controlled evaluation of school-based CBT for anxious or depressive symptoms. Depress Anxiety. 2010, 27: 945-952.

  1185. Stallard P, Velleman R, Salter E, Howse I, Yule W, Taylor G: A randomised controlled trial to determine the effectiveness of an early psychological intervention with children involved in road traffic accidents. J Child Psychol Psychiatry. 2006, 47: 127-134.

  1186. Nugent NR, Christopher NC, Crow JP, Browne L, Ostrowski S, Delahanty DL: The efficacy of early propranolol administration at reducing PTSD symptoms in pediatric injury patients: a pilot study. J Trauma Stress. 2010, 23: 282-287.

  1187. Weisz JR, Jensen-Doss A, Hawley KM: Evidence-based youth psychotherapies versus usual clinical care: a meta-analysis of direct comparisons. Am Psychol. 2006, 61: 671-689.

  1188. Chu BC, Harrison TL: Disorder-specific effects of CBT for anxious and depressed youth: a meta-analysis of candidate mediators of change. Clin Child Fam Psychol Rev. 2007, 10: 352-372.

  1189. In-Albon T, Schneider S: Psychotherapy of childhood anxiety disorders: a meta-analysis. Psychother Psychosom. 2007, 76: 15-24.

  1190. Silverman WK, Pina AA, Viswesvaran C: Evidence-based psychosocial treatments for phobic and anxiety disorders in children and adolescents. J Clin Child Adolesc Psychol. 2008, 37: 105-130.

  1191. Cartwright-Hatton S, Roberts C, Chitsabesan P, Fothergill C, Harrington R: Systematic review of the efficacy of cognitive behaviour therapies for childhood and adolescent anxiety disorders. Br J Clin Psychol. 2004, 43: 421-436.

  1192. Baer S, Garland E: Pilot study of community-based cognitive behavioral group therapy for adolescents with social phobia. J Am Acad Child Adolesc Psychiatry. 2005, 44: 258-264.

  1193. Beidel D, Turner S, Morris T: Behavioral treatment of childhood social phobia. J Consult Clin Psychol. 2000, 68: 1072-1080.

  1194. Herbert JD, Gaudiano BA, Rheingold AA, Moitra E, Myers VH, Dalrymple KL, Brandsma LL: Cognitive behavior therapy for generalized social anxiety disorder in adolescents: a randomized controlled trial. J Anxiety Disord. 2009, 23: 167-177.

  1195. Piet J, Hougaard E, Hecksher MS, Rosenberg NK: A randomized pilot study of mindfulness-based cognitive therapy and group cognitive-behavioral therapy for young adults with social phobia. Scand J Psychol. 2010, 51: 503-410.

  1196. Melfsen S, Kuhnemund M, Schwieger J, Warnke A, Stadler C, Poustka F, Stangier U: Cognitive behavioral therapy of socially phobic children focusing on cognition: a randomised wait-list control study. Child Adolesc Psychiatry Ment Health. 2011, 5: 5-

  1197. Segool NK, Carlson JS: Efficacy of cognitive-behavioral and pharmacological treatments for children with social anxiety. Depress Anxiety. 2008, 25: 620-631.

  1198. Pincus DB, May JE, Whitton SW, Mattis SG, Barlow DH: Cognitive-behavioral treatment of panic disorder in adolescence. J Clin Child Adolesc Psychol. 2010, 39: 638-649.

  1199. Franklin ME, Sapyta J, Freeman JB, Khanna M, Compton S, Almirall D, Moore P, Choate-Summers M, Garcia A, Edson AL, et al: Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial. JAMA. 2011, 306: 1224-1232.

  1200. Williams TI, Salkovskis PM, Forrester L, Turner S, White H, Allsopp MA: A randomised controlled trial of cognitive behavioural treatment for obsessive compulsive disorder in children and adolescents. Eur Child Adolesc Psychiatry. 2010, 19: 449-456.

  1201. Bolton D, Williams T, Perrin S, Atkinson L, Gallop C, Waite P, Salkovskis P: Randomized controlled trial of full and brief cognitive-behaviour therapy and wait-list for paediatric obsessive-compulsive disorder. J Child Psychol Psychiatry. 2011, 52: 1269-1278.

  1202. Turner C, Heyman I, Futh A, Lovell K: A pilot study of telephone cognitive-behavioural therapy for obsessive-compulsive disorder in young people. Behav Cogn Psychother. 2009, 37: 469-474.

  1203. O’Kearney RT, Anstey KJ, von Sanden C: Behavioural and cognitive behavioural therapy for obsessive compulsive disorder in children and adolescents. Cochrane Database Syst Rev. 2006, CD004856-

  1204. Watson HJ, Rees CS: Meta-analysis of randomized, controlled treatment trials for pediatric obsessive-compulsive disorder. J Child Psychol Psychiatry. 2008, 49: 489-498.

  1205. Smith P, Yule W, Perrin S, Tranah T, Dalgleish T, Clark DM: Cognitive-behavioral therapy for PTSD in children and adolescents: a preliminary randomized controlled trial. J Am Acad Child Adolesc Psychiatry. 2007, 46: 1051-1061.

  1206. Nixon RD, Sterk J, Pearce A: A randomized trial of cognitive behaviour therapy and cognitive therapy for children with posttraumatic stress disorder following single-incident trauma. J Abnorm Child Psychol. 2012, 40: 327-337.

  1207. Kowalik J, Weller J, Venter J, Drachman D: Cognitive behavioral therapy for the treatment of pediatric posttraumatic stress disorder: a review and meta-analysis. J Behav Ther Exp Psychiatry. 2011, 42: 405-413.

  1208. King N, Tonge B, Mullen P, Myerson N, Heyne D, Rollings S, Martin R, Ollendick T: Treating sexually abused children with posttraumatic stress symptoms: a randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2000, 39: 1347-1355.

  1209. Cohen J, Mannarino A: A treatment outcome study for sexually abused preschool children: initial findings. J Am Acad Child Adolesc Psychiatry. 1996, 35: 42-50.

  1210. Scheeringa MS, Weems CF, Cohen JA, Amaya-Jackson L, Guthrie D: Trauma-focused cognitive-behavioral therapy for posttraumatic stress disorder in three-through six year-old children: a randomized clinical trial. J Child Psychol Psychiatry. 2011, 52: 853-860.

  1211. Deblinger E, Mannarino AP, Cohen JA, Steer RA: A follow-up study of a multisite, randomized, controlled trial for children with sexual abuse-related PTSD symptoms. J Am Acad Child Adolesc Psychiatry. 2006, 45: 1474-1484.

  1212. King N, Tonge B, Heyne D, Pritchard M, Rollings S, Young D, Myerson N, Ollendick T: Cognitive-behavioral treatment of school-refusing children: a controlled evaluation. J Am Acad Child Adolesc Psychiatry. 1998, 37: 395-403.

  1213. Last C, Hansen C, Franco N: Cognitive-behavioral treatment of school phobia. J Am Acad Child Adolesc Psychiatry. 1998, 37: 404-411.

  1214. Pina AA, Zerr AA, Gonzales NA, Ortiz CD: Psychosocial interventions for school refusal behavior in children and adolescents. Child Dev Perspect. 2009, 3: 11-20.

  1215. Heyne D, King NJ, Tonge BJ, Rollings S, Young D, Pritchard M, Ollendick TH: Evaluation of child therapy and caregiver training in the treatment of school refusal. J Am Acad Child Adolesc Psychiatry. 2002, 41: 687-695.

  1216. Schneider S, Blatter-Meunier J, Herren C, Adornetto C, In-Albon T, Lavallee K: Disorder-specific cognitive-behavioral therapy for separation anxiety disorder in young children: a randomized waiting-list-controlled trial. Psychother Psychosom. 2011, 80: 206-215.

  1217. Manassis K, Mendlowitz S, Scapillato D, Avery D, Fiksenbaum L, Freire M, Monga S, Owens M: Group and individual cognitive-behavioral therapy for childhood anxiety disorders: a randomized trial. J Am Acad Child Adolesc Psychiatry. 2002, 41: 1423-1430.

  1218. O’Leary EM, Barrett P, Fjermestad KW: Cognitive-behavioral family treatment for childhood obsessive-compulsive disorder: a 7-year follow-up study. J Anxiety Disord. 2009, 23: 973-978.

  1219. Richardson T, Stallard P, Velleman S: Computerised cognitive behavioural therapy for the prevention and treatment of depression and anxiety in children and adolescents: a systematic review. Clin Child Fam Psychol Rev. 2010, 13: 275-290.

  1220. Storch EA, Caporino NE, Morgan JR, Lewin AB, Rojas A, Brauer L, Larson MJ, Murphy TK: Preliminary investigation of web-camera delivered cognitive-behavioral therapy for youth with obsessive-compulsive disorder. Psychiatry Res. 2011, 189: 407-412.

  1221. Kendall P: Treating anxiety disorders in children: results of a randomized clinical trial. J Consult Clin Psychol. 1994, 62: 100-110.

  1222. Kendall P, Flannery-Schroeder E, Panichelli-Mindel S, Southam-Gerow M, Henin A, Warman M: Therapy for youths with anxiety disorders: a second randomized clinical trial. J Consult Clin Psychol. 1997, 65: 366-380.

  1223. Walkup JT, Albano AM, Piacentini J, Birmaher B, Compton SN, Sherrill JT, Ginsburg GS, Rynn MA, McCracken J, Waslick B, et al: Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med. 2008, 359: 2753-2766.

  1224. Ginsburg GS, Kendall PC, Sakolsky D, Compton SN, Piacentini J, Albano AM, Walkup JT, Sherrill J, Coffey KA, Rynn MA, et al: Remission after acute treatment in children and adolescents with anxiety disorders: findings from the CAMS. J Consult Clin Psychol. 2011, 79: 806-813.

  1225. Kendall P, Safford S, Flannery-Schroeder E, Webb A: Child anxiety treatment: outcomes in adolescence and impact on substance use and depression at 7.4-year follow-up. J Consult Clin Psychol. 2004, 72: 276-287.

  1226. Eldar S, Apter A, Lotan D, Edgar KP, Naim R, Fox NA, Pine DS, Bar-Haim Y: Attention bias modification treatment for pediatric anxiety disorders: a randomized controlled trial. Am J Psychiatry. 2012, 169: 213-230.

  1227. Beidel DC, Turner SM, Sallee FR, Ammerman RT, Crosby LA, Pathak S: SET-C versus fluoxetine in the treatment of childhood social phobia. J Am Acad Child Adolesc Psychiatry. 2007, 46: 1622-1632.

  1228. Beidel DC, Turner SM, Young BJ: Social effectiveness therapy for children: five years later. Behav Ther. 2006, 37: 416-425.

  1229. Simons M, Schneider S, Herpertz-Dahlmann B: Metacognitive therapy versus exposure and response prevention for pediatric obsessive-compulsive disorder. A case series with randomized allocation. Psychother Psychosom. 2006, 75: 257-264.

  1230. Bolton D, Perrin S: Evaluation of exposure with response-prevention for obsessive compulsive disorder in childhood and adolescence. J Behav Ther Exp Psychiatry. 2008, 39: 11-22.

  1231. Storch EA, Geffken GR, Merlo LJ, Mann G, Duke D, Munson M, Adkins J, Grabill KM, Murphy TK, Goodman WK: Family-based cognitive-behavioral therapy for pediatric obsessive-compulsive disorder: comparison of intensive and weekly approaches. J Am Acad Child Adolesc Psychiatry. 2007, 46: 469-478.

  1232. Barrett P, Healy-Farrell L, March J: Cognitive-behavioral family treatment of childhood obsessive-compulsive disorder: a controlled trial. J Am Acad Child Adolesc Psychiatry. 2004, 43: 46-62.

  1233. Van der Oord S, Lucassen S, Van Emmerik AA, Emmelkamp PM: Treatment of post-traumatic stress disorder in children using cognitive behavioural writing therapy. Clin Psychol Psychother. 2010, 17: 240-249.

  1234. Lesmana CB, Suryani LK, Jensen GD, Tiliopoulos N: A spiritual-hypnosis assisted treatment of children with PTSD after the 2002 Bali terrorist attack. Am J Clin Hypn. 2009, 52: 23-34.

  1235. Ford JD, Steinberg KL, Hawke J, Levine J, Zhang W: Randomized trial comparison of emotion regulation and relational psychotherapies for PTSD with girls involved in delinquency. J Clin Child Adolesc Psychol. 2012, 41: 27-37.

  1236. Gilboa-Schechtman E, Foa EB, Shafran N, Aderka IM, Powers MB, Rachamim L, Rosenbach L, Yadin E, Apter A: Prolonged exposure versus dynamic therapy for adolescent PTSD: a pilot randomized controlled trial. J Am Acad Child Adolesc Psychiatry. 2010, 49: 1034-1042.

  1237. Ahmad A, Sundelin-Wahlsten V: Applying EMDR on children with PTSD. Eur Child Adolesc Psychiatry. 2008, 17: 127-132.

  1238. Ahmad A, Larsson B, Sundelin-Wahlsten V: EMDR treatment for children with PTSD: results of a randomized controlled trial. Nord J Psychiatry. 2007, 61: 349-354.

  1239. Barrett P, Dadds M, Rapee R: Family treatment of childhood anxiety: a controlled trial. J Consult Clin Psychol. 1996, 64: 333-342.

  1240. Mendlowitz S, Manassis K, Bradley S, Scapillato D, Miezitis S, Shaw B: Cognitive-behavioral group treatments in childhood anxiety disorders: the role of parental involvement. J Am Acad Child Adolesc Psychiatry. 1999, 38: 1223-1229.

  1241. Shortt A, Barrett P, Fox T: Evaluating the FRIENDS program: a cognitive-behavioral group treatment for anxious children and their parents. J Clin Child Psychol. 2001, 30: 525-535.

  1242. Nauta M, Scholing A, Emmelkamp P, Minderaa R: Cognitive-behavioral therapy for children with anxiety disorders in a clinical setting: no additional effect of a cognitive parent training. J Am Acad Child Adolesc Psychiatry. 2003, 42: 1270-1278.

  1243. Bogels SM, Siqueland L: Family cognitive behavioral therapy for children and adolescents with clinical anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2006, 45: 134-141.

  1244. Wood JJ, Piacentini JC, Southam-Gerow M, Chu BC, Sigman M: Family cognitive behavioral therapy for child anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2006, 45: 314-321.

  1245. Piacentini J, Bergman RL, Chang S, Langley A, Peris T, Wood JJ, McCracken J: Controlled comparison of family cognitive behavioral therapy and psychoeducation/relaxation training for child obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2011, 50: 1149-1161.

  1246. Cobham VE, Dadds MR, Spence SH: The role of parental anxiety in the treatment of childhood anxiety. J Consult Clin Psychol. 1998, 66: 893-905.

  1247. Eisen AR, Raleigh H, Neuhoff CC: The unique impact of parent training for separation anxiety disorder in children. Behav Ther. 2008, 39: 195-206.

  1248. Thienemann M, Moore P, Tompkins K: A parent-only group intervention for children with anxiety disorders: pilot study. J Am Acad Child Adolesc Psychiatry. 2006, 45: 37-46.

  1249. Storch EA, Merlo LJ, Larson MJ, Geffken GR, Lehmkuhl HD, Jacob ML, Murphy TK, Goodman WK: Impact of comorbidity on cognitive-behavioral therapy response in pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2008, 47: 583-592.

  1250. Jarrett MA, Ollendick TH: Treatment of comorbid attention-deficit/hyperactivity disorder and anxiety in children: A multiple baseline design analysis. J Consult Clin Psychol. 2012, 80: 239-244.

  1251. Levy K, Hunt C, Heriot S: Treating comorbid anxiety and aggression in children. J Am Acad Child Adolesc Psychiatry. 2007, 46: 1111-1118.

  1252. Najavits LM, Gallop RJ, Weiss RD: Seeking safety therapy for adolescent girls with PTSD and substance use disorder: a randomized controlled trial. J Behav Health Serv Res. 2006, 33: 453-463.

  1253. Dadds MR, Holland DE, Laurens KR, Mullins M, Barrett PM, Spence SH: Early intervention and prevention of anxiety disorders in children: results at 2-year follow-up. J Consult Clin Psychol. 1999, 67: 145-150.

  1254. Barrett P, Duffy A, Dadds M, Rapee R: Cognitive-behavioral treatment of anxiety disorders in children: long-term (6-year) follow-up. J Consult Clin Psychol. 2001, 69: 135-141.

  1255. Connolly SD, Bernstein GA: Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2007, 46: 267-283.

  1256. Practice parameter on the use of psychotropic medication in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2009, 48: 961-973.

  1257. Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2012, 51: 98-113.

  1258. Cohen JA, Bukstein O, Walter H, Benson SR, Chrisman A, Farchione TR, Hamilton J, Keable H, Kinlan J, Schoettle U, et al: Practice parameter for the assessment and treatment of children and adolescents with posttraumatic stress disorder. J Am Acad Child Adolesc Psychiatry. 2010, 49: 414-430.

  1259. Bernstein G, Borchardt C, Perwien A, Crosby R, Kushner M, Thuras P, Last C: Imipramine plus cognitive-behavioral therapy in the treatment of school refusal. J Am Acad Child Adolesc Psychiatry. 2000, 39: 276-283.

  1260. Reinblatt SP, Riddle MA: The pharmacological management of childhood anxiety disorders: a review. Psychopharmacology. 2007, 191: 67-86.

  1261. Ipser JC, Stein DJ, Hawkridge S, Hoppe L: Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev. 2009, CD005170-

  1262. Uthman OA, Abdulmalik J: Comparative efficacy and acceptability of pharmacotherapeutic agents for anxiety disorders in children and adolescents: a mixed treatment comparison meta-analysis. Curr Med Res Opin. 2010, 26: 53-59.

  1263. Geller D, Biederman J, Stewart S, Mullin B, Martin A, Spencer T, Faraone S: Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatry. 2003, 160: 1919-1928.

  1264. Alaghband-Rad J, Hakimshooshtary M: A randomized controlled clinical trial of citalopram versus fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD). Eur Child Adolesc Psychiatry. 2009, 18: 131-135.

  1265. Coskun M, Zoroglu S: Efficacy and safety of fluoxetine in preschool children with obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2009, 19: 297-300.

  1266. Ercan ES, Kandulu R, Akyol Ardic U: Preschool children with obsessive-compulsive disorder and fluoxetine treatment. Eur Child Adolesc Psychiatry. 2012, 21: 169-172.

  1267. Geller D, Hoog S, Heiligenstein J, Ricardi R, Tamura R, Kluszynski S, Jacobson J: Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry. 2001, 40: 773-779.

  1268. Riddle M, Scahill L, King R, Hardin M, Anderson G, Ort S, Smith J, Leckman J, Cohen D: Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 1992, 31: 1062-1069.

  1269. Liebowitz MR, Turner SM, Piacentini J, Beidel DC, Clarvit SR, Davies SO, Graae F, Jaffer M, Lin SH, Sallee FR, et al: Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2002, 41: 1431-1438.

  1270. Mukaddes NM, Abali O, Kaynak N: Citalopram treatment of children and adolescents with obsessive-compulsive disorder: a preliminary report. Psychiatry Clin Neurosci. 2003, 57: 405-408.

  1271. Riddle M, Reeve E, Yaryura-Tobias J, Yang H, Claghorn J, Gaffney G, Greist J, Holland D, McConville B, Pigott T, Walkup J: Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry. 2001, 40: 222-229.

  1272. Geller DA, Wagner KD, Emslie G, Murphy T, Carpenter DJ, Wetherhold E, Perera P, Machin A, Gardiner C: Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2004, 43: 1387-1396.

  1273. March J, Biederman J, Wolkow R, Safferman A, Mardekian J, Cook E, Cutler N, Dominguez R, Ferguson J, Muller B, et al: Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA. 1998, 280: 1752-1756.

  1274. De Veaugh-Geiss J, Moroz G, Biederman J, Cantwell D, Fontaine R, Greist J, Reichler R, Katz R, Landau P: Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder–a multicenter trial. J Am Acad Child Adolesc Psychiatry. 1992, 31: 45-49.

  1275. Leonard HL, Swedo SE, Rapoport JL, Koby EV, Lenane MC, Cheslow DL, Hamburger SD: Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents. A double-blind crossover comparison. Arch Gen Psychiatry. 1989, 46: 1088-1092.

  1276. Flament MF, Rapoport JL, Berg CJ, Sceery W, Kilts C, Mellstrom B, Linnoila M: Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study. Arch Gen Psychiatry. 1985, 42: 977-983.

  1277. Birmaher B, Axelson D, Monk K, Kalas C, Clark D, Ehmann M, Bridge J, Heo J, Brent D: Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2003, 42: 415-423.

  1278. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. N Engl J Med. 2001, 344: 1279-1285.

  1279. Wagner K, Berard R, Stein M, Wetherhold E, Carpenter D, Perera P, Gee M, Davy K, Machin A: A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry. 2004, 61: 1153-1162.

  1280. Isolan L, Pheula G, Salum GA, Oswald S, Rohde LA, Manfro GG: An open-label trial of escitalopram in children and adolescents with social anxiety disorder. J Child Adolesc Psychopharmacol. 2007, 17: 751-760.

  1281. Compton S, Grant P, Chrisman A, Gammon P, Brown V, March J: Sertraline in children and adolescents with social anxiety disorder: an open trial. J Am Acad Child Adolesc Psychiatry. 2001, 40: 564-571.

  1282. March JS, Entusah AR, Rynn M, Albano AM, Tourian KA: A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biol Psychiatry. 2007, 62: 1149-1154.

  1283. Mrakotsky C, Masek B, Biederman J, Raches D, Hsin O, Forbes P, de Moor C, DeMaso DR, Gonzalez-Heydrich J: Prospective open-label pilot trial of mirtazapine in children and adolescents with social phobia. J Anxiety Disord. 2008, 22: 88-97.

  1284. Rynn MA, Siqueland L, Rickels K: Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry. 2001, 158: 2008-2014.

  1285. Lepola U, Leinonen E, Koponen H: Citalopram in the treatment of early-onset panic disorder and school phobia. Pharmacopsychiatry. 1996, 29: 30-32.

  1286. Robb AS, Cueva JE, Sporn J, Yang R, Vanderburg DG: Sertraline treatment of children and adolescents with posttraumatic stress disorder: a double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol. 2010, 20: 463-471.

  1287. Kutcher SP, MacKenzie S: Successful clonazepam treatment of adolescents with panic disorder. J Clin Psychopharmacol. 1988, 8: 299-301.

  1288. Biederman J: Clonazepam in the treatment of prepubertal children with panic-like symptoms. J Clin Psychiatry. 1987, 48 (Suppl): 38-42.

  1289. Ballenger JC, Carek DJ, Steele JJ, Cornish-McTighe D: Three cases of panic disorder with agoraphobia in children. Am J Psychiatry. 1989, 146: 922-924.

  1290. Simeon JG, Ferguson HB, Knott V, Roberts N, Gauthier B, Dubois C, Wiggins D: Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders. J Am Acad Child Adolesc Psychiatry. 1992, 31: 29-33.

  1291. Bernstein GA, Garfinkel BD, Borchardt CM: Comparative studies of pharmacotherapy for school refusal. J Am Acad Child Adolesc Psychiatry. 1990, 29: 773-781.

  1292. Graae F, Milner J, Rizzotto L, Klein RG: Clonazepam in childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry. 1994, 33: 372-376.

  1293. Masi G, Pfanner C, Millepiedi S, Berloffa S: Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder. J Clin Psychopharmacol. 2010, 30: 688-693.

  1294. Grant P, Lougee L, Hirschtritt M, Swedo SE: An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2007, 17: 761-767.

  1295. Storch EA, Murphy TK, Goodman WK, Geffken GR, Lewin AB, Henin A, Micco JA, Sprich S, Wilhelm S, Bengtson M, Geller DA: A preliminary study of d-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry. 2010, 68: 1073-1076.

  1296. Larun L, Nordheim LV, Ekeland E, Hagen KB, Heian F: Exercise in prevention and treatment of anxiety and depression among children and young people. Cochrane Database Syst Rev. 2006, 3: CD004691-

  1297. Newman CL, Motta RW: The effects of aerobic exercise on childhood PTSD, anxiety, and depression. Int J Emerg Ment Health. 2007, 9: 133-158.

  1298. Diaz AB, Motta R: The effects of an aerobic exercise program on posttraumatic stress disorder symptom severity in adolescents. Int J Emerg Ment Health. 2008, 10: 49-59.

  1299. Harris E, Eng HY, Kowatch R, Delgado SV, Saldana SN: Disinhibition as a side effect of treatment with fluvoxamine in pediatric patients with obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2010, 20: 347-353.

  1300. Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D: Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med. 2004, 158: 773-780.

  1301. Findling RL, Nucci G, Piergies AA, Gomeni R, Bartolic EI, Fong R, Carpenter DJ, Leeder JS, Gaedigk A, Danoff TM: Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. Neuropsychopharmacology. 2006, 31: 1274-1285.

  1302. Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, Ren L, Brent DA: Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007, 297: 1683-1696.

  1303. Safer DJ, Zito JM: Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents. J Child Adolesc Psychopharmacol. 2006, 16: 159-169.

  1304. Gum AM, King-Kallimanis B, Kohn R: Prevalence of mood, anxiety, and substance-abuse disorders for older Americans in the National Comorbidity Survey-Replication. Am J Geriatr Psychiatry. 2009, 17: 769-781.

  1305. Grenier S, Preville M, Boyer R, O’Connor K, Beland SG, Potvin O, Hudon C, Brassard J: The impact of DSM-IV symptom and clinical significance criteria on the prevalence estimates of subthreshold and threshold anxiety in the older adult population. Am J Geriatr Psychiatry. 2011, 19: 316-326.

  1306. Streiner DL, Cairney J, Veldhuizen S: The epidemiology of psychological problems in the elderly. Can J Psychiatry. 2006, 51: 185-191.

  1307. Hollingworth SA, Burgess PM, Whiteford HA: Affective and anxiety disorders: prevalence, treatment and antidepressant medication use. Aust N Z J Psychiatry. 2010, 44: 513-519.

  1308. Jorm A: Does old age reduce the risk of anxiety and depression? A review of epidemiological studies across the adult life span. Psychol Med. 2000, 30: 11-22.

  1309. Calleo J, Stanley MA, Greisinger A, Wehmanen O, Johnson M, Novy D, Wilson N, Kunik M: Generalized anxiety disorder in older medical patients: diagnostic recognition, mental health management and service utilization. J Clin Psychol Med Settings. 2009, 16: 178-185.

  1310. Cairney J, Corna LM, Streiner DL: Mental health care use in later life: results from a national survey of Canadians. Can J Psychiatry. 2010, 55: 157-164.

  1311. Byers AL, Arean PA, Yaffe K: Low use of mental health services among older Americans with mood and anxiety disorders. Psychiatr Serv. 2012, 63: 66-72.

  1312. Scott T, Mackenzie CS, Chipperfield JG, Sareen J: Mental health service use among Canadian older adults with anxiety disorders and clinically significant anxiety symptoms. Aging Ment Health. 2010, 14: 790-800.

  1313. Brenes GA, Miller ME, Stanley MA, Williamson JD, Knudson M, McCall WV: Insomnia in older adults with generalized anxiety disorder. Am J Geriatr Psychiatry. 2009, 17: 465-472.

  1314. Spira AP, Stone K, Beaudreau SA, Ancoli-Israel S, Yaffe K: Anxiety symptoms and objectively measured sleep quality in older women. Am J Geriatr Psychiatry. 2009, 17: 136-143.

  1315. Mehta K, Simonsick E, Penninx B, Schulz R, Rubin S, Satterfield S, Yaffe K: Prevalence and correlates of anxiety symptoms in well-functioning older adults: findings from the health aging and body composition study. J Am Geriatr Soc. 2003, 51: 499-504.

  1316. Beaudreau SA, O’Hara R: The association of anxiety and depressive symptoms with cognitive performance in community-dwelling older adults. Psychol Aging. 2009, 24: 507-512.

  1317. Butters MA, Bhalla RK, Andreescu C, Wetherell JL, Mantella R, Begley AE, Lenze EJ: Changes in neuropsychological functioning following treatment for late-life generalised anxiety disorder. Br J Psychiatry. 2011, 199: 211-218.

  1318. Sinoff G, Werner P: Anxiety disorder and accompanying subjective memory loss in the elderly as a predictor of future cognitive decline. Int J Geriatr Psychiatry. 2003, 18: 951-959.

  1319. Scott Mackin R, Lesselyong JA, Yaffe K: Pattern of cognitive impairment in older veterans with posttraumatic stress disorder evaluated at a memory disorders clinic. Int J Geriatr Psychiatry. 2012, 27: 637-642.

  1320. Mehta KM, Yaffe K, Brenes GA, Newman AB, Shorr RI, Simonsick EM, Ayonayon HN, Rubin SM, Covinsky KE: Anxiety symptoms and decline in physical function over 5 years in the health, aging and body composition study. J Am Geriatr Soc. 2007, 55: 265-270.

  1321. Porensky EK, Dew MA, Karp JF, Skidmore E, Rollman BL, Shear MK, Lenze EJ: The burden of late-life generalized anxiety disorder: effects on disability, health-related quality of life, and healthcare utilization. Am J Geriatr Psychiatry. 2009, 17: 473-482.

  1322. Diefenbach GJ, Tolin DF, Gilliam CM: Impairments in life quality among clients in geriatric home care: associations with depressive and anxiety symptoms. Int J Geriatr Psychiatry. 2012, 27: 828-835.

  1323. Cairney J, Corna LM, Veldhuizen S, Herrmann N, Streiner DL: Comorbid depression and anxiety in later life: patterns of association, subjective well-being, and impairment. Am J Geriatr Psychiatry. 2008, 16: 201-208.

  1324. King-Kallimanis B, Gum AM, Kohn R: Comorbidity of depressive and anxiety disorders for older Americans in the National Comorbidity Survey-Replication. Am J Geriatr Psychiatry. 2009, 17: 782-792.

  1325. Wetherell JL, Ayers CR, Nuevo R, Stein MB, Ramsdell J, Patterson TL: Medical conditions and depressive, anxiety, and somatic symptoms in older adults with and without generalized anxiety disorder. Aging Ment Health. 2010, 14: 764-768.

  1326. Schoevers R, Deeg D, van Tilburg W, Beekman A: Depression and generalized anxiety disorder: co-occurrence and longitudinal patterns in elderly patients. Am J Geriatr Psychiatry. 2005, 13: 31-39.

  1327. Wolitzky-Taylor KB, Castriotta N, Lenze EJ, Stanley MA, Craske MG: Anxiety disorders in older adults: a comprehensive review. Depress Anxiety. 2010, 27: 190-211.

  1328. Qureshi SU, Kimbrell T, Pyne JM, Magruder KM, Hudson TJ, Petersen NJ, Yu HJ, Schulz PE, Kunik ME: Greater prevalence and incidence of dementia in older veterans with posttraumatic stress disorder. J Am Geriatr Soc. 2010, 58: 1627-1633.

  1329. Vogele C, von Leupoldt A: Mental disorders in chronic obstructive pulmonary disease (COPD). Respir Med. 2008, 102: 764-773.

  1330. Smoller JW, Pollack MH, Wassertheil-Smoller S, Jackson RD, Oberman A, Wong ND, Sheps D: Panic attacks and risk of incident cardiovascular events among postmenopausal women in the Women’s Health Initiative Observational Study. Arch Gen Psychiatry. 2007, 64: 1153-1160.

  1331. Tully PJ, Baker RA, Knight JL: Anxiety and depression as risk factors for mortality after coronary artery bypass surgery. J Psychosom Res. 2008, 64: 285-290.

  1332. Bryant C, Jackson H, Ames D: The prevalence of anxiety in older adults: methodological issues and a review of the literature. J Affect Disord. 2008, 109: 233-250.

  1333. Mohlman J, Bryant C, Lenze EJ, Stanley MA, Gum A, Flint A, Beekman AT, Wetherell JL, Thorp SR, Craske MG: Improving recognition of late life anxiety disorders in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition: observations and recommendations of the Advisory Committee to the Lifespan Disorders Work Group. Int J Geriatr Psychiatry. 2012, 27: 549-556.

  1334. Brenes GA, Knudson M, McCall WV, Williamson JD, Miller ME, Stanley MA: Age and racial differences in the presentation and treatment of generalized anxiety disorder in primary care. J Anxiety Disord. 2008, 22: 1128-1136.

  1335. Wetherell JL, Petkus AJ, McChesney K, Stein MB, Judd PH, Rockwell E, Sewell DD, Patterson TL: Older adults are less accurate than younger adults at identifying symptoms of anxiety and depression. J Nerv Ment Dis. 2009, 197: 623-626.

  1336. Jeste DV, Blazer DG, First M: Aging-related diagnostic variations: need for diagnostic criteria appropriate for elderly psychiatric patients. Biol Psychiatry. 2005, 58: 265-271.

  1337. Ayers CR, Sorrell JT, Thorp SR, Wetherell JL: Evidence-based psychological treatments for late-life anxiety. Psychol Aging. 2007, 22: 8-17.

  1338. Pinquart M, Duberstein PR: Treatment of anxiety disorders in older adults: a meta-analytic comparison of behavioral and pharmacological interventions. Am J Geriatr Psychiatry. 2007, 15: 639-651.

  1339. Goncalves DC, Byrne GJ: Interventions for generalized anxiety disorder in older adults: systematic review and meta-analysis. J Anxiety Disord. 2012, 26: 1-11.

  1340. Hendriks GJ, Oude Voshaar RC, Keijsers GP, Hoogduin CA, van Balkom AJ: Cognitive-behavioural therapy for late-life anxiety disorders: a systematic review and meta-analysis. Acta Psychiatr Scand. 2008, 117: 403-411.

  1341. Thorp SR, Ayers CR, Nuevo R, Stoddard JA, Sorrell JT, Wetherell JL: Meta-analysis comparing different behavioral treatments for late-life anxiety. Am J Geriatr Psychiatry. 2009, 17: 105-115.

  1342. Gould RL, Coulson MC, Howard RJ: Efficacy of cognitive behavioral therapy for anxiety disorders in older people: a meta-analysis and meta-regression of randomized controlled trials. J Am Geriatr Soc. 2012, 60: 218-229.

  1343. Mohlman J, Gorenstein E, Kleber M, de JM, Gorman J, Papp L: Standard and enhanced cognitive-behavior therapy for late-life generalized anxiety disorder: two pilot investigations. Am J Geriatr Psychiatry. 2003, 11: 24-32.

  1344. Stanley M, Hopko D, Diefenbach G, Bourland S, Rodriguez H, Wagener P: Cognitive-behavior therapy for late-life generalized anxiety disorder in primary care: preliminary findings. Am J Geriatr Psychiatry. 2003, 11: 92-96.

  1345. Bradford A, Cully J, Rhoades H, Kunik M, Kraus-Schuman C, Wilson N, Stanley M: Early response to psychotherapy and long-term change in worry symptoms in older adults with generalized anxiety disorder. Am J Geriatr Psychiatry. 2011, 19: 347-356.

  1346. Stanley MA, Wilson NL, Novy DM, Rhoades HM, Wagener PD, Greisinger AJ, Cully JA, Kunik ME: Cognitive behavior therapy for generalized anxiety disorder among older adults in primary care: a randomized clinical trial. JAMA. 2009, 301: 1460-1467.

  1347. Wetherell J, Gatz M, Craske M: Treatment of generalized anxiety disorder in older adults. J Consult Clin Psychol. 2003, 71: 31-40.

  1348. Hendriks GJ, Keijsers GP, Kampman M, Oude Voshaar RC, Verbraak MJ, Broekman TG, Hoogduin CA: A randomized controlled study of paroxetine and cognitive-behavioural therapy for late-life panic disorder. Acta Psychiatr Scand. 2010, 122: 11-19.

  1349. Schuurmans J, Comijs H, Emmelkamp PM, Gundy CM, Weijnen I, van den Hout M, van Dyck R: A randomized, controlled trial of the effectiveness of cognitive-behavioral therapy and sertraline versus a waitlist control group for anxiety disorders in older adults. Am J Geriatr Psychiatry. 2006, 14: 255-263.

  1350. Thorp SR, Stein MB, Jeste DV, Patterson TL, Wetherell JL: Prolonged exposure therapy for older veterans with posttraumatic stress disorder: a pilot study. Am J Geriatr Psychiatry. 2012, 20: 276-280.

  1351. Pachana NA, Woodward RM, Byrne GJ: Treatment of specific phobia in older adults. Clin Interv Aging. 2007, 2: 469-476.

  1352. Brenes GA, Miller ME, Williamson JD, McCall WV, Knudson M, Stanley MA: A randomized controlled trial of telephone-delivered cognitive-behavioral therapy for late-life anxiety disorders. Am J Geriatr Psychiatry. 2012, 20: 707-716.

  1353. Pasco JA, Williams LJ, Jacka FN, Henry MJ, Coulson CE, Brennan SL, Leslie E, Nicholson GC, Kotowicz MA, Berk M: Habitual physical activity and the risk for depressive and anxiety disorders among older men and women. Int Psychogeriatr. 2011, 23: 292-298.

  1354. Montgomery S, Chatamra K, Pauer L, Whalen E, Baldinetti F: Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry. 2008, 193: 389-394.

  1355. Karaiskos D, Pappa D, Tzavellas E, Siarkos K, Katirtzoglou E, Papadimitriou GN, Politis A: Pregabalin augmentation of antidepressants in older patients with comorbid depression and generalized anxiety disorder-an open-label study. Int J Geriatr Psychiatry. 2013, 28: 100-105.

  1356. Davidson J, Allgulander C, Pollack MH, Hartford J, Erickson JS, Russell JM, Perahia D, Wohlreich MM, Carlson J, Raskin J: Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies. Hum Psychopharmacol. 2008, 23: 519-526.

  1357. Lenze EJ, Mulsant BH, Shear MK, Dew MA, Miller MD, Pollock BG, Houck P, Tracey B, Reynolds CF: Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial. Am J Psychiatry. 2005, 162: 146-150.

  1358. Blank S, Lenze EJ, Mulsant BH, Dew MA, Karp JF, Shear MK, Houck PR, Miller MD, Pollock BG, Tracey B, Reynolds CF: Outcomes of late-life anxiety disorders during 32 weeks of citalopram treatment. J Clin Psychiatry. 2006, 67: 468-472.

  1359. Mohamed S, Osatuke K, Aslam M, Kasckow J: Escitalopram for comorbid depression and anxiety in elderly patients: a 12-week, open-label, flexible-dose, pilot trial. Am J Geriatr Pharmacother. 2006, 4: 201-209.

  1360. Schuurmans J, Comijs H, Emmelkamp PM, Weijnen IJ, van den Hout M, van Dyck R: Long-term effectiveness and prediction of treatment outcome in cognitive behavioral therapy and sertraline for late-life anxiety disorders. Int Psychogeriatr. 2009, 21: 1148-1159.

  1361. Rampello L, Alvano A, Raffaele R, Malaguarnera M, Vecchio I: New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram. J Clin Psychopharmacol. 2006, 26: 67-70.

  1362. Wylie M, Miller M, Shear M, Little J, Mulsant B, Pollock B, Reynolds C: Fluvoxamine pharmacotherapy of anxiety disorders in later life: preliminary open-trial data. J Geriatr Psychiatry Neurol. 2000, 13: 43-48.

  1363. Gardner M, Malone D, Sey M, Babington M: Mirtazapine is associated with less anxiolytic use among elderly depressed patients in long-term care facilities. J Am Med Dir Assoc. 2004, 5: 101-106.

  1364. Schatzberg A, Kremer C, Rodrigues H, Murphy G: Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry. 2002, 10: 541-550.

  1365. Benitez CI, Smith K, Vasile RG, Rende R, Edelen MO, Keller MB: Use of benzodiazepines and selective serotonin reuptake inhibitors in middle-aged and older adults with anxiety disorders: a longitudinal and prospective study. Am J Geriatr Psychiatry. 2008, 16: 5-13.

  1366. Uchida H, Suzuki T, Mamo DC, Mulsant BH, Kikuchi T, Takeuchi H, Tomita M, Watanabe K, Yagi G, Kashima H: Benzodiazepine and antidepressant use in elderly patients with anxiety disorders: a survey of 796 outpatients in Japan. J Anxiety Disord. 2009, 23: 477-481.

  1367. Preville M, Vasiliadis HM, Bosse C, Dionne PA, Voyer P, Brassard J: Pattern of psychotropic drug use among older adults having a depression or an anxiety disorder: results from the longitudinal ESA study. Can J Psychiatry. 2011, 56: 348-357.

  1368. Mallet L, Spinewine A, Huang A: The challenge of managing drug interactions in elderly people. Lancet. 2007, 370: 185-191.

  1369. Hines LE, Murphy JE: Potentially harmful drug-drug interactions in the elderly: a review. Am J Geriatr Pharmacother. 2011, 9: 364-377.

  1370. Klotz U: Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009, 41: 67-76.

  1371. Boyce RD, Handler SM, Karp JF, Hanlon JT: Age-related changes in antidepressant pharmacokinetics and potential drug-drug interactions: a comparison of evidence-based literature and package insert information. Am J Geriatr Pharmacother. 2012, 10: 139-150.

  1372. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST: Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008, 300: 2867-2878.

  1373. Takkouche B, Montes-Martinez A, Gill SS, Etminan M: Psychotropic medications and the risk of fracture: a meta-analysis. Drug Saf. 2007, 30: 171-184.

  1374. Zint K, Haefeli WE, Glynn RJ, Mogun H, Avorn J, Sturmer T: Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults. Pharmacoepidemiol Drug Saf. 2010, 19: 1248-1255.

  1375. Ziere G, Dieleman JP, van der Cammen TJ, Hofman A, Pols HA, Stricker BH: Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol. 2008, 28: 411-417.

  1376. Chatterjee S, Chen H, Johnson ML, Aparasu RR: Risk of falls and fractures in older adults using atypical antipsychotic agents: a propensity score-adjusted, retrospective cohort study. Am J Geriatr Pharmacother. 2012, 10: 83-94.

  1377. FDA requests boxed warnings on older class of antipsychotic drugs. [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116912.htm]

  1378. Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K, Bell CM, Lee PE, Fischer HD, Herrmann N, et al: Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007, 146: 775-786.

  1379. Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C, Cunningham F, Schneider LS, Blow FC: Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2012, 169: 71-79.

  1380. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS: Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007, 176: 627-632.

  1381. Pizzi C, Rutjes AW, Costa GM, Fontana F, Mezzetti A, Manzoli L: Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol. 2011, 107: 972-979.

  1382. Meng X, D’Arcy C: Common and unique risk factors and comorbidity for 12-month mood and anxiety disorders among Canadians. Can J Psychiatry. 2012, 57: 479-487.

  1383. Goldstein BI, Levitt AJ: The specific burden of comorbid anxiety disorders and of substance use disorders in bipolar I disorder. Bipolar Disord. 2008, 10: 67-78.

  1384. O’Neil KA, Podell JL, Benjamin CL, Kendall PC: Comorbid depressive disorders in anxiety-disordered youth: demographic, clinical, and family characteristics. Child Psychiatry Hum Dev. 2010, 41: 330-341.

  1385. Green BL, Krupnick JL, Chung J, Siddique J, Krause ED, Revicki D, Frank L, Miranda J: Impact of PTSD comorbidity on one-year outcomes in a depression trial. J Clin Psychol. 2006, 62: 815-835.

  1386. Andreescu C, Lenze EJ, Dew MA, Begley AE, Mulsant BH, Dombrovski AY, Pollock BG, Stack J, Miller MD, Reynolds CF: Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled study. Br J Psychiatry. 2007, 190: 344-349.

  1387. Goes FS, McCusker MG, Bienvenu OJ, Mackinnon DF, Mondimore FM, Schweizer B, Depaulo JR, Potash JB: Co-morbid anxiety disorders in bipolar disorder and major depression: familial aggregation and clinical characteristics of co-morbid panic disorder, social phobia, specific phobia and obsessive-compulsive disorder. Psychol Med. 2012, 42: 1449-1459.

  1388. Otto MW, Simon NM, Wisniewski SR, Miklowitz DJ, Kogan JN, Reilly-Harrington NA, Frank E, Nierenberg AA, Marangell LB, Sagduyu K, et al: Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders. Br J Psychiatry. 2006, 189: 20-25.

  1389. Sala R, Goldstein BI, Morcillo C, Liu SM, Castellanos M, Blanco C: Course of comorbid anxiety disorders among adults with bipolar disorder in the U.S. population. J Psychiatr Res. 2012, 46: 865-872.

  1390. McWilliams LA, Cox BJ, Enns MW: Mood and anxiety disorders associated with chronic pain: an examination in a nationally representative sample. Pain. 2003, 106: 127-133.

  1391. Mittal D, Fortney JC, Pyne JM, Edlund MJ, Wetherell JL: Impact of comorbid anxiety disorders on health-related quality of life among patients with major depressive disorder. Psychiatr Serv. 2006, 57: 1731-1737.

  1392. Katz C, Yaseen ZS, Mojtabai R, Cohen LJ, Galynker II: Panic as an independent risk factor for suicide attempt in depressive illness: findings from the National Epidemiological Survey on Alcohol and Related Conditions (NESARC). J Clin Psychiatry. 2011, 72: 1628-1635.

  1393. Brown LA, Gaudiano BA, Miller IW: The impact of panic-agoraphobic comorbidity on suicidality in hospitalized patients with major depression. Depress Anxiety. 2010, 27: 310-315.

  1394. Schaffer A, McIntosh D, Goldstein BI, Rector NA, McIntyre RS, Beaulieu S, Swinson R, Yatham LN: The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry. 2012, 24: 6-22.

  1395. Silverstone P, Salinas E: Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry. 2001, 62: 523-529.

  1396. Maneeton N, Maneeton B, Srisurapanont M, Martin SD: Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials. BMC Psychiatry. 2012, 12: 160-

  1397. Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG: Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011, 306: 1359-1369.

  1398. McIntyre A, Gendron A: Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety. 2007, 24: 487-494.

  1399. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC: Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007, 64: 543-552.

  1400. Young S, Pfaff D, Lewandowski KE, Ravichandran C, Cohen BM, Ongur D: Anxiety disorder comorbidity in bipolar disorder, schizophrenia and schizoaffective disorder. Psychopathology. 2013, 46: 176-185.

  1401. Achim AM, Maziade M, Raymond E, Olivier D, Merette C, Roy MA: How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull. 2011, 37: 811-821.

  1402. Simon NM, Zalta AK, Otto MW, Ostacher MJ, Fischmann D, Chow CW, Thompson EH, Stevens JC, Demopulos CM, Nierenberg AA, Pollack MH: The association of comorbid anxiety disorders with suicide attempts and suicidal ideation in outpatients with bipolar disorder. J Psychiatr Res. 2007, 41: 255-264.

  1403. Nakagawa A, Grunebaum MF, Sullivan GM, Currier D, Ellis SP, Burke AK, Brent DA, Mann JJ, Oquendo MA: Comorbid anxiety in bipolar disorder: does it have an independent effect on suicidality?. Bipolar Disord. 2008, 10: 530-538.

  1404. Pallanti S, Quercioli L, Hollander E: Social anxiety in outpatients with schizophrenia: a relevant cause of disability. Am J Psychiatry. 2004, 161: 53-58.

  1405. Makara-Studzinska M, Wolyniak M, Krys K: Influence of anxiety and depression on quality of life of people with schizophrenia in the eastern region of poland. ISRN Psychiatry. 2012, 2012: 839324-

  1406. Barnes TR: Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011, 25: 567-620.

  1407. Sheehan DV, McElroy SL, Harnett-Sheehan K, Keck PE, Janavs J, Rogers J, Gonzalez R, Shivakumar G, Suppes T: Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. J Affect Disord. 2009, 115: 376-385.

  1408. Maina G, Albert U, Rosso G, Bogetto F: Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: a randomized, single-blind, pilot study. J Clin Psychiatry. 2008, 69: 609-616.

  1409. Hirschfeld RM, Weisler RH, Raines SR, Macfadden W: Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006, 67: 355-362.

  1410. McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, Agambaram V, Merideth C, Nordenhem A, Young AH: A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010, 71: 163-174.

  1411. Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, Paulsson B, Brecher M: A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 2010, 71: 150-162.

  1412. Sagman D, Lee B, Chandresena R, Jones B, Brunner E: A Canadian naturalistic study of a community-based cohort treated for bipolar disorder. BMC Psychiatry. 2010, 10: 24-

  1413. Tohen M, Calabrese J, Vieta E, Bowden C, Gonzalez-Pinto A, Lin D, Xu W, Corya S: Effect of comorbid anxiety on treatment response in bipolar depression. J Affect Disord. 2007, 104: 137-146.

  1414. Perugi G, Toni C, Frare F, Ruffolo G, Moretti L, Torti C, Akiskal HS: Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity?. J Clin Psychopharmacol. 2002, 22: 584-591.

  1415. Davis LL, Bartolucci A, Petty F: Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord. 2005, 85: 259-266.

  1416. Vieta E, Martinez-Aran A, Nieto E, Colom F, Reinares M, Benabarre A, Gasto C: Adjunctive gabapentin treatment of bipolar disorder. Eur Psychiatry. 2000, 15: 433-437.

  1417. Wender PH, Wolf LE, Wasserstein J: Adults with ADHD. An overview. Ann N Y Acad Sci. 2001, 931: 1-16.

  1418. Dulcan M: Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 1997, 36: 85S-121S.

  1419. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M: Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry. 1993, 50: 565-576.

  1420. Weiss G, Hechtman L: Hyperactive children grown up: ADHD in children, adolescents, and adults. 1993, New York, NY: Guilford Press

  1421. Pary R, Lewis S, Matuschka PR, Rudzinskiy P, Safi M, Lippmann S: Attention deficit disorder in adults. Ann Clin Psychiatry. 2002, 14: 105-111.

  1422. Wilens TE, Biederman J, Spencer TJ: Attention deficit/hyperactivity disorder across the lifespan. Annu Rev Med. 2002, 53: 113-131.

  1423. Wilens TE, Faraone SV, Biederman J: Attention-deficit/hyperactivity disorder in adults. JAMA. 2004, 292: 619-623.

  1424. Garcia SP, Guimaraes J, Zampieri JF, Martinez AL, Polanczyk G, Rohde LA: Response to methylphenidate in children and adolescents with ADHD: does comorbid anxiety disorders matters?. J Neural Transm. 2009, 116: 631-636.

  1425. Blouin B, Maddeaux C, Stanley Firestone J, van Stralen J: Predicting response of ADHD symptoms to methylphenidate treatment based on comorbid anxiety. J Atten Disord. 2010, 13: 414-419.

  1426. Kratochvil CJ, Newcorn JH, Arnold LE, Duesenberg D, Emslie GJ, Quintana H, Sarkis EH, Wagner KD, Gao H, Michelson D, Biederman J: Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005, 44: 915-924.

  1427. Goodman DW, Thase ME: Recognizing ADHD in adults with comorbid mood disorders: implications for identification and management. Postgrad Med. 2009, 121: 20-30.

  1428. Gabriel A, Violato C: Adjunctive atomoxetine to SSRIs or SNRIs in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety (GA): an open-label study. Atten Defic Hyperact Disord. 2011, 3: 319-326.

  1429. Gabriel A: The mixed amphetamine salt extended release (Adderall XR, Max-XR) as an adjunctive to SSRIS or SNRIS in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety: an open-label study. Atten Defic Hyperact Disord. 2010, 2: 87-92.

  1430. El-Gabalawy R, Mackenzie CS, Shooshtari S, Sareen J: Comorbid physical health conditions and anxiety disorders: a population-based exploration of prevalence and health outcomes among older adults. Gen Hosp Psychiatry. 2011, 33: 556-564.

  1431. Vogelzangs N, Seldenrijk A, Beekman AT, van Hout HP, de Jonge P, Penninx BW: Cardiovascular disease in persons with depressive and anxiety disorders. J Affect Disord. 2010, 125: 241-248.

  1432. Huang KL, Su TP, Chen TJ, Chou YH, Bai YM: Comorbidity of cardiovascular diseases with mood and anxiety disorder: a population based 4-year study. Psychiatry Clin Neurosci. 2009, 63: 401-409.

  1433. Demyttenaere K, Bonnewyn A, Bruffaerts R, De Graaf R, Haro JM, Alonso J: Comorbid painful physical symptoms and anxiety: prevalence, work loss and help-seeking. J Affect Disord. 2008, 109: 264-272.

  1434. Asmundson GJ, Katz J: Understanding the co-occurrence of anxiety disorders and chronic pain: state-of-the-art. Depress Anxiety. 2009, 26: 888-901.

  1435. Hartford JT, Endicott J, Kornstein SG, Allgulander C, Wohlreich MM, Russell JM, Perahia DG, Erickson JS: Implications of pain in generalized anxiety disorder: efficacy of duloxetine. Prim Care Companion J Clin Psychiatry. 2008, 10: 197-204.

  1436. Beesdo K, Hartford J, Russell J, Spann M, Ball S, Wittchen HU: The short- and long-term effect of duloxetine on painful physical symptoms in patients with generalized anxiety disorder: results from three clinical trials. J Anxiety Disord. 2009, 23: 1064-1071.

  1437. Russell JM, Weisberg R, Fava M, Hartford JT, Erickson JS, D’Souza DN: Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms. Depress Anxiety. 2008, 25: E1-11.

  1438. Jackson JL, Shimeall W, Sessums L, Dezee KJ, Becher D, Diemer M, Berbano E, O’Malley PG: Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ. 2010, 341: c5222-

  1439. Saarto T, Wiffen PJ: Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007, CD005454-

  1440. Denollet J, Maas K, Knottnerus A, Keyzer JJ, Pop VJ: Anxiety predicted premature all-cause and cardiovascular death in a 10-year follow-up of middle-aged women. J Clin Epidemiol. 2009, 62: 452-456.

  1441. Chamberlain AM, Vickers KS, Colligan RC, Weston SA, Rummans TA, Roger VL: Associations of preexisting depression and anxiety with hospitalization in patients with cardiovascular disease. Mayo Clin Proc. 2011, 86: 1056-1062.

  1442. Doering LV, Moser DK, Riegel B, McKinley S, Davidson P, Baker H, Meischke H, Dracup K: Persistent comorbid symptoms of depression and anxiety predict mortality in heart disease. Int J Cardiol. 2010, 145: 188-192.

  1443. McIntyre RS, Alsuwaidan M, Goldstein BI, Taylor VH, Schaffer A, Beaulieu S, Kemp DE: The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. Ann Clin Psychiatry. 2012, 24: 69-81.

  1444. Ramasubbu R, Taylor VH, Saaman Z, Sockalingham S, Li M, Patten S, Rodin G, Schaffer A, Beaulieu S, McIntyre RS: The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. Ann Clin Psychiatry. 2012, 24: 91-109.

  1445. Ramasubbu R, Beaulieu S, Taylor VH, Schaffer A, McIntyre RS: The CANMAT task force recommendations for the management of patients with mood disorders and comorbid medical conditions: diagnostic, assessment, and treatment principles. Ann Clin Psychiatry. 2012, 24: 82-90.

  1446. Engum A: The role of depression and anxiety in onset of diabetes in a large population-based study. J Psychosom Res. 2007, 62: 31-38.

  1447. Aujla N, Davies MJ, Skinner TC, Gray LJ, Webb DR, Srinivasan B, Khunti K: The association between anxiety and measures of glycaemia in a population-based diabetes screening programme. Diabet Med. 2011, 28: 785-788.

  1448. Serretti A, Mandelli L: Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010, 71: 1259-1272.

BACA JUGA:   What to ask a massage therapist

Also Read

Wall street journal underrated therapy for stress

Is there a link between cancer and stress

Mental health counseling programs in minnesota

Therapy in a nutshell anxiety attack

Recreational therapy in mental health nursing

Bagikan:

Contact me

[email protected]